Impediments to the Historical Development of the Clinical Pap Test in the United States: Their Relevance in Optimizing Cervical Cancer Screening in the State of Qatar by Chantziantoniou, Nikolaos
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Summer 8-9-2019 
Impediments to the Historical Development of the Clinical Pap 
Test in the United States: Their Relevance in Optimizing Cervical 
Cancer Screening in the State of Qatar 
Nikolaos Chantziantoniou 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Chantziantoniou, Nikolaos, "Impediments to the Historical Development of the Clinical Pap Test in the 
United States: Their Relevance in Optimizing Cervical Cancer Screening in the State of Qatar" (2019). 
Theses & Dissertations. 391. 
https://digitalcommons.unmc.edu/etd/391 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
 
 
IMPEDIMENTS TO THE HISTORICAL DEVELOPMENT OF THE 
CLINICAL PAP TEST IN THE UNITED STATES: THEIR 
RELEVANCE IN OPTIMIZING CERVICAL CANCER 








Presented to the Faculty of 
the University of Nebraska Graduate College 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
 
 
Medical Sciences Interdepartmental Area Graduate Program 
(Preventive & Societal Medicine) 
 
Under the Supervision of Professor Amber D. Donnelly 
 







Denise H. Britigan, Ph.D. Stanley J. Radio, MD 
Maheswari S. Mukherjee, Ph.D. R. Marshall Austin, MD, Ph.D. 





 This dissertation is dedicated foremost to my wife, Stavroula Chantziantoniou, 
for a life adorned by her unreserved affection, support, and wisdom as we navigated 
through my meandering international career - my Everest would never have been 
championed had it not been for her intuition and selflessness; to my children, Dimitra, 
Nick, and Adonis Chantziantoniou, and Javier Anagnostopulos, for their 
encouragement and fortitude; to my adorable grandchildren, Leonidas and Anna, whose 
nuances kept me dedicated and eager to surmount this task; and, to the University of 
Nebraska Medical Center for seeing merit in this scientific work. 
 I remain humbled and eternally obliged to all our parents for the teachings and 
trust they bestowed unto us through their own unique ways. To my father, Dimitrios 
Chantziantoniou, who taught me the meaning of perseverance, meanwhile all that I 
shall ever endeavor ought to be done to the best of my ability or not at all. 
 I remain sincerely indebted to my mentor and advisor throughout this graduate 
program, Dr. Amber D. Donnelly, for her kindness, thoughtfulness, and steadfastness as 
we considered the methodical execution of this research work, and the character of this 
dissertation. A similar sense of indebtedness and gratitude is extended to all members of 
my graduate committee: Dr. Maheswari S. Mukherjee, Dr. Eleanor G. Rogan, Dr. Denise 
H. Britigan, and Dr. Stanley J. Radio (University of Nebraska Medical Center), and to Dr. 
R. Marshall Austin (University of Pittsburgh Medical Center), for their suggestions and 
ii 
 
viewpoints. Similar sentiments are extended to Dr. Laura Bilek (Associate Dean of 
Research, Co-Chair of Medical Sciences Interdepartmental Areas graduate program, 
University of Nebraska Medical Center) for her guidance and support of this work; and, 
to all my professors that instilled into me the necessary passion and theoretical and 
practical foundations upon which to construct this commitment. 
 A major aspect of this dissertation involved the organization and methodical 
analysis of scattered historical scientific and non-scientific information. In this spirit, I 
acknowledge a heartfelt indebtedness to Dr. R. Marshall Austin not only for 
encouraging me to pursue this project, but also for helping me amass obscure 
publications and materials that would otherwise have been unattainable, or utterly 
unknown to the profession of Diagnostic Cytopathology. Likewise, for his kindness and 
willingness to share with me various other artifacts and original hand-written 
correspondences the discipline has inherited from the late Dr. George N. Papanicolaou. I 
thank Maria Nanos and her sister, Stella Nanos, for contributing invaluable research 
materials in support of this work left behind by their late aunt, Stella Nanos senior, who 
had collaborated with Dr. Papanicolaou. Similarly, to Olga Stamatiou, and to Georgia 
Kokkori, both grand-nieces of Dr. Papanicolaou, for providing additional research 
materials to help redefine the legacy of Dr. Papanicolaou’s life and career, hence our 
knowledge of the background dynamics that ultimately led to the development of the 
clinical Pap test. I also extend sincere thanks to Nikolaos Piteros, Secretary General of 
the Cultural Association Of Kymi, Greece, and to his officials, for their hospitality and the 
iii 
 
remarkable Greek publications they so generously donated in support of this research 
work from the George N. Papanicolaou Institute And Museum exhibit in Kymi. 
 It is without question neither this dissertation nor our awareness of the scientific 
evolution of the Pap test could have been complete without such materials garnered 
between two continents, two languages, and essentially from four generations of 
humanity. 
 No communication of indebtedness may be complete without mention of The 
Commonwealth Fund, New York, for its ongoing consideration of my work, and for 
honoring my requests for Dr. Papanicolaou’s and Hashime Murayama’s color 
illustrations of cells to be reprinted in my publications. Accordingly, I am obliged to all 
editors that reviewed, challenged, and reproduced my work. 
 Sincere thanks are extended to the International Academy of Cytology for 
courteously providing the complete transcript of Symposium A (1957) for this research. 
Symposium A reflected a significant milestone in the historical evolution of Gynecological 
Cytopathology which captured in its entirety the first ever Issue and Volume of Acta 
Cytologica. Such literature would have been otherwise unavailable, and largely unknown 
to contemporary cytologists. Thanks are also extended for the Academy’s ongoing 
acknowledgment of my career’s work. 
 I remain grateful to Dr. Mathilde E. Boon for her continuous encouragement and 
guidance throughout my career and for her kind consideration of my contributions as 
co-author in the book, Papanicolaou Revisited (2013). I have stood both fortunate and 
iv 
 
privileged to inherit fundamentals from Dr. Papanicolaou through Dr. Boon that she in 
turn had inherited from her mentor, the late Dr. Bernard Naylor, who was also a close 
associate of Dr. Papanicolaou in the latter part of his career and life. In part, aspects of 
these insights manifest through this dissertation. 
 I extend sincere thanks to Dr. R. Marshall Austin, to Dr. Mathilde E. Boon, and to 
Dr. Hanan I. Farghaly, whom upon my invitation enthusiastically participated as 
speakers in the symposium, entitled The 1st Century Of Gynecological Cytopathology, The 
Pap test – Then, Now And The Future, conducted in Doha, Qatar, on December 7, 2014. 
That symposium inspired a series of initiatives in the State of Qatar that set cervical 
cancer under the medical and public spotlight. Those initiatives ultimately transcended 
into the basis of this dissertation. Those outcomes may not have materialized without 
their expert contributions, and willingness to participate in that event without 
reservation. 
 I also acknowledge the support received for this graduate work from my 
superiors at Sidra Medicine, Department of Pathology, Doha, Qatar: Haythem Makki, 
and Drs. Jason C. Ford, and Adrian K. Charles. I thank my research team collaborators at 
Sidra Medicine: Ghada Al-Najar, and Drs. Denise Howard and Colin A. Clelland, for 
their advice and propositions in the needs-assessment survey structure and execution; 
and to Khadra Abdi of the Sidra Research Department for facilitating the Institutional 
Review Board application and approval process. Special thanks are extended to Dr. 
Mohammed El Anbari for his expert assistance in the biostatistical data computations. 
v 
 
Likewise, thanks are extended to Dr. Nady M. Nady and to Kate Herod for their project 
support, and to Anthea O’Brien and to Matthew Hand for their expert assistance with 
the formatting of the dissertation document. To the many unnamed friends and 
colleagues that, in one way or another, also empowered me to champion this Everest, I 
thank you with sincere gratitude in the hope that this dissertation will prove to be a 
commensurate reflection of your confidence in me. 
 Through the University of Nebraska Medical Center, this dissertation aims to 
uncover the impediments that obstructed progress towards the development, 
acceptance, and application of the clinical Pap test in societal and preventive medicine in 
the United States of America. It is hoped that knowledge gained from the North 
American experience may be strategically considered in the contemporary clinical 
setting of the State of Qatar to optimize cervical cancer prevention through improved 
Pap test screening, and advance the assault against cervical cancer to rein in this disease 
burden upon women. 
 It is also my hope that this work will immortalize the substantive contributions 
to societal medicine that humanity has inherited from Dr. George N. Papanicolaou and 
from his wife, Andromache Papanicolaou. 
 In memory of my late father, and in this very effort to honor his astuteness, these 
sentiments and acknowledgments comprise the initial texts of this dissertation. 





IMPEDIMENTS TO THE HISTORICAL DEVELOPMENT OF THE CLINICAL PAP 
TEST IN THE UNITED STATES: THEIR RELEVANCE IN OPTIMIZING CERVICAL 
CANCER SCREENING IN THE STATE OF QATAR 
Nikolaos Chantziantoniou, Ph.D. 
University of Nebraska Medical Center, 2019 
Supervisor: Amber D. Donnelly, Ph.D. 
 Three hundred surveys listing 31 questions were distributed amongst women 
and men at Sidra Medicine, Doha, State of Qatar, to assess knowledge and perceptions 
of: Cervical cancer (CxCa); preventive Pap test screening; Human Papilloma Virus 
(HPV) vaccination; and, need for population-based screening. Survey questions 
captured categorical statistical data through four categories: (1) Socio-demographic; (2) 
Healthcare Services; (3) Health Literacy; and, (4) Self-efficacy and Perceptions. 
Hypothesis 1: 12 survey questions pertaining to CxCa and Pap testing revealed 8 
statistically-significant dependencies; notably, 70% of respondents were aware of CxCa; 
however, 31.8% were unaware that CxCa may be curable; 33.7% were unaware of the 
Pap test; and, 35.2% were unaware that HPV vaccination may protect against CxCa. 
Hypothesis 2: Two survey questions pertaining to screening practice revealed no 
statistically-significant dependencies; however, 67.4% of respondents strongly agreed for 
establishment of population-based screening in Qatar. Hypothesis 3: Three salient 
parallels were revealed between the Qatar and US clinical experiences: (1) Greater than 
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60% of symptomatic women in Qatar presented with Stage II/III CxCa in 2014, relative to 
60% of women in the US with inoperable disease before 1957; (2) Estimated CxCa death 
rates in Qatar are 26.7%, relative to 32.2% in the US; and, (3) The burden of CxCa was 
under-estimated prior to emergence of death registries and epidemiologic data in the US 
in 1914 and 1952 respectively, relative to 2014 in Qatar. 
 Impediments to Pap test development and application in the US stemmed from 
macro-dynamics (i.e., societal, economic, political situations); and, reactive micro-
dynamics (i.e., professional conflicts, skepticism, conceptualization of cervical 
precancer). Pap test screening practices in the State of Qatar may be optimized through: 
(1) Tumor Registry for inclusion of precancer cases to ascertain actual CxCa incidence; (2) 
Organized screening with initial call to screening for asymptomatic women deemed at risk; and, 
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 The clinical (morphology-based) Papanicolaou (Pap) test is a medical procedure 
applied to ideally detect precancerous (i.e., precursor) lesions of the uterine cervix 
through cytological grading of abnormal epithelial cells. A plethora of literature in the 
cytopathology and public health bibliographies establish the clinical Pap test as being 
the first effective cancer prevention tool in the history of medicine (Chang, 1999; Austin 
& Chantziantoniou, 2014; El-Mazny, 2014). However, the global impact of the Pap test in 
preventive medicine varies depending on its availability, accessibility, promotion, 
endorsement, and uptake. 
 Since the early experimental work conducted by Dr. George Nicholas 
Papanicolaou at Cornell Medical College, New York (CMC-NY) that ultimately 
conceived gynecological cytopathology starting in 1917, and more formally since 1928, 
29 years transpired before the clinical Pap test was understood, optimized and field 
tested, and deployed in screening service in the United States of America (US) by 1957 
(Christopherson & Scott, 1977; Chantziantoniou, 20141; Cibas & Ducatman, 2014; 
Chantziantoniou, 2017). In those intervening 29 years various scientific and non-
scientific factors disrupted or utterly impeded the evolutionary course of the Pap test 




 It is impractical to speculate upon the ramifications to society or to public health 
that may have compounded over time due to those impediments disrupting progress to 
effective cervical cancer (CxCa) management. Nevertheless, detailed knowledge of those 
impediments, of their impact, and how they were overcome, may hold relevance when 
considered to optimize contemporary Pap test screening systems that may be 
underperforming. 
 The efficacy of the Pap test remains a testament to a favorable balance between 
its technical and procedural simplicity, and its far-reaching clinical benefits. Historically, 
during specific timeframes in the US, system imbalances led to conflicts that were 
gradually overcome with advancing knowledge of the disease’s preinvasive phases, and 
the Pap test’s potential in differentiating them from frank carcinoma. Despite advanced 
automation in modern cytopathology, the Pap test remains a simple medical procedure 
whereby cells from ecto- and endo-cervical epithelia may be salvaged and processed to 
facilitate methodical, cytological grading. In stark contrast to its simplicity, however, 
was a complex evolutionary warren that continues to elicit speculation in society and in 
diagnostic medicine (Foltz & Kelsey, 1978; Reagan, 1997; Dickey, 2001; Lowy, 2010). The 
collective dynamics remain in a state of transition. They also continue to influence the 
Pap test’s scope of practice both in the US and in other nations. As a result, the Pap test’s 
scope of practice globally is inconsistent, as also are the public health ramifications 





 Since its promotion by the American Cancer Society (ACS) starting in 1948, the 
Pap test has steadily and significantly reduced the incidence and mortality rates of CxCa 
in the US by revealing occult, eradicable precancerous lesions (Koss, 1993; Casper & 
Clarke, 1998; Michalas, 2000; American Cancer Society, 20171). The impact of the Pap test 
globally has been similarly favorable, but typically in developed nations deploying 
systematic, population-based Pap test screening programs with adequate patient call 
and recall as dictated through enforced rescreening guidelines and robust patient-case 
registries (Christopherson & Scott, 1977; Koss, 1989; Habbema, De Kok, & Brown, 2012; 
Vaccarella, Lortet-Tieulent, Plummer, Franceschi, & Bray, 2013; Cibas & Ducatman, 
2014). In contrast, in developing and in resource-poor regions, where Pap test uptakes 
may be inaccessible, opportunistic or utterly unavailable, advanced CxCa at diagnosis 
continues to pose major public health priorities associated with disparaging clinical and 
societal outcomes (Garner, 2003; Lowy, 2010). 
 As CxCa is currently regarded a preventable disease in adequately-screened 
women, cases presenting with advanced-stage malignancy at diagnosis may serve as 
surrogates reflecting screening disparities or system underperformances (Chang, 1999; 
Garner, 2003; Gorin, Gauthier, Hay, Miles, & Wardle, 2008). Therefore, system 
underperformance may be appraisable through such cases as the natural progression of 
asymptomatic precursor lesions through to infiltrating disease may span numerous 
years (Garner, 2003). Hence, with optimal population-based Pap test screening coupled 




exploited to identify and ablate lesions when still precancerous. Hallmarks of effective 
screening are therefore repeated Pap test sampling and timely ablation of intraepithelial 
lesions. However, opportunistic screening systems are typically reactive to suspicious 
symptomatology and not governed by initial patient call to screening or surveillance 
strategies (Seoud, 2013; Alemrayat, Abu-Abbas, Al-Naemi, AlTwaisi, Saibi, Zaheer, 
Khattab, & Adnan, 2018). 
 Despite the success of CxCa prevention through Pap test screening in the US and 
in other industrialized nations, not all global regions deploy like practices for the 
surveillance of precancer in asymptomatic women deemed at risk for developing this 
disease (Gustafsson, Ponten, Zack, & Adami, 1997). 
 As discussed in Chapter 3, at the time of this writing, the State of Qatar has not 
implemented a formal, organized, national population-based Pap test screening 
program for CxCa prevention for all resident women inclusive of strategic patient call 
and recall. Although, Pap test sampling is available through various public and private 
medical providers in Qatar. Creditably, through the Qatar Ministry of Public Health 
(QMoPH), the Primary Health Care Corporation (PHCC), and the Qatar Cancer Society 
(QCS), the State has recently invested extensively to support remarkable campaigns to 
increase public awareness of CxCa, and to encourage women to actively seek Pap test 
sampling opportunities. Nevertheless, Pap test uptakes in the State of Qatar remain 




setting (QMoPH National Cancer Framework, 2017; Sancho-Garnier, Khazraji, Cherif, 
Mahnane, Hsairi, El Shalakamy, Osgul, Tuncer, Jumaan, & Seoud, 2013; Seoud, 2013). 
 The State of Qatar is a member country of the Extended Middle East and North 
Africa (EMENA) region (Seoud, 2013). According to Sancho-Garnier et al. (2013), 
essentially all member territories and countries of the EMENA region deploy 
opportunistic Pap test screening in public and private medicine, mainly reactive to 
presenting symptoms. Consequently, according to Sancho-Garnier et al. (2013), and 
more recently to Alemrayat et al. (2018), the majority of cervical cancers in the EMENA 
countries are initially diagnosed when clinically advanced. 
 Cervical cancer ranks as the 5th most common malignancy in women in the State 
of Qatar according to the Institut Catala d’Oncologica (ICO) (Institut Catala 
d’Oncologica, 20172). The ICO has also published an estimated annual CxCa burden of 
15 cases for Qatar; whereas, four cases would prove fatal, reflecting an estimated annual 
death rate of 26.7% (Institut Catala d’Oncologica, 20172). In line with these estimates, the 
Qatar National Cancer Registry 2014 report (Appendix A) published by the National Cancer 
Program, QMoPH, revealed that of the 18 cases of CxCa registered in 2014, greater than 
60% of those cases harbored Stage II/III disease at presentation (QMoPH National 
Cancer Program, 2014). 
 As the contemporary experience in Qatar is not unlike the historical experience 
of CxCa presentation and diagnosis in the US prior to expansion of Pap test screening by 




opportunity for detailed study of its public health and epidemiologic elements. The State 
of Qatar is a relatively small country with a small female clinical population deemed at 
risk for developing CxCa; and, is serviced by premier tertiary medical institutions with 
accredited Diagnostic Cytopathology (DC) operations. The State is modern and 
developed (Institut Catala d’Oncologica, 20172). 
 The parallels between the historical-US and contemporary-Qatar experiences 
pertaining to CxCa presentation and diagnosis led to the presumptions, research aims, 
and hypotheses herein considered. 
Dissertation Fundamentals - Presumptions 
 The intents and purposes of this dissertation are conceptually based upon the 
overarching epidemiological dictum that disease in general, and CxCa notwithstanding, 
is not randomly distributed throughout humanity (Gordis, 2014). It is presumed, 
therefore, that prevalence and clustering of CxCa globally may manifest specific 
commonalities. Commonalities may involve risk factors; Human Papilloma Virus (HPV) 
subtypes and potential co-infections; CxCa etiology and pathobiology; symptoms at 
presentation; behavioral attitudes reflecting perceived etiology and likely prevention 
and cure; women’s perceptions of barriers to screening; cultural norms and prohibitions; 
and, ultimately, the organizational infrastructures that either promote or compromise 
availability, access, or uptake of Pap test sampling (Chang, 1999; Garner, 2003). 
 It is from these core presumptions that a detailed understanding of the historical 




of CxCa screening practices in non-US regions. Insights from the US model may guide 
optimization of existing screening practices by facilitating identification of shortcomings 
or inadequacies. Likewise, historical insights may address modern public health 
challenges stemming from rapid technological change, life-style and societal attitudes, 
financial disparities, and the cultural norms typifying conservative societies, as those 
characteristic of the EMENA region. 
Dissertation Fundamentals - Literature Review 
 A methodical review of the pertinent cytopathology and public health literature 
was conducted to support an analysis and categorization of the factors that impeded the 
historical development, acceptance, and application of the clinical Pap test in the US 
(Chapter 2). 
 The literature review also involved a supplementary analysis of chronologically-
relevant personal correspondences of Dr. George N. Papanicolaou. It also included a 
review of pertinent literature in the Greek bibliography to glean obscure perspectives 
that may embellish the overall understanding of impediments to the development of the 
clinical Pap test (Diamantis & Magiorkinis, 2012 – translated from Greek). 
Dissertation Fundamentals - Aims And Hypotheses 
 The principal aim of this dissertation involved the generation of original, 
relevant health promotion data to facilitate transformation of existing opportunistic 
screening practices into more effective population-based Pap test screening programs for 





 It is hypothesized that women and men in the State of Qatar have adequate 
health literacy of CxCa; however, they may lack commensurate awareness of disease 
prevention possible through Pap test screening and HPV vaccination; and, that they 
would support the establishment of a formal Pap test screening program for all resident 
women in this nation. It is also hypothesized that, based on likely similarities of CxCa 
extent at presentation and diagnosis between the contemporary Qatar experience and 
the historical US experience prior to clinical Pap test screening, insights gained from the 
US model may provide actionable considerations to facilitate optimization of Pap test 
screening practices in the State of Qatar, and potentially in other countries in the 
EMENA region. 
Dissertation Aim 1 
 Evaluate the degree of health literacy in women and men in the State of Qatar of 
CxCa; of Pap test screening, and of its benefits and uptakes; and, of HPV vaccination. 
 To evaluate the degree of health literacy in women and men pertaining to CxCa, 
the disease prevention benefits possible through Pap test screening, and those through 
HPV vaccination in the State of Qatar, specific questions are incorporated in a needs-
assessment survey to generate supporting Socio-demographics, Healthcare Services, 







 It is hypothesized that the majority of women and men in the State of Qatar have 
adequate health literacy of CxCa; however, they lack commensurate awareness of the 
disease prevention benefits possible through Pap test screening and HPV vaccination. 
Dissertation Aim 2 
 Evaluate the degree of support in women and men in the State of Qatar for the 
establishment of a formal Pap test screening program for all women. 
 To evaluate the degree of support by women and men in the State of Qatar for 
the establishment of a formal Pap test screening program for all women, specific 
questions are incorporated in a needs-assessment survey to generate supporting socio-
demographic and self-efficacy & perceptions statistical data (Appendix B). 
Hypothesis 
 It is hypothesized that the establishment of a formal Pap test screening program 
for CxCa for all women in the State of Qatar is strongly supported by women and men. 
Dissertation Aim 3 
 Evaluate possible similarities of extent of CxCa at presentation and diagnosis 
between the contemporary Qatar experience and the historical experience in the US 
prior to the introduction of clinical population-based Pap test screening in 1957. 
 To evaluate possible similarities of extent of CxCa at presentation and diagnosis 




Pap test screening, pertinent literature reviews were conducted to ascertain historical 
information. To facilitate comparisons, equivalent epidemiological data for CxCa arising 
from the State of Qatar was researched and correlated. 
Hypothesis 
 It is hypothesized that the extent of CxCa at presentation and diagnosis in the 
historical US experience, prior to the introduction of clinical population-based Pap test 
screening in 1957, bears similarities with the current experience of CxCa presentation in 






CHAPTER 2: HISTORICAL IMPEDIMENTS TO THE 
DEVELOPMENT OF THE CLINICAL PAP TEST ARISING FROM 
MACRO- AND MICRO-DYNAMICS IN THE US 
 
 Chapter 2 details the salient macro- and micro-dynamics that historically 
impacted upon the evolution of the clinical Pap test in 20th century US. The literature 
reviews revealed a wide range of factors that influenced the development of the clinical 
Pap test. This Chapter describes events occurring primarily between 1900 and 1957. This 
period represents the experience arising from the detection and diagnosis of CxCa prior 
to robust Pap test screening in the US starting in 1957. The salient impediments revealed 
through this period were stratified through specific categories and timeframes, and 
summarized in subsequent sub-sections and tables in this Chapter (Tables 1-9). 
  The literature revealed that establishment of the clinical Pap test, and by 
extension gynecological DC, was not a phenomenon occurring in isolation of major 
historical milestones. These entities were rooted in various facets of history, in the 
emerging burden of cancer, and in the societal and public health apprehensions and 
priorities that ensued. They also stemmed from the changing cultural fabric of the US 
along with prevailing economic and political situations since 1900. They were likewise 
influenced by events occurring during and immediately following the two World Wars. 
The overall saga was complex. For the purposes of this dissertation, the following sub-
sections were structured to elucidate the most impactful events in an effort to sustain 




Knowledge Of Foundational Events In Diagnostic Cytopathology 
 Knowledge of the foundational events in DC was formed from information 
collated from a wide array of literary sources. Pertinent information in the DC and 
public health bibliographies was reviewed, as were relevant narratives in the medical 
and political history bibliographies. Accounts from individuals being either confidantes 
of Dr. Papanicolaou, close professional associates, relatives, moderate or staunch critics 
of him or of the cytologic method were also reviewed. In addition, Papanicolaou’s 
statements through his personal correspondences in English and Greek were correlated. 
All materials were cross-checked to build the overall experience through utmost 
contextual and chronological relevance. 
Impediments To The Development Of The Clinical Pap Test Arising From 
Historical Macro-Dynamics 
 Macro-dynamics reflected greater forces that either directly or indirectly 
influenced the inception, development, and application of the clinical Pap test in the US. 
These dynamics were primarily due to societal, economical, and political developments 
over the course of time. Although they revolved outside the realm of DC, they 
predisposed reactive micro-dynamics within the discipline. From a practical perspective, 
macro-dynamics were inevitable. They were external forces that characterized an 






Cervical Cancer In The US In The Early-1900s  
 Epidemiological data pertaining to CxCa incidence per se from the early-1900s is 
practically unavailable. From information referring to death registries, it became evident 
that mortality due to CxCa changed remarkably between 1900 and 1957, when Pap test 
screening practices started to make an impact in disease prevention throughout the US. 
 Accounts referring to the burden of CxCa in the early-1900s appear mainly in 
secondary-source works by medical historians. Although devoid of specific 
epidemiological detail, these works described the impact of CxCa, and the attitudes and 
fears elicited in both women and clinicians. These works underscored the sensitivities 
and stigmatization associated with this disease throughout the wider dimensions of 
American society. Such accounts also referred to racial differences seen in CxCa 
mortality at the turn of the 20th century. 
 Remarkable descriptions of the overall impact of cancer in the US were 
organized in a book, entitled The Secret History Of The War On Cancer (2007), by Devra 
Davis. One poignant statement in Davis’ book notably embodied the essence of CxCa at 
the start of the 20th century. According to Davis (2007): 
“At the start of the twentieth century, cervical cancer was a death sentence, and 
often a secret one. It was not unusual for women to go to their graves never 
knowing what was wrong.” 
 In the early-1900s, CxCa posed particular challenges that tried the patient and 




this was hampered by human attitudes and sensitivities at a time when the disease was 
regarded a societal menace that inexorably led to silent, painful deaths in relatively 
young women indiscriminately (Gardner, 2006; Skloot, 2010). 
Detection Of Cervical Cancer In The Early-1900s 
 Research by Lowy (2010) revealed that the vaginal speculum was developed in 
the early 19th century. Using the speculum, gynecologists gained visual access to the 
uterine cervix and, after shining light upon it, assessed its gross anatomy with the naked 
eye. This practice allowed gynecologists to raise clinical suspicions and target 
exploratory biopsies. This in turn helped anatomical pathologists correlate the ensuing 
histopathologic findings with the gross, clinical cervical features (Lowy, 2010). Based on 
such correlations, in 1908, a German physician, Dr. Walther Schauenstein, advocated 
that the naked eye may adequately inspect the cervix to distinguish a healthy cervix 
from one that may be cancerous. The healthy cervix “looks soft, pink and rosy”, whereas 
the diseased cervix appears “gray and full of pus” (Davis, 2007). 
 Visual inspection of the cervix with clinical correlation of its gross appearance 
thus became the standard-of-practice in the US. This practice led to early speculations of 
the disease’s genesis. At the turn of the 20th century, doctors associated CxCa with sexual 
habits as Jewish women and nuns demonstrated the lowest rates of the disease. They 
also related the disease to multi-parity and, likely, to cervical trauma during childbirth 
(Olson, 1989). But unlike other human ailments, the perceptions of CxCa and of its likely 




Collectively, these dynamics had a profound effect upon clinicians required to not only 
discover the disease, but to also understand it, and to deliver effective care to all women 
impartially. According to Davis (2007): 
“Doctors had long known that cervical cancer did not arise overnight. But it was 
accepted as an inevitable result of some poorly understood deficiency, perhaps a 
moral one. Disease of any kind was seen as a result of not trying hard enough to 
be good enough. Then, as now, far more black women got the disease and died 
of it. The fact that this ailment was uniquely a women’s disease that 
disproportionately affected those then called “coloreds” combined to make 
cervical cancer less than a high priority for doctors.” 
 Cervical cancer posed additional barriers for both patients and clinicians given 
its anatomical origin. The intimacies arising from this disease along with its outcomes 
relative to other malignancies in women made CxCa a unique clinical challenge, and one 
often avoided leading to grave consequences. Both the disease in women and its 
detection by doctors were embedded within a web of societal attitudes, mutually-
perceived taboos and embarrassment, and both implicit and explicit prohibitions 
(Gardner, 2006; Skloot, 2010). According to Davis (2007): 
“More accessible forms of cancer might produce visible or palpable lesions, 
lumps and bumps that, once found and recognized, gave doctors a fighting 
chance to cut out the growth and arrest the disease. But the cervix, the most 




whose means of access was closed to all eyes. At a time when women felt shame 
at the mere mention of their genitals, the topic of cancer of their private parts was 
not considered appropriate for public discussion.” 
 Yet, CxCa could not remain overlooked. The clinical detection of the disease and 
its treatment posed foremost dilemmas in society and in medicine. These priorities 
obliged gynecologists to nonetheless align their efforts against the disease applying the 
standard practice: Advocating visual inspections of the uterine cervix in search of 
obvious lesions in women. In the early-1900s radical hysterectomy was the mainstay 
procedure for treatment of CxCa with an associated surgical mortality rate of 20% 
(Olson, 1989). 
 The overall problem of CxCa was neither trivial in society, nor in medicine. The 
predecessor organization to the modern ACS, the American Society for the Control of 
Cancer (ASCC), was formed precisely in response to these emerging priorities. 
Establishment Of The American Society For The Control Of Cancer 
 The ASCC was established in 1913 in response to the problems arising from the 
management of CxCa when initially diagnosed in advanced stages (Greenwald, Cullen, 
& McKenna, 1987; American Cancer Society, 20172). 
 The ASCC was formed by a group of businessmen and gynecologists in New 
York City with the founding mission to: “Fight Cancer With Knowledge” (Holleb, 1988; 
Davis, 2007; American Cancer Society, 20172). The ASCC promoted the then standard-of-




and managed through hysterectomy (Holleb, 1988; Davis, 2007). However, the founding 
members of the ASCC had no illusions of the imminent challenge pertaining to cervical 
visualization. Dr. James S. Ewing served the founding committee of the ASCC. 
According to Davis (2007), in an effort to promote the principles of CxCa detection and 
diagnosis, the ASCC had a “simple aim”: 
“…to persuade physicians to learn how to look at the cervix and persuade 
women to allow regular exams... It never has been easy to get women to take 
their clothes off and lie…with their feet in cold metal stirrups. A leading ASCC 
pathologist, James Ewing, ruefully conceded in 1926 that even if doctors became 
convinced of its value, the prospects for persuading women to undergo this 
exam twice a year were slim and daunting. It was not clear at the time whether it 
was harder to find physicians who understood the value of performing the exam 
or to persuade women of its value.” 
Linear Model Of Cervical Carcinogenesis 
 In the early 20th century in the US, it was surmised that malignant disease 
progressed linearly starting from a physiological normal (Croswell, Ransohoff, & 
Kramer, 2010). The linear model of carcinogenesis thus emerged. Based on this theory, 
CxCa developed incrementally through progressive pathobiological phases. Therefore, 
CxCa could be hypothetically eliminated through periodic inspections of the cervix for 
apparent symptomatology however trivial (Croswell, Ransohoff, & Kramer, 2010; Olson, 




health examinations in search for subtle anatomical changes in the uterine cervix 
(Croswell, Ransohoff, & Kramer, 2010). The ASCC, and its descendant organization the 
ACS, adopted authoritative roles in promoting such practices. The development of the 
colposcope in 1924 by Dr. Hans Von Hinselmann produced additional tools to support 
this clinical model (Olson, 1989). The early rationalization of medical screening for 
apparent CxCa thus emerged in the US. 
Mortality From Cancer And Other Malignant Tumors - In The Registration Area Of The 
United States 1914 
 Within the first year of its mandate, in 1914, in its inaugural attempt to generate 
knowledge of cancer, the ASCC collaborated with the Department Of Commerce, United 
States of America, Bureau Of The Census, to produce a detailed registry of deaths 
throughout the US based on estimated population growth; cancer type; patient age 
group; gender; and, State of residence. In the mammoth publication that ensued under 
the directorship of Sam L. Rogers in 1916, entitled Mortality From Cancer And Other 
Malignant Tumors - In The Registration Area Of The United States 1914, death rate statistics 
were organized spanning the years 1900 through 1914 (Department Of Commerce, 
Bureau Of The Census, 1916). From the data published, when comparing figures 
specifically from the terminal-end years of 1900 and 1914; for: (a) the estimated 
population growth; (b) the crude deaths due to all cancer types in women and men; and 
(c) the deaths specifically due to cancer of the ‘female genital organs’, the differences in 





 The trend in the number of deaths due to all cancer types in those 14 years out-
paced estimated US population growth. Meanwhile, the trend in deaths specifically due 
to gynecological cancer out-paced the trends of all cancers combined for the same 
period. 
 As it were, during the first 14 years of the 20th century in the US, CxCa posed an 
anomaly evidently set upon an unnerving, perhaps geometric trajectory. 
 Enigmatic problems like CxCa along with other undesirable human ailments 
formed the bedrock fundamentals of the Eugenics movement in the US. It was during 
World War I, and thereafter, that the Eugenics movement flourished across the nation 
(Davis, 2007). The impact of the Eugenics movement in the US was extensively 
researched in a book, entitled War Against The Weak – Eugenics And America’s Campaign 
To Create A Master Race (2003), by Edwin Black. According to Black (2003): 
“During the war years, eugenic organizations proliferated in America. Like-
minded citizens found ethnic solace and self-vindication in the idea of biological 
superiority. The Race Betterment Foundation was among the leading eugenic 
organizations that sprouted around the country…In 1914, Dr. Kellogg organized 
the First Race Betterment Conference in Battle Creek, Michigan. The conference’s 
purpose was to lay the foundations for the creation of a super race…” 
 Coincidentally, it was also in September 1914 that Dr. George N. Papanicolaou 
took employment at CMC-NY, starting the research work that ultimately led to the 




1973; Chantziantoniou, 20141). The reactive micro-dynamics and the ensuing 
impediments specific to Papanicolaou’s work at CMC-NY are described in subsequent 
sub-sections in this Chapter. 
Cancer In The US And Impact Of The Great Depression 
 The literature likewise revealed that the historical juxtaposition between the 
development of the clinical Pap test and specific events occurring during the Great 
Depression was not coincidental. 
 The Great Depression, spanning a 12-year period from 1929 to 1941, was 
undoubtedly the most challenging period in US history nested economically and 
politically between two major World Wars (Amadeo, 2018). It was during the Great 
Depression that extraordinary shifts emerged in epidemiology and in public health, and, 
consequently in ensuing societal attitudes (Turnock, 2012). These shifts were widely 
impactful, not just within the realms of science and medicine, and public health (Tapia 
Granados & Diez Roux, 2009; Amadeo, 2018). 
 Since the beginning of the 20th century, and throughout the Great Depression, life 
expectancy in the US was gradually increasing in pace with incrementally-efficacious 
treatment for infectious diseases (Armstrong, Conn, & Pinner, 1999). The threat of death 
from cancer eventually surpassed that likely from communicable disease by the time the 
Depression started dissipating in 1941. Cancer usurped all other ailments, becoming the 
foremost public health priority coupled with societal distress; casting a profound sense 




 In 1928, against the backdrop of mounting economical and societal decline, and 
increasing burden due to advanced CxCa, Papanicolaou introduced the vaginal fluid 
smear method (VFSM) as being an effective diagnostic test to detect the disease. 
Conclusions drawn from his research at CMC-NY were reported through a presentation, 
entitled New Cancer Diagnosis, delivered in the 3rd Race Betterment Conference organized 
for eugenicists (Papanicolaou, 1928). As Papanicolaou’s discoveries clashed with then 
standard-of-practice for CxCa detection, his proposals were dismissed by the medical 
community as being clinically unnecessary (Papanicolaou-Kokkori, 2008; Naylor, 1988). 
This setback was highly adverse and most unfortunate throughout Papanicolaou’s 
career, but also for the detection and management of CxCa at the start of the Depression. 
Due to this failure, Papanicolaou ceased working towards refining the diagnosis of CxCa 
through the cytologic method, and this disruption led to the ‘lost decade of 
cytopathology’ (Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017). The 
significance of these events in the overall evolution of the clinical Pap test is detailed in 
subsequent sub-sections in this Chapter. 
 In 1929, as the Depression deepened, Dr. Clarence Cook Little directed the ASCC 
(Davis, 2007). Due to the widespread economic decline, the ASCC faced financial 
difficulties alongside dismal fundraising campaigns and unable to sustain its objective: 
To manage the control of cancer. Nonetheless, the intensifying impact of CxCa in the US 
by 1930 exerted considerable pressure upon the organization to act and to project 




“By then more than 140,000 Americans were dying of cancer each year, and the 
disease had become the nation’s second leading cause of death after heart 
disease. The sobering fact was that more women than men were dying of cancer 
and usually from cancers of the cervix, stomach and breast.” 
Cervical Cancer Burden In The US In The 1930s 
 Knowledge of the incidence and burden of CxCa in the 1930s was mainly 
ascertained retrospectively from cross-referenced information appearing in the more 
recent DC bibliography proper, mainly in publications after 1941. 
 In the 1930s, cervical and uterine cancers in the US caused the highest death 
burden of all cancers in women exerting a heavy societal toll of life-years-lost (Casper & 
Clarke, 1998; Cibas & Ducatman, 2014). Prior to cytologic screening, CxCa was 
conventionally discovered through opportunistic biopsy, as classical symptoms 
secondary to advancing disease (i.e., pelvic pain, abnormal bleeding, and discharge) 
prompted women to seek the care of a gynecologist. Epidemiological and biographical 
research by Olson (1989) revealed that in 1931, CxCa was predominantly seen in poorer 
women during the Depression years. Coupled with unfavorable surgical success rates, a 
key parameter that emerged in the 1930s was time, exemplifying a sense of urgency 
posed by presenting symptoms and the need for prompt medical intervention to 
facilitate relief and treatment. Time became the essence for CxCa control. As well, time 




 By 1931, time was relatable with CxCa cure outcomes. This relationship was 
reflected in 1945 by Meigs, Graham, Fremont-Smith, Janzen, & Nelson (1945): 
“Early, accurate diagnosis of cancer of the female genital tract has long been the 
goal of gynecologists. Ewing states that in 1931, 14,464 women died of cancer of 
the uterus or 12 per cent of all cancer deaths were due to this type…Ewing 
arrived at figures of an average of 10 per cent approximate 5 year cures for 
uterine cancer. He calculated that the possible cure under ideal conditions, i.e., 
intelligent public, skillful and experienced specialists, and modern equipment, 
would be 40 per cent. The discrepancy between the possible rate of cure and of 
actual cure bears a direct relationship to the time at which diagnosis is 
established and treatment instituted.” 
 To simplify the apparent relationship between timely intervention and possible 
cure for CxCa, with extent of disease at time of intervention, Meigs, Graham, Fremont-
Smith, Kapnick, & Rawson (1943) stated: 
“Cancer of the cervix and body of the uterus is a curable condition. Early 
diagnosis and treatment are prerequisites for cure…Approximately the same 
statement is given for carcinoma of the cervix by Todd who reports that from the 
onset of abnormal bleeding the chance of cure decreases 3.24 per cent a week. 
The average time from the onset of symptoms to operation is stated to be 7.5 
months. Eleven of a hundred women with cancer of the cervix reach the surgeon 




60 are totally inoperable when treatment is begun…Delay is thus responsible for 
a majority of deaths from cervical cancer, a delay to which both patient and 
physician contribute.” 
 An understanding of the shared contributions and impact of advanced CxCa at 
presentation and diagnosis in the 1930s, and how this disease tormented patients and 
clinicians alike, is herein relevant. But given the aims of this dissertation, these 
associations ought to be viewed from broader perspectives to reveal their influence 
throughout the wider dimensions of societal medicine. These perspectives included yet 
another parameter: The extent of disease at presentation. According to Davis (2007): 
“By the time its physical tracks could be felt, the illness had often been brewing 
for more than a decade. The warning signs of bleeding, shortness of breath and 
pain – then touted as the indications of cancer – were not at all clear in the 
disease’s early stages. After all, women have been bleeding, sometimes 
uncomfortably, for as long as the species has existed. By the time the strange 
discharges, unstoppable cramps, and relentless full-belly feeling were evident, 
the cancer was unstoppable.” 
 The evolution of gynecological DC was thus inextricable from two enduring 
parameters: Time and Bleeding. The clinical significance of these factors became 
gradually apparent alongside incremental scientific advancements that led, ultimately, 
to an understanding of the disease’s natural progression and pathobiology, and how 




that the association of HPV in cervical carcinogenesis was not known until 1978 
(Syrjanen, 2017). In the 1930s, the importance of Time and Bleeding likewise stemmed 
from greater historical and societal situations. Abundant scientific and lay literature 
substantiated the revolutionary advances that characterized the 20th century in North 
America and elsewhere. In the US particularly, significant technological innovations 
rapidly transformed medicine and the methods applied to diagnose and treat disease 
against a backdrop of unprecedented scientific, political, and socio-economical changes. 
 Amid these dynamics, the extent of public knowledge of the classical symptoms 
of CxCa became another important variable in an effort to discover cancer as early as 
possible. The ASCC took these challenges seriously in order to defend the touted 
urgency for timely disease detection. For the ASCC, sufficient public literacy became a 
governing organizational objective. 
 The health literacy campaigns developed in the US to disseminate knowledge of 
cancer and of its symptoms were researched in a book, entitled Early Detection – Women, 
Cancer, And Awareness Campaigns In The Twentieth-Century United States (2006), by 
Kirsten E. Gardner. 
The Women’s Field Army 
 In an effort to deliver on the expectations posed upon the ASCC, Dr. Clarence C. 
Little considered an unprecedented idea in 1933. He wanted to disseminate knowledge 
of cancer to the general public to gain its allegiance in the effort to discover the disease 




Federation seeking assistance. Dr. Marjorie B. Illig, a radiologist, was the serving Chair 
of the Federation’s Public Health Division. Little’s proposal to her was the formation 
and mobilization of a women’s group to spread knowledge of cancer (Gardner, 2006; 
Davis, 2007). 
 The General Women’s Federation was then active in spreading public health 
information throughout the US. The organization encouraged its members to educate 
the public of medical services still available throughout the Depression years, but to also 
protest the ongoing budget cuts to healthcare (Gardner, 2006). 
 Little’s proposal gained Illig’s support and materialized in 1936. It led to a robust 
public health awareness expedition: The Women’s Field Army (WFA) (American Cancer 
Society, 20172). The women’s movement adopted para-military hierarchies and marched 
strategically under the motto: ‘Cancer Thrives On Ignorance. Fight It With Knowledge’. 
According to Davis (2007): 
“At its peak the army numbered over 2 million. Set up as the ASCC’s public 
education arm and fielding battalions in every State, WFA members marched 
door-to-door collecting money and handing out pamphlets. They organized 
public events…to raise money and generally spread the word about cancer…”  
 Dr. Illig supported the WFA given her professional experiences and convictions 




“As a radiologist, she had seen dozens of young women whose x-rays revealed 
abdomens riddled with spreading white blotches of disease. Illig explained to 
her colleagues at the federation that doctors could identify subtle abnormalities 
of the cervix long before cancer showed up on x-rays. Women’s lives could be 
saved if they would show up for regular physical exams. The suggestion that 
early detection could prevent deaths provided a radical and hopeful solution for 
a problem that had come to be fatalistically accepted. If women could be 
mobilized against this devastating disease, the world would be better off.” 
 The WFA was established in the mid-west States by 1937 (Gardner, 2006). Based 
in Cedar Rapids, the Iowa WFA phalanx organized various projects relying on the 
prominence of Dr. Arthur Wright Erskine, a local physician. Collaborating with Erskine, 
the Iowa WFA produced various educational materials for dissemination throughout the 
mid-west States. As radio was the mainstay technology by which to reach the public 
widely, their initiatives included live broadcasts in an effort to reach households 
dispersed throughout the rural farming landscapes. And it was through these initiatives 
that Erskine uncovered another impediment to the timely detection of CxCa: The 
geographic vastness of the mid-west US, and the varied urban and rural population 
clustering throughout the heartland States. According to Gardner (2006): 
“The Iowa WFA, female activists, and Erskine expressed concern about teaching 
female cancer awareness in rural areas, with scattered populations of women. 




perhaps psychological conditions in our state, and in other rural states” that 
might interfere with early detection efforts. Iowa cancer activists recognized that 
many people would not want to travel to remote urban cancer centers for 
treatment: “They get homesick and discouraged and abandon treatment before 
they should. In practice, therefore, the great majority of patients with cancer 
must now, and for some time to come, be treated in or near their communities. 
We must do the best we can with what we have.” Through the medical lens, 
Erskine realized that local treatment facilities might be inferior to centralized, 
better-equipped urban centers, but he also considered the unique behavioral 
tendencies of his target population. Less superior treatment was better than no 
treatment.” 
 Nevertheless, with increased public awareness of cancer because of the WFA, 
with expanded organizational exposure, and with the imperative to fight the disease as 
early as possible, the ASCC faced potent public relations predicaments. Davis (2007) 
stated: 
“Folks began to believe the claim that early detection was the key to treating the 
disease, but such claims raised serious questions. Why were cancer rates 
increasing when more people were seeing their doctors sooner? Why was so little 
real progress being made against finding and treating the disease? Why were 
more and more women dying of cervical cancer? Significant numbers were 




The National Cancer Act Of 1937 
 Despite the expanded general awareness of cancer, the worsening patterns 
between population growth and mortality trends due to cancer became profoundly 
alarming throughout the late-1930s. 
 In response, US Congress was compelled to enact the National Cancer Act of 
1937 (Holleb, 1988; National Cancer Institute, 2016). The Act, signed into law by 
President Franklin D. Roosevelt, created the National Cancer Institute (NCI) from an 
allocation of $750,000 accompanied by ambitious aims during a period in US history 
marked by devastating economic and societal setbacks. The NCI became the foremost 
research organization in the US Public Health Service (Habbema, De Kok, & Brown, 
2012). Amongst the initial mandates of the NCI was the redistribution of an additional 
$700,000 in the form of research grants cascaded to scientists through affiliated 
governmental organizations (Holleb, 1988; National Cancer Institute, 2016). The 
underlying intent of the Act was to stimulate research and development and training, to 
unravel the causes of cancer, its diagnosis, its effective treatment, and eradication. 
 The National Cancer Act of 1937 was enacted in the depths of the Great 
Depression (Amadeo, 2018). The Act therefore symbolized a stark paradox between the 
magnitude of the public health urgency posed by increasing burdens of cancer, and the 
funding seemingly necessary to rein in this plight upon humanity during the severest 




 In 1939, following a change in prospects at CMC-NY, the ‘lost decade’ of DC 
ended. Papanicolaou was then encouraged to revive his work on CxCa working in 
collaboration with Dr. Herbert F. Traut, a gynecological oncologist at CMC-NY. 
 By 1941, as the Depression ended, Papanicolaou and Traut had transformed the 
previously-dismissed VFSM from a diagnostic test into a screening test accompanied by an 
awareness of its secondary disease-prevention potential (Papanicolaou & Traut, 1941). 
However, the method’s resurrection and transformation through to the clinical Pap test 
in 1948 occurred following specific events stemming, in large part, from the National 
Cancer Act of 1937, and bold advocacy demonstrated by the ACS. These events are 
detailed in dedicated subsequent sub-sections in this Chapter. 
 What facilitated this shift in prospects was primarily the urgency posed by 
increasing deaths due to CxCa and, secondarily, by the conceptualization of cervical 
precancer arising from Papanicolaou’s and Traut’s work in 1941. As such, another 
worrisome paradox began to emerge for the ASCC that contrasted increasing deaths due 
to invasive CxCa with the possible cures for precancer through VFSM detection. 
However, the screening test remained under scrutiny; notably, it lacked a characteristic, 
unambiguous diagnostic nomenclature to allow alignment with the diagnostic language 
of anatomical pathology. But perhaps more importantly in 1941, the VFSM lacked 
widespread consensus as to what would be its true role in the burgeoning medicine of 




 Despite the imperfections, the cytologic method offered promising clinical 
advantages at a most opportune time. The VFSM offered an alternative by which to 
detect and ablate precancerous lesions through timely intervention; an alternative that 
may arrest the natural biology of the disease towards invasive cancer. Papanicolaou’s 
simple procedure thus offered far-reaching clinical benefits, not merely the detection of 
advanced disease through vaginal secretion analysis. The cytologic method lessened the 
detriments of time, the urgency due to presenting symptoms, and the grave 
consequences typical of delayed surgery. This alternative appealed to gynecologists 
facing the sensitivities and therapeutic challenges of advanced, oftentimes inoperable 
CxCa in their patients in the early-1940s. 
 Against a background of escalating enthusiasm in gynecological DC, 
Papanicolaou and Traut’s monograph, entitled Diagnosis Of Uterine Cancer By The Vaginal 
Smear (1943), published by The Commonwealth Fund, became a cornerstone for the 
subsequent events that led towards the establishment of the clinical Pap test 
(Papanicolaou & Traut, 1943). Their monograph formed the catalyst for ongoing 
technical and procedural advancements, but also for the realization of population-based 
cytologic screening for cervical precancer in asymptomatic women (Boon & 
Chantziantoniou, 2013). 
Rebranding Of The American Society For The Control Of Cancer Into The American 
Cancer Society 
 One year after Papanicolaou and Traut’s epic monograph in 1943, the ASCC was 




Society in 1944 because of the initiatives commanded by Mrs. Mary Woodard Lasker, 
and of her convictions and political influence. 
 Mary W. Lasker was a wealthy, prominent philanthropist dismayed by the lack 
of progress in research and apparent inaction by the ASCC to address the growing 
threat of cancer. Noting the ASCC’s limited cash flow and chronic inability to uphold its 
mission, she actively raised $4 million for the organization demanding, in return, major 
restructuring of its constitution (Holleb, 1988). 
 Mary Lasker transformed the ASCC into an authoritative, agile organization 
supported by astonishing financial leverage during the depths of World War II. She thus 
became an influential member on the ACS Board. Following her command, ACS 
policymakers espoused funding for cancer research as so dictated by Mary Lasker: That, 
“…out of every $4 raised the organization would spend $1 on research” (Davis, 2007; 
American Cancer Society, 20172). 
 Due to Mary Lasker’s enterprises the ASCC reemerged in 1944 as the 
emboldened ACS, poised to tackle the mounting problem of ineffective cancer control in 
the US. The re-profiling of the ASCC coincided favorably with Papanicolaou’s work at 
CMC-NY and with the ongoing developments in the cytologic methods (Hinsey, 1962). 
It was following these specific dynamics that barriers impeding the acceptance and use 
of the VFSM started to weaken following the extensive research work in DC funded by 




a staunch supporter of Papanicolaou’s work (Hinsey, 1962; Koss, 1993; Papanicolaou-
Kokkori, 2008). 
 Amid growing interest in the VFSM in 1945, the ACS was compelled to review its 
public awareness and advocacy policies to assess organizational alignment with the 
rapidly changing societal and medical developments in the US as World War II ended. 
Its Board then deemed the WFA as being utterly unfitting in a post-war period. Being a 
quasi-military operation predominantly made up of amateurs and activists with little 
formal education in medicine or cancer, the ACS Board decided the WFA be disbanded 
to mitigate likely bruising public relations quandaries (Davis, 2007). 
 Alternatively, in 1946, to disseminate scientific knowledge formally, the ACS 
inaugurated its intramural program for epidemiological research responding to a 5-fold 
increase in lung cancer in the US during the Great Depression years (Thun, Calle, 
Rodriguez, & Wingo, 2000). The intramural program was designed to track cancer 
incidence trends, risk factors, screening methods, and treatment statistics. However, it 
was not until 1952, and henceforth, that the ACS published Cancer Facts And Figures 
annually to include data for CxCa (Thun, Calle, Rodriguez, & Wingo, 2000). 
 The timing of the ACS’s Cancer Facts And Figures for CxCa in 1952 was not 
immaterial. It followed two significant events in the evolutionary timeline of the clinical 
Pap test, both occurring in 1951: The death of Mrs. Henrietta Lacks to CxCa; and, 




Tennessee, trial sponsored by the NCI - a direct consequence of the National Cancer Act 
of 1937. 
Death Of Henrietta Lacks To Cervical Cancer: The HeLa Cell Line 
 The story of Henrietta Lacks was detailed in a remarkable book, entitled The 
Immortal Life Of Henrietta Lacks (2010), by Rebecca Skloot. 
 Henrietta Lacks was an African-American woman that died from advanced 
CxCa at Johns Hopkins Hospital, Baltimore, on October 4, 1951. Although her clinical 
course may have been similar to that of other women dying of CxCa at that time, her 
case proved extraordinary and scientifically significant. 
 Henrietta Lacks had noticed abnormal vaginal bleeding, and self-felt a nodule in 
her uterine cervix. Appropriately, upon visual inspection, her local physician noted the 
nodule but suspected it was syphilitic. When Henrietta’s tests returned negative for 
syphilis, she was led to a gynecologist at the Johns Hopkins Hospital. A cervical biopsy 
confirmed she had infiltrating squamous CxCa (Skloot, 2010). However, her cancer 
proved highly malignant and was widely extensive at diagnosis. Henrietta Lacks, a 
young mother of five children, succumbed to CxCa 31 years old. 
 Skloot (2010) described Henrietta Lacks’ suffering in vivid detail. In the context 
of this dissertation, her book also manifested the attitudes and bleak realities of 
advanced CxCa prevailing in the early-1950s. According to Skloot (2010): 
“…Henrietta told her doctors several times that she thought the cancer was 




wrong with her. “The patient states that she feels fairly well,” one doctor wrote 
in her chart, “however she continues to complain of some vague lower 
abdominal discomfort…No evidence of recurrence. Return in one month.” 
There’s no indication that Henrietta questioned him; like most patients in the 
1950s, she deferred to anything her doctors said. This was a time when 
“benevolent deception” was a common practice – doctors often withheld even 
the most fundamental information from their patients, sometimes not giving 
them any diagnosis at all. They believed it was best not to confuse or upset 
patients with frightening terms they might not understand, like cancer. Doctors 
knew best, and most patients didn’t question that…Especially black patients in 
public wards.” 
 The case of Henrietta Lacks altered the history of medicine as malignant cells 
from her cervix were removed just months before her death without her knowledge or 
permission. This was done to salvage cells for cancer research based on cell cultures. 
Unlike other cell cultures of malignant cells that follow finite cell division cycles, 
Henrietta Lacks’ cells continue dividing in vitro through to this day. They are 
biologically immortal. Her cells are otherwise scientifically known as: The HeLa cell line. 
Her CxCa cells have facilitated revolutionary advancements in vaccine development, 
virology, oncology, and chemotherapy due to their immortality allowing research to be 
conducted and repeatedly validated. Nonetheless, along with the infamous Tuskegee 




establishment of the Discipline of Medical Ethics, and its ramifications in the conduct of 
modern medical research globally (Skloot, 2010). 
 The overall impact of CxCa in 1951 in the US, with a glimpse of the impediments 
to Pap test uptakes, was also alluded to by Skloot (2010): 
“At that point, more than 15,000 women were dying each year from cervical 
cancer. The Pap smear had the potential to decrease that rate by 70 percent or 
more, but there were two things standing in its way: first, many women – like 
Henrietta – simply didn’t get the test; and, second, even when they did, few 
doctors knew how to interpret the results accurately, because they didn’t know 
what the various stages of cervical cancer looked like under the microscope. 
Some mistook cervical infections for cancer and removed a woman’s entire 
reproductive tract when all she needed was antibiotics. Others mistook 
malignant changes for infection, sending women home with antibiotics only to 
have them return later, dying from metastasized cancer. And even when doctors 
correctly diagnosed precancerous changes, they often didn’t know how those 
changes should be treated.” 
 Dr. Richard Wesley TeLinde was a gynecological surgeon amongst the medical 
team attending to Henrietta Lacks at Johns Hopkins Hospital. He was then actively 
involved in the US-wide debate of: “What qualified as cervical cancer, and how best to 




of CxCa, the following narrative embodied the state of gynecological healthcare in the 
US in the early-1950s (Skloot, 2010): 
“In 1951, most doctors in the field believed that invasive carcinoma was deadly, 
and carcinoma in situ wasn’t. So they treated the invasive type aggressively but 
generally didn’t worry about carcinoma in situ because they thought it couldn’t 
spread. TeLinde disagreed – he believed carcinoma in situ was simply an early 
stage of invasive carcinoma that, if left untreated, eventually became deadly. So 
he treated it aggressively, often removing the cervix, uterus, and most of the 
vagina. He argued that this would drastically reduce cervical cancer deaths, but 
his critics called it extreme and unnecessary…TeLinde presented his argument 
about carcinoma in situ to a major meeting of pathologists in Washington, D.C., 
and the audience heckled him off the stage.” 
The Memphis And Shelby County, Tennessee, Trial For Cervical Carcinoma In Situ 
 The Memphis and Shelby County, Tennessee, clinical trial was launched in 1951 
to test the VFSM’s potential to identify carcinoma in situ (CIS) in asymptomatic women, 
and to distinguish this lesion from invasive CxCa in symptomatic women (Dunn & 
Sprunt, 1955). The study was among the first population-based trials in the history of 
gynecological DC to assess a screening test, not a diagnostic test. The trial was authorized 
and funded by the NCI and produced promising results in favor of VFSM-based 




County trial produced important epidemiological data reflecting that local, clinical 
population. 
 The Memphis and Shelby County trial was furthermore significant as it 
considered societal attitudes, professional attitudes, and the deployment of a non-
medical workforce to analyze the arising volumes of smears, instead of pathologists who 
only reviewed abnormal smears brought to their attention. As such, the Memphis and 
Shelby County trial tested and introduced a model by which to analyze and report 
VFSM cases for the detection of cervical precancer. 
 The Memphis trial had four objectives (Dunn & Sprunt, 1955): “(1) To determine 
whether periodic vaginal exfoliative cytology as a screening procedure can be used to 
diagnose cancer in the preinvasive stage; (2) To accumulate data for determining age-
specific incidence and prevalence rates for both preinvasive and invasive cervical cancer; 
(3) To estimate the frequency with which vaginal cytology needs to be applied to be 
effective as a case-finding procedure; and (4) To determine whether, through this case-
finding procedure, cervical cancer can become largely a curable disease.” 
 Dunn and Sprunt (1955) emphasized that, in this trial, “cytology is used for 
screening; it is not competing with the tissue study for relative accuracy in final 
diagnosis.” Controversy and suspected professional encroachment between DC and 
cervical biopsy were pervasive in 1951. And these conflicts became increasingly more 
acute alongside the growing volumes of cervical smears generated through screening, 




 Nevertheless, the Memphis and Shelby County trial also revealed gaps in public 
literacy despite the extensive awareness campaigns conducted by the ACS, by its 
predecessor the ASCC since 1913, and by the robust WFA. According to Dunn and 
Sprunt (1955): 
“It soon became evident that the public was not overly conscious of cancer as a 
personal problem, and that more aggressive educational measures were needed. 
Yet it was necessary that publicity should not antagonize practicing physicians 
since their cooperation is a necessary part of the project… 
Any apprehension about the public’s over-consciousness of cancer has been 
completely dispelled. Enlightenment and motivation have become the leitmotivs 
of the publicity program in the effort to reach women individually through every 
possible medium, until they accept the fact that they can have cervical cancer, 
and that the cytology examination is a means of detecting this cancer in a curable 
stage.” 
 The political push-back exerted upon the cytologic method and its alleged 
potential to detect cervical precancer in the early-1950s, were also manifested through 
the Memphis trial. According to Dunn and Sprunt (1955): 
“In a few instances, skeptics have put the cytology program to the test by 
submitting specimens from known or clinically obvious cases. There are no 





The American Cancer Society At 75: Despair To Hopefulness, And Cancer Prevention 
 By 1988, the ACS had undergone a notable metamorphosis since its simple 
beginnings. Commenting upon the significant organizational changes since 1913, the 
Senior Vice President for Medical Affairs at the ACS, Dr. Arthur I. Holleb (1988) stated: 
“From this vantage point we can say we have had a good 75 years at the wheel of 
change:…Change in the way that cancer is understood by the medical profession 
and the public as a group of more than 100 diseases, a growing number of which 
are now clearly curable. Change in the focus of the patient from despair to 
hopefulness for increased length of life and improved quality of life. And change 
to the idea that cancer prevention, at home and in the workplace, is an achievable 
goal for a broad spectrum of the population.” 
The American Cancer Society At 100: Increasing Life Expectancy In The US, And Burden 
Of Cervical Cancer 
 In 2013, as the ACS celebrated its centennial, reflecting upon lingering 
epidemiological realities, Stobbe (2013) commented in the Daily Herald (New York): 
“Back in 1913 when it [the ACS] was formed, cancer was a lesser threat for most 
Americans. The biggest killers then were flu, pneumonia, tuberculosis, and 
stomach bugs. At the time when average life expectancy was 47, few lived long 
enough to get cancer...Cancer became the nation’s no. 2 killer in 1938, a ranking it 




 The above excerpt from the feature article by Stobbe (2013) was predated 
through more explicit epidemiological detail by Dr. Charles S. Cameron, the serving 
Medical and Scientific Director of the ACS in 1956. Cameron stated (1956): 
“In certain countries – especially the United States – cancer seems to be getting 
more prevalent, but the amount of its increase approximately parallels the 
lengthening span of life in those countries. In 1900, the death-rate from cancer in 
the United States was 64 per 100,000; a baby boy could expect to live to be 48 
years old and a baby girl could anticipate 51 years of life. Today, the life 
expectancy of males is 68 years, and of women 72 years. But these added years 
have not been won without paying a price – for the cancer death rate in U.S.A. is 
now 147 per 100,000.” 
 Dr. Cameron’s speculations sustained their legitimacy since 1956. Pertaining 
specifically to CxCa deaths in the US for the period spanning 1999 through to 2015, the 
Centers for Disease Control and Prevention (CDC) validated Cameron’s deductions by 
declaring (Centers for Disease Control and Prevention, 2017): 
“While rates of cancer diagnoses and cancer deaths continue to decline each year, 
the number of new cases and deaths are going up. This happens because the size 
of our population is growing and aging each year.” 
 To conclude this account of macro-dynamics and arising impediments, despite 
efficacious screening systems deployed to identify cervical precancerous lesions and 




proportionately with global population growth. In addition, the global discipline of 
CxCa control may be vulnerable to societal, economic, political, and epidemiological 
changes. 
Impediments To The Development Of The Clinical Pap Test Arising From 
Historical Micro-Dynamics 
 In large part, the development of the clinical Pap test was a derivative of 
inevitable, impactful public health and historical macro-dynamics that orbited around 
the realm of DC in the first half of the 20th century in the US in the context of CxCa. The 
reactive discipline-specific micro-dynamics that impacted from within the realm of DC 
were substantially more complex, but equally important. They in turn led to various 
impediments related to Papanicolaou’s aspirations, his work, his professional 
qualifications, and the conflicts that ensued following the introduction of the VFSM and 
its proposed deployment in clinical screening service. Micro-dynamics also emerged due 
to specific individuals that nonetheless played significant roles; either by contributing 
towards the developmental evolution of the clinical Pap test, or by obstructing it. 
Dr. George N. Papanicolaou: PhD Research, Employment At Cornell Medical College, 
New York 
 Relevant to DC and the assessment of cellular morphology through microscopy, 
Papanicolaou’s graduate studies proved exceptionally important. 
 George N. Papanicolaou was born on May 13, 1883, in Kymi, Greece. His father, 




1973). Although George’s early study interests were philosophy and the violin, he 
abided by his father’s wishes and enrolled into medical school at the University of 
Athens in 1898. In 1904, he graduated with honors at the age of 21. His knowledge of 
anatomy, clinical symptoms, and disease proved invaluable throughout his career at 
CMC-NY. These foundations assured the contentious concepts he introduced and 
crafted in DC were credible, and not clinically irrelevant (Carmichael, 1973; Boon & 
Chantziantoniou, 2013; Chantziantoniou, 20141). 
 Nonetheless, Papanicolaou remained uninterested in practicing medicine and 
eventually refused to work as such in the family clinic in Kymi (Papanicolaou-Kokkori, 
2008). Instead, he painfully gained his father’s support to pursue PhD studies in 
Germany to study philosophy and the biological sciences (Carmichael, 1973; Boon & 
Chantziantoniou, 2013; Chantziantoniou, 20141). In the first decade of the 20th century, 
the role of chromosomes in Mendelian genetics and the fundamentals of Darwinian 
biology for trait inheritance were the prominent subject matters for research and study. 
These sciences were irresistible for Papanicolaou. These sciences were also the pillars of 
Eugenics ideology (Black, 2003). 
 In the spring of 1907, Papanicolaou attended studies at the University of Jena, in 
Germany, under the renowned Ernst Haeckel. Within his first semester he doubted the 
suitability of his program. He thereafter relocated to Freiburg, Germany, to study under 
the mentorship of August Weisman. But after another six months he was convinced that 




Professor Richard Hertwig. The Zoological Institute of Munich was then regarded the 
eminent academic center for biological and zoological research (Carmichael, 1973; 
Papanicolaou-Kokkori, 2008). 
 One activity assigned to Papanicolaou’s initial studies at the Institute was 
termed: “Fertility day”. During such studies, he and his classmates observed the process 
of fertilization and cell division in sea urchin cells under the microscope. These 
phenomena were enthralling and proved life-changing for Papanicolaou. It was then he 
chose to devote his life to biological research and not to the service of medicine per se 
(Papanicolaou-Kokkori, 2008). Papanicolaou was assigned the doctorate research topic 
of differentiation and determination of sex in Daphnides. 
 Shortly after obtaining his PhD degree in 1910, Papanicolaou returned to Kymi. 
There he struggled between his personal desire to pursue biological research and his 
father’s pleas he practice medicine in Kymi to promote the family clinic. Papanicolaou 
stood adamant against this proposition. On September 15, 1910, he married 
Andromache Mavroyeni, the daughter of a prominent military official in Greece, and the 
couple journeyed immediately to France in pursuit of suitable employment 
opportunities (Chantziantoniou, 20143). Fortuitously between 1911 and 1912 
Papanicolaou worked as a marine zoologist at the Oceanographic Museum in Monaco, 
and accompanied Prince Albert I of Monaco on Mediterranean expeditions to classify 
marine species. After the death of his mother, Papanicolaou and Andromache returned 




support in the Balkan War in 1912 (Papanicolaou-Kokkori, 2008; Boon & 
Chantziantoniou, 2013). 
 During his Balkan War service Papanicolaou befriended Greek-American 
volunteers that spoke to him of the promise of opportunity in the far off land of the US. 
These acquaintances convinced Papanicolaou that what he longed for was to pursue 
biological research in the United States of America; a new life, and the opportunity to 
achieve what it was that he was destined for (Boon & Chantziantoniou, 2013; 
Chantziantoniou, 20142). Despite opposition from their respective families, on October 
19, 1913, Dr. George N. Papanicolaou and his wife, Andromache, landed in New York, 
and registered as newly-arriving immigrants to the US. Papanicolaou was then 30 years 
old (Carmichael, 1973; Papanicolaou-Kokkori, 2008). 
 Coincidentally, it was also in 1913 that the ASCC was established in response to 
the growing problem of CxCa in the US. 
 Soon after their arrival to New York, Dr. Papanicolaou and Andromache faced 
inevitable problems, and the need for employment became imperative. Shortly 
thereafter Papanicolaou met with the distinguished zoologist and Nobel Laureate at 
Columbia University, Dr. Thomas Hunt Morgan, seeking his advice. In 1913, Morgan 
had published a book, entitled Heredity And Sex, in which he incorporated data from 
Papanicolaou’s PhD thesis (Carmichael, 1973; Chantziantoniou, 20141). This coincidence 




Elser, of the Department of Pathology and Bacteriology, at the New York Hospital. Elser 
promptly hired Papanicolaou as part-time laboratory technician (Koss, 2000). 
 Noting Papanicolaou’s skills and passion for biological research, Elser brought 
Papanicolaou to the attention of Dr. Charles Rupert Stockard at CMC-NY for possible 
employment in a formal research setting. Stockard hired Papanicolaou as Instructor of 
Anatomy in September 1914. Andromache Papanicolaou was thereafter permitted to 
volunteer as laboratory assistant alongside her husband to manage the technical work 
arising from his research starting in November 1914 (Carmichael, 1973; 
Chantziantoniou, 20141). 
 It was also in 1914 that “negative eugenics” practices prevailed across the US to 
address undesirable human diseases such as CxCa; a disease perceived to be associated 
with societal immorality; and, one likely genetically transmissible (Black, 2003). 
Development Of The Experimental Vaginal Fluid Smear Method In Lower Mammals 
(1915-1920) 
 When Papanicolaou joined CMC-NY in 1914, Stockard was researching the 
genetic transmission of acquired chromosomal aberrations to Guinea pig progeny. 
Chromosomal impairments were induced in Guinea pigs through exposure to alcohol 
vapors. Laboratory animals were bred in controlled studies to assess the inheritance of 
alcohol-induced chromosomal damage against the resulting congenital anomalies 
(Carmichael, 1973). Given the large colony of experimental Guinea pigs at CMC-NY, 




through X and Y chromosome analysis. Both Stockard’s and Papanicolaou’s research 
was mutually dependent on chromosomal analysis in mitotically-active cells in Guinea 
pig ovaries at ovulation (Koss, 2000). 
 Papanicolaou had to surgically harvest ovaries precisely at ovulation. As the time 
of ovulation was unapparent, an excessive number of laboratory animals were sacrificed 
without scientific advantage. Papanicolaou considered that these mammals 
menstruated, although feebly. He also considered if vaginal secretions, however 
miniscule, may perhaps reveal clues to help him pinpoint time of ovulation. To acquire 
vaginal fluids, he obtained a nasal speculum and, using a pipette, blindly collected 
vaginal fluids from animals every day over a course of months. Fluids were smeared 
onto glass slides, air-dried, stained with Hematoxylin and Eosin (H&E), and 
microscopically examined for repeating cellular characteristics (Chantziantoniou, 
Donnelly, Mukherjee, Boon, & Austin, 2017). 
 Using this simple method Papanicolaou observed epithelial cell alterations that 
reflected cyclical ovarian and hormonal physiology. Based on their observations, 
Stockard and Papanicolaou defined the Guinea pig oestrous cycle and revealed time of 
ovulation precisely. These findings were published in an obscure 3-page report in 
Science in 1917 (Stockard & Papanicolaou, 19171). Concerned that the scientific 
significance of their research may not be represented by 3 pages, Papanicolaou 
republished their data in greater detail also in 1917 in the American Journal Of Anatomy 




cell cytomorphology with ovarian and uterine histology, and introduced terms and 
concepts that transcended into modern DC practice (Boon & Chantziantoniou, 2013; 
Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017; Chantziantoniou, 2017). 
Transformation Of The Experimental Vaginal Fluid Smear Method Into The Clinical 
VFSM In Women (1920-1948) 
 In 1920, being also a trained physician, Papanicolaou questioned whether the 
epithelial cell changes noted in the Guinea pig experimental model may possibly occur 
in the human model. However, not being a licensed clinician in New York, he had no 
access to women to test this curiosity. It was in 1920 that he started applying the very 
same method on Andromache. He collected a sample daily and analyzed the epithelial 
cells in her vaginal secretions. This practice lasted 21 years, till 1941, from which exercise 
Papanicolaou perfected the Pap stain method (Chantziantoniou, Donnelly, Mukherjee, 
Boon, & Austin, 2017). It was from Andromache’s cells that baseline ‘typical’ 
gynecological cytomorphology was established, forming the contrast against the 
morphology of ‘atypical’, malignant cells arising from CxCa (Boon & Chantziantoniou, 
2013). 
 In 1925, Papanicolaou started analyzing vaginal fluids collected from other 
women in the New York Hospital under a special professional arrangement. Some of 
those women were being followed for cervical pathology. As such, in 1925, he 
encountered malignant cells arising from CxCa. These encounters sparked a new 
chapter in Papanicolaou’s career that ultimately led to the development of the clinical 




 With gained confidence in the cytologic method and in his abilities to identify 
malignant cells exfoliated from CxCa, Papanicolaou embarked on a journey in 1928 to 
propose the clinical VFSM as being an effective diagnostic test to confirm cervical cancer 
through a presentation, entitled New Cancer Diagnosis (Papanicolaou, 1928). His 
discoveries were utterly disregarded by the medical community accompanied by overt 
resistance even hostility (Papanicolaou-Kokkori, 2008; Naylor, 1988). The notion that the 
VFSM could become an alternative to cervical biopsy was sharply contested by his 
peers. According to Davis (2007): 
“…in the 1930s, the medical world was not moved by Papanicolaou’s work, and 
women, black and white, continued to die at alarming rates.” 
 After the dismissal of the clinical VFSM following Papanicolaou’s New Cancer 
Diagnosis presentation, he scaled back his research work on CxCa succumbing to a sense 
of failure, and to what he feared the most in life: Embarrassment and professional 
ridicule (Koss, 1973; Papanicolaou-Kokkori, 2008). Papanicolaou attributed his failure to 
the poor staining of malignant cells that simply did not impress pathologists (Casper & 
Clarke, 1998). This belief sparked a campaign for Papanicolaou to perfect a stain for 
CxCa cells that lasted until just before his death in 1962 (Chantziantoniou, Donnelly, 
Mukherjee, Boon, & Austin, 2017). 
 However, his 1928 presentation was also perceived as being inspired by the then 
raging negative Eugenics movement in the US (Casper & Clarke, 1998; Austin & 




nuances of Eugenics ideology in the lay press was incongruent with the importance of 
the revolutionary work that ultimately established gynecological DC (Chantziantoniou, 
20141). 
 The clinical VFSM was evidently perceived as being a method through which to 
identify and weed-out cancer patients for the generation of a well-bred elite race; one 
immune to cancer, presumably leading to societal betterment (Carmichael, 1973; Casper 
& Clarke, 1998). Papanicolaou’s presentation was delivered in the 3rd Race Betterment 
Conference in Battle Creek Michigan, on January 4, 1928 (Cameron, 1962). That 
conference was a conclave of “negative” eugenicists envisioning population control 
through human sterilization and other tactics. It was not a formal medical meeting to 
address the mounting challenges posed by a worrisome malignancy in women 
(Papanicolaou, 1928; Casper & Clarke, 1998; Black, 2003; Austin & Chantziantoniou, 
2014). 
 Four days after Papanicolaou’s 1928 Battle Creek presentation, an article 
appeared in the Buffalo Evening News on January 8, 1928, by Watson Davis, entitled 
Cancer Diagnosing System Discovered (Chantziantoniou, 20142). Davis stated (Davis, 1928): 
“The discovery was made as a byproduct of fundamental work on the nature of 
sex in women, following successful investigations of the sexual cycle of guinea 
pigs and other animals, the same method of research were applied to women in 




human race just as soon as they are developed and taboos are overcome to allow 
their application.” 
 Davis’ article manifested Eugenics undertones and alluded to “taboos” or to 
prohibitions pertaining to the acceptance and application of the VFSM. 
 In 1928, Papanicolaou’s chairman, Dr. Charles R. Stockard, was an active and 
prominent participant in the Eugenics campaign through his teachings and research at 
CMC-NY (Casper & Clarke, 1998). Likewise, the director of the ASCC in 1929, Dr. 
Clarence C. Little pioneered research in targeted breeding and genetic experiments in 
laboratory mice at Harvard University. Little proposed that the experience arising from 
the experimental mouse model may also be applied to humans. He participated in the 
Eugenics movement in the US, and although immigration laws then protected the 
“American gene pool from defectives, he urged sterilization of the mentally and 
criminally deficient” (Davis, 2007). 
 Another prominent eugenicist in the US was the zoologist, Dr. Charles Benedict 
Davenport, a Harvard graduate (Black, 2003). The core mantra of the eugenicists was the 
control of human defects thus the menace they posed upon society; and, therefore, 
protection of the purity of American society. According to Black (2003): 
“Several principle areas of scholarly investigation were identified from the 
worthy realms of geophysics, astronomy and plant biology. Now another 
scientific endeavor would be added: negative eugenics. The program would 




plasm” and would embrace a gamut of remedies from segregation to sterilization 
to euthanasia. The radical human engineering program would sprint not from 
the medical schools and health clinics of America, but from the pastures, barns 
and chicken coops – because the advocates of eugenics were primarily plant and 
animal breeders.” 
 Therefore, any relationship perceived between Davenport, a zoologist and 
prominent eugenicist, and Papanicolaou, a former zoologist researching sex 
differentiation in Guinea pig breeding experiments at CMC-NY, could easily cloud the 
scientific significance of the VFSM, or its relevance in diagnostic medicine and CxCa 
management. 
 During the ‘lost decade’ that followed his 1928 Battle Creek presentation, 
Papanicolaou experimented with staining techniques and developed medical 
procedures and hormonal cytopathology in collaboration with Dr. Ephraim Shorr, an 
endocrinologist, and avid researcher at CMC-NY (Casper & Clarke, 1998; 
Chantziantoniou, 20141). To achieve workable tools by which to indirectly assay 
circulating hormones, Papanicolaou engineered dyes and colors to act as markers of 
varied epithelial cell origin, maturity, and viability. Along with these objectives, he also 
experimented with wet fixation and staining protocols to improve the visualization of 
CxCa cells in smears believing that this problem led to his professional demise 
(Chantziantoniou, Donnelly, Mukherjee, Boon, & Austin, 2017). Despite the 1928 Battle 




eased - neither did encouragement from his wife and laboratory assistant, Andromache 
(Mary) Papanicolaou, for him to stay the course (Hinsey, 1962; Chantziantoniou, 20143). 
 As it were, in 1939, Papanicolaou’s professional prospects changed utterly when 
Dr. Joseph Clarence Hinsey became Chairman of the Department of Anatomy at CMC-
NY following the passing of Stockard. After reviewing Papanicolaou’s professional 
portfolio, Hinsey was particularly impressed by Papanicolaou’s New Cancer Diagnosis 
presentation and saw potential in the VFSM. But he also saw weakness. Hinsey urged 
Papanicolaou to reinstate his research work channeling his efforts towards the 
prevention of CxCa, not solely its diagnosis (Papanicolaou-Kokkori, 2008). The 
following excerpt reflected Hinsey’s recollections of their encounters in 1939 (Hinsey, 
1962): 
“His first paper on this subject was presented to the Third Race Betterment 
Conference and was published in its proceedings in 1928…It was met with 
indifference and skepticism. He said: “I failed to create much faith among my 
colleagues in the practicability of this procedure.” The prevailing opinion, 
expressed to him by one of the outstanding pathologists of the time, was that 
“since the uterine cervix was accessible to diagnostic exploration by biopsy, a 
relatively simple procedure, the use of a cytologic examination was 
superfluous.” Others less persistent and dedicated might have given up but 




 Hinsey was amply cognizant of the background macro-socio-political 
developments in the US following the National Cancer Act enactment in 1937, and 
assertively leveraged financial support for Papanicolaou’s work from The 
Commonwealth Fund, and subsequently from the ACS. Until 1941, Papanicolaou’s work 
had been supported through CMC-NY; thereafter, The Commonwealth Fund provided 
an initial grant of $1,800, while their total support had amounted to $124,000 by 1952 
(Hinsey, 1962). Also according to Hinsey (Hinsey, 1962): 
“He [Papanicolaou] came to me one day to get approval for a grant of some $4,000 
from one of the pharmaceutical firms to support a project in endocrinology. He 
was somewhat taken back when I urged him not to take it, but instead to devote 
all his time to developing his cytologic method for diagnosis of early cancer in 
the reproductive tracts of women. I told him then how I had been impressed by 
his work first reported in 1928. He told me of his previous disappointments and 
his fears about securing adequate support and sufficient clinical material. The 
American Cancer Society was not then as vigorous as it is today and the Federal 
programs for research support had not been begun. I assured him of my whole 
hearted support and we both agreed that he should proceed step-wise, (1) to 
develop the method and establish its validity, (2) to train others to use it, (3) then 
to educate the profession and the public as to what it had to offer.” 
 Hinsey was visionary, and administratively savvy. He foresaw potential but also 




medical credentials in the US thus had no access to patients; he also lacked formal 
training in anatomical pathology thus had neither qualifications nor authority in the 
field; also, that he needed ample clinical material for analysis with tissue correlation to 
test and validate his work. In light of these vulnerabilities, against a backdrop of 
pervasive skepticism, Hinsey brokered the collaboration of Dr. Herbert F. Traut, a 
gynecological oncologist at CMC-NY with knowledge in anatomical pathology. 
Papanicolaou and Traut’s synergy, and their epic publications in 1941 and in 1943, 
manifested in the renaissance of gynecological DC (Papanicolaou & Traut, 1941; Boon & 
Chantziantoniou, 2013). Their works created a sensation, thrusting the discipline of DC 
into the formal arena of CxCa diagnostic medicine in the US (Papanicolaou-Kokkori, 
2008). These dynamics also created resistance and opposition. 
 Hinsey’s decision-making was the spark that catalyzed the subsequent course of 
events that led to the establishment of the clinical Pap test in 1948, and to its deployment 
in screening practice in the US since 1957. In a short article published in the Journal 
Oncologia, in memory of Papanicolaou’s life and career, entitled Necrologia – Obituary For 
George N. Papanicolaou, M.D., Ph.D., Traut referred to additional impediments in the 
backdrop of World War II (Traut, 1963): 
“As the material from pathological specimens became available, and the vaginal 
smears matched with the observations from this material, it became probable 
that the vaginal smear might adequately represent the presence of early cancer. 




data accumulated so that the collaborators could make a definite statement with 
regard to the reliability of vaginal smears as an indication of the growth of 
cancerous changes. The paper, read before the New York Obstetrical-
Gynecological Society in 1938, by Papanicolaou and Traut, was the first 
contribution announcing these possibilities. The studies were not readily 
acceptable to pathologists in general, and the idea was not grasped with great 
vigor, partly because it appeared at the time when the United States were 
involved in World War II, and had many other matters to consider.” 
 Nevertheless, Papanicolaou and Traut’s publications and the VFSM appealed to 
weary gynecologists facing the problem of advanced CxCa in their patients in the mid-
1940s. Among them were two prominent gynecologists: Dr. J. Ernest Ayre (Montreal, 
Canada), and Dr. Joe V. Meigs (Boston, US). Ayre and Meigs promptly adopted and 
tested the method in their respective clinical practices. Their contributions eventually 
redefined the clinical VFSM and formalized the concept of early detection of cervical 
precancer and its surgical ablation. Collectively, Ayre and Meigs entrenched the 
feasibility of prevention of advanced disease through systematic screening in 
asymptomatic women (Hinsey, 1962; Traut, 1963; Stewart, 1971; Hutter, 1981; Koss, 
1993). 
 After World War II, being a gynecological surgeon, Meigs modified the practice 
of radical hysterectomy for advanced CxCa and his methods led to a significant decrease 




epidemiological evidence in the mid-1940s then associated higher rates of CxCa with 
married or widowed women, rekindling the suspicion of disease causality through 
sexual activity (Olson, 1989). 
 Yet, the VFSM, and the cytologic method it embodied, required procedural 
overhauling to offer attractive, undeniable advantages to both gynecologists and 
pathologists. In this regard, Ayre’s resourcefulness proved invaluable. 
 J. Ernest Ayre was a gynecologist turned cytopathologist, and a staunch 
proponent of Papanicolaou’s work and of the VFSM. Ayre’s hybrid skillsets afforded 
him unique advantages. As a cytopathologist, he naturally related with malignant cells 
arising from CxCa, the target disease of the VFSM. Meanwhile, as a former gynecologist, 
Ayre understood the reservations voiced by his clinical colleagues accustomed to 
confirming the disease visually and through conventional biopsies. Attempting to 
reconcile these polarities, and to render the VFSM more attractive to gynecologists, Ayre 
proposed a modification in Papanicolaou’s simple test in a key publication, entitled A 
Simple Office Test For Uterine Cancer Diagnosis, appearing in the Canadian Medical 
Association Journal, in 1944 (Ayre, 1944). 
 In essence, Ayre identified major deficiencies in Papanicolaou’s method of blind 
vaginal pool fluid collection through a pipette. He thus redefined the VFSM making it a 
two-smear test performed under direct cervical visualization. He wanted the test to be 
successful but also simple enough for any clinician to perform in the office setting, 




sampling could then become ubiquitous, performed by family physicians throughout 
the US, not unlike a blood test. This innovation vastly expanded the scope of practice 
and outreach for the screening VFSM. Ayre proposed that under direct cervical 
visualization, a standard smear be prepared from vaginal pool secretions as proposed by 
Papanicolaou to include exfoliated epithelial cells from the vaginal and external cervical 
surfaces. Thereafter, another dedicated smear could be prepared from mucus sampled 
directly from the cervical external os to include exfoliated cells from the transformation 
zone and endocervical canal (Ayre, 1944). 
 In 1946, Ayre reported his success in detecting cervical precancer using the two-
smear modification (Ayre, 1946). But as it was subsequently questioned if his approach 
may miss lesions adjacent to the cervical os on the ecto-cervix, Ayre developed the 
eponymous Ayre spatula to sample the outer epithelial circumference of the cervix and 
internal os (Ayre, 1947). The spatula smear Ayre termed: “surface biopsy”, contending it 
would make the procedure “more rapid and more efficient” (Ayre, 1951). Ayre’s 
intuitive choice of terminology conjoined the disciplines of gynecology and DC for the 
sampling and screening for cervical precancer through the modified clinical VFSM. 
 Ayre’s work also targeted particular impediments to the deployment of the 
VFSM. According to Ayre (1944): 
“The statement that uterine cancer may be accurately diagnosed by the vaginal 
or cervical os smear probably arouses an initial skepticism in the minds of many. 




impression of some that the vaginal smears consist only of vaginal epithelial cells 
scraped off from the vaginal mucosa, and that the diagnosis of cancer is 
attempted from the morphological and staining characteristics of the vaginal 
cells themselves. It is difficult to conceive how any diagnosis of uterine cancer 
could be made from a study of these cells alone. When one considers, however, 
that the vaginal secretions contain not only vaginal cells but also cells thrown off 
from the cervix, the endometrium, and the tubal epithelium, the horizon of the 
diagnostic possibilities might appear to be broadened.” 
 Ayre defended the two-smear VFSM as follows (Ayre, 1944): 
“Uterine cancer annually takes a toll of 26,000 lives in the United States. There 
has been little improvement in these statistics during the last 20 years. According 
to the findings of Bigelow and Lombard, the average time lost in uterine cancer 
cases from the first signs of bleeding to the time of operation is almost eight 
months. Therefore, delay in diagnosis is a major factor in maintaining the high 
mortality rate. So often when the patient in the menopausal age presents herself 
with irregular bleeding the physician finds it impossible to differentiate between 
the more frequent menopausal changes and a beginning malignant growth. 
A simple office test which may be taken by any physician when the first signs of 
spotting are reported should be of great value speeding up the diagnosis. It is 




is not so simple when there is nothing abnormal palpable or visible to be found. 
This is the stage when diagnosis would allow more certain cure.” 
 In 1947, in Iowa, Dr. Arthur W. Erskine also adopted the VFSM but ensured it 
stayed locally accessible as an office test as previously advocated by Ayre, rather than it 
being administered solely through distant urban medical clinics. Erskine’s approach 
proved transformational in the evolution of Pap test screening. According to Gardner 
(2006): 
“Such local commitment, experience, and activism, coupled with women’s 
traditional philanthropy, made the Iowa ACS a breeding ground for new 
programs. While the national ACS debated the best way to proceed with the 
vaginal smear as a screening tool for the population at large, locally the Iowa 
ACS embarked on a small and specific study that would determine the test’s 
effect in this community… 
It was Erskine who first convinced the Iowa ACS to subsidize a local study of the 
Pap smear. The ACS donated $12,000 to the program, which started in 1947 
when personnel at the Gynecology Department of the State University of Iowa 
City performed vaginal smears on all women over thirty years of age who were 
admitted to the hospital. In addition, physicians performed vaginal smears on all 
female residents of the two state mental hospitals. Clinicians collected a total of 




By 1948, preliminary results of the Iowa study confirmed the effectiveness of the 
Pap smear as an effective screening tool. Cancer activists in Cedar Rapids 
proposed an expansion of the Pap study to include routine tests in both Cedar 
Rapids hospitals and private offices in the area. Vaginal smears could be 
collected in any location, cells could be fixed to slides there, and then slides could 
be transported to a central cytology lab in Iowa City for final reading. The Iowa 
ACS approved the proposal, and in 1948 Cedar Rapids became the first city in 
Iowa, and one of the first cities in the United States, to begin mass screening of 
women using Pap smears. 
The Iowa study would ultimately serve as a model for a national program for 
cervical cancer screening.” 
 The favorable reports produced by Ayre and Meigs demonstrating clinical 
progress and the outcomes from Erskine’s initiatives gave the national ACS the traction 
it needed. The ACS capitalized upon these post-World War II dynamics to reconsider its 
approach. It encouraged deployment of the clinical VFSM in diagnostic medicine 
disregarding skepticism amongst pathologists. 
 As World War II had ended, and as American society yearned for a sense of 
victory and enlightenment, the ACS achieved a much needed signature triumph in 
public health and in societal medicine: The alleged defeat of CxCa. Collectively, these 
developments were effective in raising the levels of national optimism following the 




of the National Cancer Act of 1937, that of Mrs. Mary W. Lasker, and that of the 
repositioned ACS. 
The Clinical Pap Test (1948 Henceforth) 
 It was under the directorship of the astute Dr. Charles S. Cameron that the 
national ACS coined the term Pap test for the clinical VFSM in 1948. 
 The ACS then actively funded major educational meetings to disseminate 
knowledge, and boldly promoted the Pap test into screening service to mitigate the 
growing number of unnecessary deaths due to lacking or delayed sampling (Koss, 1993). 
Cameron served the ACS as its Medical and Scientific Director from 1948 to 1958 (Davis, 
2007). That was the most critical decade in the history of DC, and the last decade of 
Papanicolaou’s career at CMC-NY (Boon & Chantziantoniou, 2013). Nonetheless, despite 
the energy projected by the ACS during the 1950s, advanced CxCa reemerged as a 
profound dilemma in the US. Accounts of deaths due to purportedly preventable CxCa, 
such as that of Henrietta Lacks in 1951, stoked societal distress not unlike that 
experienced in the 1930s during the Great Depression, and in the 1940s prior to the 
understanding of cervical precancer. Referring specifically to CxCa in the early-1950s, 
Hendrix stated (The Washington Post, 2017): 
“…when Lacks, a mother of five, was being treated in East Baltimore during the 
Truman era, it was an illness clouded in secrecy, shame and dread.” 
 In post-World War II US society characterized by advancing modernization and 




CxCa became a source of awkwardness for the ACS. This was particularly poignant for 
Charles Cameron. He needed to foster a paradigm shift to eternalize the notion that 
CxCa had indeed been successfully defeated through availability of the Pap test. To 
achieve this, he altered the direction and organizational culture of the ACS. 
 Until the mid-1950s, the ACS had focused essentially all its efforts towards 
identifying a cure for cancer, a “downstream approach”; Cameron then advocated that, 
instead, energy ought to be invested towards cancer prevention, an “upstream 
approach” (Casper & Clarke, 1998). The paradigm shift that Cameron envisaged started 
to materialize riding on the positive outcomes from the Memphis and Shelby County 
trial, and Erskine’s accomplishments in Iowa. 
 On October 24, 1952, the New York Times published a poignant article, entitled 
Cancer Care Seen Saving More Lives – Up To 100,000 A Year Forecast By Dr. C. S. Cameron In 
Full Use Of Detection Centers. The article not only revealed the political and professional 
push-back Cameron faced, it also communicated his frustration. However, it also 
introduced his concept of specialized medical centers that would be dedicated to detect 
thus prevent cancer, and his justification for them. Cameron’s assertion was based upon 
Ayre’s proposition of the “simple office test” (Ayre, 1944). In the context of this 
dissertation, the New York Times article warrants complete reproduction as follows (New 
York Times, 1952): 
“Dr. Charles S. Cameron, medical and scientific director of the American Cancer 




annually if physicians and clinics gave each of their patients a six-point cancer 
check-up. The examination would include the following danger areas: skin, oral 
cavity, female generative tract, breast, rectum and lung with the lung requiring 
the further check of an x-ray. 
Dr. Cameron told the thirty-ninth annual meeting of the society at the Park 
Sheraton Hotel that its cancer detection programs were coolly received by 
individual doctors and local medical groups. He said the cancer detection center 
idea was criticized as threatening to dislocate the traditional doctor-patient 
relationship. Another program to promote cancer detection in the doctor’s office 
in cooperation with state or county medical societies, he added, also had “hardly 
encouraging results”. 
Dr. Cameron reported that in some localities where doctors were asked to 
provide cancer detection examination service, five out of six doctors indicated 
their unwillingness to cooperate. 
In his annual report he defended the early detection principle, replied to criticism 
of the cancer detection center by holding that it served to establish direct 
relations between private physicians and patients and urged reappraisal of the 
program to make the doctor’s office a detection center. 
He proposed a new program for detecting cancer early by centering upon the 
3,500,000 persons receiving social security, all of whom are over 65 years old. Dr. 




Observing that 3,500,000 persons could be examined once yearly or oftener by 
100,000 doctors, he maintained that such a program could save 75,000 to 100,000 
lives. 
He suggested that the society might embark on a five-year plan for this special 
segment of the public. He contended that if the precision weapons designed to 
detect early cancer could not produce measurable results in five years there 
would be reason to reconsider the validity of all cancer control.” 
 Four years after Cameron’s ultimatum to the ACS, in an effort to quell lingering 
skepticism and societal anxiety, without belittling the plight that cancer posed upon 
humanity, Cameron stated (Cameron, 1956): 
“Incurable cancer, then, need no longer be a sentence to unremitting agony. 
Medical science is steadily making it possible for more patients with cancer, even 
though it cannot be cured, to live longer, to live more fully, and to enjoy greater 
comfort. But these are not always easy to come by. They require all the ingenuity 
and resourcefulness the doctor has. They call for understanding, persistence, and 
gentle firmness on the part of the family. And they call for determination in the 
patient to fight a good fight.” 
 Being the Medical and Scientific Director of the ACS in 1956, Cameron’s 
statements were calculated. The responsibility perceived to be shared between clinician 
and patient in the war against cancer was undeniable. But Cameron’s rhetoric inferred 




medical establishment at large also shared in that war. Cameron likewise alluded to the 
fervor and clinical significance of the developments then occurring in DC overall. 
 Along with Hinsey, Cameron was equally aware of the politics impeding the Pap 
test’s development and deployment, and was fretful of ongoing delays particularly 
when time was a proven determinant of the likely success or failure of CxCa 
management. Time was a predictable variable to delays in diagnosis and treatment. In 
turn, delays were a predictable variable to extent of disease at presentation and 
diagnosis. These key, interrelated elements were detailed by Davis, from which the 
following remarks about Cameron’s frustrations are reproduced (Davis, 2007): 
“Cameron’s outrage over delays in using the Pap smear in medicine finally 
boiled over in 1956…Women were dying while doctors debated who should be 
in charge and proposed ever more elaborate studies on the issue. At the 1956 
annual ACS meeting, Cameron demanded that the board of directors stop 
stalling and put the Pap test into place nationwide. “I hold that we need not wait 
for more evidence; that there is enough evidence”, he declared; “that there is 
enough evidence on hand to justify taking the position – women over 40, vaginal 
smear twice a year. Can we justify any longer delaying a vigorous campaign to 
press the use of the smear? …My conscience and the opinion of those with the 
widest experience in its use say no.” 
 The emergence of cervical precancer from Papanicolaou’s and Traut’s work had 




gynecology gained the trust and buy-in from most gynecologists. Conversely, in 
anatomical pathology, skepticism and opposition prevailed. At issue was the underlying 
proposition of non-infiltrating cervical precancer (i.e., carcinoma in situ). 
 Although the concept of cervical CIS was described by another prominent 
gynecologist in New York, Dr. Isidor Clinton Rubin, in 1910 (Olson, 1989), this concept 
sparked a controversy amongst leading pathologists as to if cervical precancer was 
indeed cancer. That is, was treated cervical intraepithelial precancerous disease truly 
cured CxCa? The prospect of cervical precancer challenged the core tenets and then 
understanding of cancer - being, exclusively and conceptually, an invasive, progressive, 
irreversible disease (Stewart, 1971; Hutter, 1981; Koss, 1993). 
 These controversies resurfaced intensely in 1951 when Henrietta Lacks presented 
with advanced CxCa and soon thereafter died of it age 31; after never having a cervical 
smear test although it was available since 1941, when she was 21 (Skloot, 2010). Lacks’ 
case projected worrisome inadequacies in societal and diagnostic medicine overall that 
could have conceivably affected, and taken the life of, any woman. Collectively, these 
issues posed contentious impediments that lingered beyond Papanicolaou’s death in 
1962, well into the late-1970s. This debate lingered until the HPV-associated etiology of 
CxCa was unraveled, and high-grade squamous intraepithelial lesion (HSIL) became a 





 The indiscriminate menace of CxCa and its widespread societal ramifications in 
humanity were underscored in an article in The Washington Post, entitled When Henrietta 
Lacks Had Cervical Cancer, It Was A ‘Death Sentence’. Her Cells Would Help Change That, by 
Steve Hendrix, published on April 22, 2017. According to Hendrix (The Washington 
Post, 2017): 
“One month after Lacks was buried, another woman whose name would live 
forever was wheeled into an operating room to be treated for cervical cancer, and 
she didn’t even know it. Eva Peron, the glamorous and powerful wife of 
Argentinian President Juan Peron, was never told she had the disease. 
Evita thought she was having a procedure by a leading Buenos Aries surgeon to 
stop some cervical bleeding. Instead, after she was anesthetized, George Pack, a 
cancer specialist from New York who had been flown secretly to South America, 
entered the O.R. and performed a radical hysterectomy. 
There was such a taboo around cancer that many doctors didn’t want to use the 
C-word at all, lest the patient lose hope – or commit suicide – at a time when 
cancer seemed always to lead to a coffin. 
With Peron, of course, politics and power also played a role in the secrecy. But 
even when the surgery failed to stop the cancer, and she went into a painful 




Peron and Lacks fell to cervical cancer right at the beginning of a new age in 
fighting the disease. The biggest breakthrough was the introduction of a 
remarkably effective test for pre-cancerous cells developed by a Greek-born 
violin player and doctor named George Papanicolaou. His simple “pap smear”, 
which allowed doctors to treat and cure the cancer before it became established, 
was just coming into general use as a screening tool when Lacks fell ill. 
Cervical cancers are now considered one of the more treatable malignancies, but 
not everywhere. In poor areas, where screening and treatment remain out-of-
reach for many women, it’s still 1951.” 
 In 1956, due to his growing frustration, Cameron produced a book aimed for the 
general public but to also implicitly press the medical establishment for unacceptable 
behavior in its efforts to control cancer in the US. His book was written to increase 
layman’s awareness of cancer and to arouse action in seeking medical attention early. 
Cameron’s book framed time as being the key determinant between possible cure or 
death from cancer, entitled The Truth About Cancer (1956), Cameron stated (1956): 
“The woman who is wise enough to play it safe, then, will insist on a careful 
examination of her pelvis twice a year – no matter how strong and healthy she 
seems to be. Do you doubt the wisdom of this procedure? Then just compare the 
curability of cancer of the uterus in very early, moderately advanced stages with 
its curability in late stages: Treatment of very early cancer of the uterus will cure 




which is the condition in which most women with the disease are first seen by 
the doctor, can be cured. And of the late and extensive cases, fewer than 10 per 
cent can be saved.” 
 As the clinical Pap test was being increasingly deployed into service, Cameron’s 
book in 1956 alluded to unfavorable odds for 5-year survivals from advanced cervical 
cancer despite the availability of the clinical VFSM since 1941 and improved surgical 
procedures developed by Meigs (Olson, 1989). Cameron aimed to persuade the general 
public to exercise self-empowerment and advocacy through increased knowledge of 
cancer and of its symptoms. Cameron transferred ownership and political leverage to 
the public and, particularly, to the patient. His commentaries also aimed to subtly off-set 
the lagging medical establishment as screening practices for CxCa were being 
frustratingly deliberated in the US in the latter-1950s primarily due to widespread 
skepticism and inaction. Nonetheless, in the absence of promising therapies, and due to 
poor long-term survival outcomes for all cancer patients, the disease remained dreaded 
as an indiscriminate hindrance to societal betterment throughout the US (Cameron, 
1956). 
 As screening services were being implemented throughout the US, other 
impediments promptly emerged. A prominent issue became the lack of laboratories and 
therefore the lack of expertise to manage the growing volumes of smears that were being 
prepared as a result of increased health literacy. Secondly, pathologists remained 




glass slides using unfamiliar stains (Boon & Chantziantoniou, 2013). Thirdly, neither 
reporting nomenclature nor therapeutic approach was consistent throughout the US. 
And, fourthly, the deployment of low-paid, non-medical cytologists to read the 
cumbersome smears became yet another matter of contention (Casper & Clarke, 1998). 
As the majority of screening cytologists were women, the overall system became 
imbalanced with engendered polarities: Most pathologists were men, and most 
screening cytologists were women. These situations led to serious problems for the 
burgeoning clinical Pap test and for the ACS struggling to establish it through 
Cameron’s insistence (Casper & Clarke, 1998). 
 Furthermore, the expanding screening system for early detection of a dreaded 
woman’s cancer, supported by women cytologists, for the benefit of all women, 
rekindled the gender sensitivities surrounding the woman-physician relationship in the 
context of CxCa. Sensitivities implied: Could male doctors truly understand and 
prioritize the defeat of cervical cancer in all women? (Casper & Clarke, 1998).  
 In a commemorative article published in the Journal Of The American Medical 
Association in 1962, entitled Dedication Of The Papanicolaou Cancer Research Institute, 
Cameron summed-up the salient accomplishments arising from Papanicolaou’s 50-year 
journey in research and in CxCa diagnosis and prevention (Cameron, 1962): 
“He devised a means of identifying cancer of the uterus in the presymptomatic 
stage and thereby placed beyond 80% the curability of the second most fatal 




uterine cervix and demonstrated that the smear will discover the precursor to 
invasive cancer before it can be seen with the naked eye and when it can be 
eradicated in 100% of cases. By these 2 achievements he has provided the means 
of delivering women from the threat of death by uterine cancer… 
He has provided science with a precision system of investigation which makes 
possible the detailed analysis of cellular morphologic changes – in transition 
from wholly normal to the frankly neoplastic – and thereby he has opened to 
scientists a new avenue of the study of mechanisms of carcinogenesis.” 
 Nevertheless, CIS altered the epidemiology and understanding of CxCa. It also 
impacted on screening practice, the concepts of cervical pathobiology, and how these 
parameters may ultimately yield the control of CxCa. 
Screening Principles And World Health Organization Targets 
 Preclinical CxCa prompted reassessment of the linear model of cervical 
carcinogenesis considered in the 1920s. By the late 1960s, sufficient knowledge of CxCa 
had been garnered through Pap test screening whereby the fundamentals of medical 
‘screening’ required reformulation. It became evident that screening for cervical 
precancer in asymptomatic women was synonymous with CxCa prevention. That is, by 
detecting the intraepithelial entity, the invasive entity may be negated through 
intervention. The Pap test was therefore aligned for the preclinical entity; although, it 
could detect either entity. The complexities of CxCa gradually challenged the theory of 




relative to progressive lesions that quickly led to invasive disease although variably, and 
not inevitably between patients. The inability for the profession to explain these 
phenomena was problematic. But they did nonetheless manifest yet another mysterious 
dimension of CxCa. 
 These developments compelled the WHO to formulate its Principles and Practice 
of Screening for Disease in 1968 (Croswell, Ransohoff, & Kramer, 2010). The WHO’s 
principles aimed to guide the development of screening methods. The WHO’s criteria 
follow (Croswell, Ransohoff, & Kramer, 2010): 
 The condition sought should be an important health problem. 
 There should be an accepted treatment for patients with recognized disease, 
and treatment should be better at an earlier stage. 
 Facilities for diagnosis and treatment should be available. 
 There should be a recognizable latent or early symptomatic stage. 
 There should be a suitable test or examination. 
 The test should be acceptable to the population. 
 The natural history of the condition, including development from latent to 
declared disease, should be adequately understood. 
 There should be an agreed-upon policy on whom to treat as patients. 
 The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible 




 Case-finding should be a continuing process and not a “once and for all” 
project. 
From a contemporary lens, both the nature of CxCa and the experience generated 
by Pap test screening collectively aligned with the criteria set out by the WHO in 1968. 
But outcomes arising from the intensifying screening practices throughout the US since 
the mid-1950s revealed an even greater complexity for CxCa prevention stemming from 
the subjective, interpretive nature of the Pap test itself, and its inherent diagnostic error 
rates. These problems of course played into the hands of myopic skeptics, but they also 
influenced future design and application of screening practices, and screening interval 
guidelines. 
 Eventually, the Pap test resolved the very issue that obstructed its establishment 
in 1928: That cervical CIS was a lesion typically unapparent for biopsy; therefore, biopsy 
alone may be insufficient to negate CxCa. This reality was repeatedly cautioned by Ayre 
since 1944 (Ayre, 1944). This outcome governed the foundations for prospective 
cytologic screening. Effective precancer surveillance, and ensuing disease prevention, 
commanded that the Pap test and cervical biopsy become one in purpose: Mutually-
dependent. 
Sequential (Two-Stage) Testing Model For Cervical Cancer Prevention Through 
Screening 
 Due to its preclinical phase and invasive phase, CxCa was branded a two-phase 




characterization and the complement formed between the Pap test and biopsy led to the 
Sequential Two-Step Testing model for CxCa screening. According to Gordis (2014): 
“In sequential or two-stage screening, a less expensive, less invasive, or less 
uncomfortable test is generally performed first, and those who screen positive 
are recalled for further testing with a more expensive, more invasive, or more 
uncomfortable test, which may have greater sensitivity and specificity. It is 
hoped that bringing back for further testing only those who screen positive will 
reduce the problem of false positives.” 
 The Sequential Two-Stage Testing model manifested the basis for Pap test 
screening. From the effort to identify a subgroup of women in a given population, two 
additional factors emerged: (a) Classification of individuals at risk for developing this 
disease; and (b) Qualification of disease prevention through screening (Gordis, 2014). 
Therefore, with definition of the at risk subgroup, the benefits of screening may be 
maximized; and as the Pap test could detect preclinical disease in asymptomatic women, 
it was destined to serve as a tool for secondary disease prevention. 
 Reports by Foltz and Kelsey (1978), Greenwald, Cullen and McKenna (1987), and 
Foulks (1998), methodically described the incremental expansion of the theoretical and 
practical essentials pertaining to Pap test screening for CxCa. But with expanding 
screening practices throughout the US, previously unforeseen epidemiological 
limitations soon emerged. These problems were due to biases produced from screening, 




The dominant biases were: Healthy volunteer bias; Lead-time bias; and, Over-diagnosis 
bias (Croswell, Ransohoff, & Kramer, 2010). 
 It is nonetheless important to impress that the eventual acceptance of the clinical 
Pap test by 1957 was a direct result of its transformation from the 1928 VFSM prototype 
driven by key modifications incorporated into the method, and into the organizational 
infrastructure supporting and promoting Pap test screening. Major improvements 
included the dedicated Papanicolaou staining method (Chantziantoniou, Donnelly, 
Mukherjee, Boon, & Austin, 2017); the Ayre two-smear VFSM and office test, and the 
subsequent Ayre collection spatula (Ayre, 1944; Ayre, 1947); conceptualization of 
precancerous (i.e., carcinoma in situ) cervical lesions (Meigs, 1947; Ayre & Ayre, 1949; 
Ayre, 1949; Papanicolaou & Koprowska, 1951; Koss & Durfee, 1956; Ayre, 1961); method 
verification through large population trials such as the Iowa Cedar Rapids project, and 
the Memphis and Shelby County study with corroboration from prominent institutions 
(Dunn & Sprunt, 1955; Gardner, 2006); women’s advocacy and empowerment (Reagan, 
1997); and, the establishment of a low-paid, non-medical workforce trained to analyze 
the growing numbers of smears arising from expanding screening practices (Casper & 
Clarke, 1998). 
Promotion And Endorsement Of Pap Test Screening In The US 
 In 1957, despite the ongoing achievements, the control of CxCa remained dismal. 
The ACS was left with little alternative but to once again bolster the significance of time, 




 Television had then supplanted radio as being the prominent technology by 
which to reach the public throughout the vastness of the US. To reemphasize the 
significant impact of time in the diagnosis and management of CxCa, and to highlight 
accrued knowledge for the lay public, the ACS commissioned a television documentary 
in 1957 narrated by the prominent gynecologist, Dr. Joe V. Meigs. The program was 
titled: Time And Two Women. The transcript of that documentary, along with specific 
photos and images of gynecological anatomy, was also published in the Journal Of The 
American Medical Association by Meigs in 1957 (Meigs, 1957). The Abstract from that 
publication follows (Meigs, 1957): 
“Seeking to motivate women to adopt the lifesaving habit of health checkups, 
this film was released as a part of a broad education program which will be 
undertaken in communities where technical facilities are available for 
interpreting vaginal smears, and where the county medical societies approve use 
of this film. The uterine cancer cell examination, the “Pap” smear, is explained in 
an effort to alert women to the urgency of early detection of uterine cancer. The 
film deals with diagnosis of cancer of the uterus with special emphasis on 
cytology and dramatizes the fate of two women: one who ignored warning 
signals and saw her doctor too late and the other whose early cervical cancer was 
detected in the course of a periodic checkup.” 
 Although the transcript alluded to possibly inadequate infrastructure throughout 




documentary, it may be stated that subsequent to 1957, the clinical Pap test was 
arguably understood, established, and decisively set upon a US-wide course of 
deployment supported by remarkable health literacy and promotion, and the vested 
interests of the ACS. According to Gardner (2006): 
“The history of the vaginal smear offers one illustration of the technological 
innovations that redefined female cancers in the second half of the twentieth 
century. As scientists, practitioners, female patients, and cancer activists sought 
ways to detect cancer as early as possible, screening technology gained 
impressive financial and academic support that shaped cancer awareness 
advocacy. Undoubtedly, Mary Lasker’s influence and emphasis on funding 
cancer research contributed to the promotion of the Pap smear in U.S. culture. 
Although cancer educators waited until the late 1950s to launch a cervical cancer 
screening awareness campaign, the evolution of the technology and the scientific 
responses to cancer screening dated back to the early twentieth century.” 
Dr. George N. Papanicolaou: Personal Letters, Character, Aspirations, And Professional 
Conflicts 
 Papanicolaou’s sensitivities may be appreciated through his major (i.e., larger) 
publications listing laborious narratives describing preceding work by his peers 
(Chantziantoniou, 20141). This may be evident in the publications through which he 
introduced novel methods or concepts; such as: The introduction and role of the 
experimental VFSM in Guinea pigs (Stockard & Papanicolaou, 19172), and the 




method (Papanicolaou, 1933). To him, the more novel and potentially controversial the 
concept, the more support it demanded. Papanicolaou structured commensurate 
scientific evidence upon which to frame his observations, hypotheses, and conclusions. 
 Papanicolaou’s intuitive style of writing may also be appreciated in his personal 
correspondences that were reviewed for this dissertation. During the difficult period 
when he was trying to convince his father of what he wanted in life and why, 
Papanicolaou composed letters mirroring a ‘scientific’ defense. Laborious 
correspondences were exchanged between 1907 and 1910 designed to debate yet frame 
his preferences and counter-arguments against the prospect of him practicing medicine. 
The similarities between his personal and scientific writings are striking; revealing 
Papanicolaou’s ability to precisely organize and set, and communicate convincing 
propositions (Papanicolaou-Kokkori, 2008). 
 After reviewing the pertinent English and Greek literature, and Papanicolaou’s 
personal correspondences in the context of this dissertation, it may be argued that his 
character remained unchanged throughout life. Since boyhood, Papanicolaou yearned to 
understand and to champion the forces of nature (Carmichael, 1973; Boon & 
Chantziantoniou, 2013; Chantziantoniou, 20141). He frequently and purposely put 
himself in perilous situations to test his determination and resilience (Papanicolaou-
Kokkori, 2008). Throughout life, he also remained awestruck by the rhythmic vitality 
and demise of cells and living organisms in nature’s Kingdoms. These grand aspirations 




energy, and determination encoded within the fabric of his scientific work in DC. These 
aspirations allowed him to dare curiosity and failure, to surpass defeats, but also to 
intuitively organize observations into articulate scientific deductions. 
 It is important to reiterate that although Dr. George N. Papanicolaou held a 
Medical Doctor degree from the University of Athens, he was not a practicing clinician 
in the US. Neither had he pursued formal training in anatomical pathology. Throughout 
his 43-year career at CMC-NY, he was employed in the Department of Anatomy 
working in the research and academic arenas. His career’s work at CMC-NY was upheld 
by his post-graduate PhD degree from the University of Munich. Papanicolaou was not 
a formal anatomical pathologist. 
 Understandably, Papanicolaou’s work on the diagnosis of CxCa inevitably led to 
various professional conflicts. These conflicts manifested into impediments due to him 
lacking qualifications thus authority in the field of anatomical pathology (Koss, 1973). 
He was never oblivious of the realities however, nor viewed the risks as being trivial 
(Carmichael, 1973). Papanicolaou’s sensing of controversial concepts in DC as being 
potential obstacles to his progress was highly intuitive. 
 Papanicolaou’s character and aspirations were important throughout his career, 
affording him the necessary tools by which to overcome and navigate past contentious 
issues, and what seemed oftentimes as impassable obstacles. Nevertheless, his career’s 
journey was neither painless nor straightforward and support, through various forms, 




Papanicolaou sustained a life-long fear of embarrassment and of insecurity in general 
(Carmichael, 1973; Papanicolaou-Kokkori, 2008). In the professional setting, he was 
particularly sensitive to producing work that may attract ridicule from pathologists; and 
particularly when his conceptualizations over-extended onto their realms of authority 
(Koss, 1973). These problems became most profound in 1943 and in 1951 when 
Papanicolaou introduced his concepts of CIS in gynecological and pulmonary 
cytopathology respectively, and the existence of dyskaryotic cells. 
Dr. George N. Papanicolaou: Dyskaryotic Cells Pathognomonic Of Cervical Precancer 
 The cytomorphology of the dyskaryotic cells Papanicolaou asserted as being 
pathognomonic of non-infiltrating cancer became another major impediment. The topic 
of dyskaryotic cells was a highly contentious issue in cervical DC in the mid-1950s. Dr. 
Leopold G. Koss was an enduring skeptic of Papanicolaou’s propositions. In 1956, Koss 
and Grace R. Durfee stated (Koss & Durfee, 1956): 
“The cellular abnormalities characterizing koilocytotic atypias, of course, have 
been noticed before. They fall into Papanicolaou’s category of superficial, 
intermediate, and parabasal cell dyskaryosis. This classification of abnormal cells 
is of didactic value only, since pathologic findings clearly indicate that large 
atypical cells may be found at all levels of the epithelium.” 
 The matter of dyskaryotic cells became an extraordinary flashpoint. These cells 
posed a challenge squarely on pathologists accustomed to reading histologic sections, as 




epithelial cells in smears arising from CIS (Foote & Li, 1948; Carson & Gall, 1953; Ayre & 
Scott, 1961; Johnson, Easterday, Gore, & Hertig, 1964; Hutter, 1981). Despite the 
opposition, and lack of authority, Papanicolaou stood adamant to the proposed 
diagnostic value of dyskaryotic cells. His posturing was not always welcome, and this 
led to conflicts with prominent pathologists. But unlike pathologists, Papanicolaou had 
the advantage of not being bound by cells in histologic sections, nor by H&E staining. 
This matter led to various confrontations and was exceptional enough that it captured 
entirely the texts and discussions of Symposium A published in the maiden issue and 
volume of Acta Cytologica in 1957 (Koprowska, 1997; Bibbo, 2011; Chantziantoniou, 
2017). 
Divides Of Authority Between Papanicolaou’s Experimental Work And Clinical 
Practice 
 Throughout the saga of the clinical Pap test, Papanicolaou’s wife and closest 
associates helped him persevere and stay the course. Andromache, Hinsey, Traut, 
Cameron, Hashime Muryama, Dr. Andrew A. Marchetti, and Dr. Irena Koprowska were 
equally as conscious of his character and risks, and from their own personal efforts 
allayed Papanicolaou’s weaknesses facilitating incremental progress (Hinsey, 1962; 
Marchetti, 1969; Carmichael, 1973; Koprowska, 1997). 
 From all the historical dynamics, perhaps, Hinsey’s thoughtfulness and 
administrative stances resolved the majority of impediments. Hinsey’s decision to 
broker the collaboration between Papanicolaou and Traut (and later to include the 




authority between Papanicolaou’s experimental work and clinical practice (Carmichael, 
1973). This was imperative for progress. Their synergy, and their publications describing 
the cytomorphology of cervical CIS, cemented a bond between the VFSM and 
beleaguered gynecologists facing the dire challenges of advanced CxCa, and family 
physicians eager for guidance. Hinsey successfully managed the tethering between 
experimental laboratory methods with the clinical management of a dreaded 
malignancy in women. Traut’s involvement in that historical juncture was crucial. Like 
Ayre, Traut understood the language of anatomical pathology; he also understood the 
histological patters of CxCa, and he readily assimilated with the respective dyskaryotic 
cells scattered in smears arising from those cancers. Being a gynecologist, Traut also 
understood the problems posed by occult cervical precancer in asymptomatic women, 
and the urgencies and surgical challenges posed by advanced cancer in symptomatic 
women. Traut successfully entrenched the clinical relevance of Papanicolaou’s work in 
preventive medicine; something Papanicolaou almost certainly may not have been able 
to achieve solely. However, the triangulation between subjective DC, anatomical 
pathology, and clinical gynecological oncology, did not materialize with ease. Koss 
stated the following in 2010 (Koss, 2010): 
“Dr. Pap himself was a rather insecure diagnostician. Instead of using clear 
terminology to describe his findings, he used classes; he subdivided his smears 
into classes from I to V because he felt safer if he used the term “Class III” rather 




It became quite evident to me that there were some serious problems with that 
technique, that the people who were interpreting smears, such as Dr. Pap, had 
really no idea of the underlying pathology. The pathologists on the other hand, 
had a very vague idea of what cytology could offer. It became clear to me from 
the beginning that there ought to be someone who would know both areas of 
diagnosis and could combine them. Ultimately, I wrote a number of books, 
which were attempting to explain or to clarify the relationship of the techniques 
for the benefit of mankind.” 
 It must also be emphasized that development of gynecological cytopathology 
through its arduous evolutionary course was a testament of Papanicolaou’s personality. 
Our understanding of his nature, and of its pertinence during this saga, may be formed 
as gleaned from his personal letters, and from various remarks and accounts 
communicated by his closest associates and relatives, but also from his critics (Hinsey, 
1962; Koss, 1963; Koss, 1973; Koss, 1983; Koprowska, 1997; Papanicolaou-Kokkori, 2008). 
 Overall, he was a patient, sentimental, soft-spoken man; although, one reserved, 
and painfully steadfast in his convictions and decisions. No matter the hardship, he was 
determined to pursue what he regarded logical, scientifically sound, and beneficial to 
humanity. Papanicolaou was also naturally intelligent and briskly aware of imminent 
risk or opportunity. He was introverted and overly cautious, oftentimes difficult to be 




dynamism occasionally reared interpersonal conflicts with various colleagues, they also 
ultimately governed his overall sense of vision, and sense of purpose. 
 In the late-1940s, supported by the ACS, Papanicolaou, Traut, and Marchetti, 
were actively speaking in various academic and professional forums to disseminate 
knowledge of cervical DC and the value of the clinical Pap test in preventing disease. 
After all, dissemination of knowledge was one of the mutually-agreed upon 
recommendations posed to Papanicolaou by Hinsey in 1939 (Hinsey, 1962). Following 
one such meeting, Marchetti recollected as follows (Marchetti, 1969): 
“At the greater number of these meetings it was the pathologists who were the 
most vehement in stating that Dr. “Pap’s” smear was a superfluous procedure 
when the more reliable biopsy of the cervix was already available for cancer 
diagnosis. I could sense that during a discussion the then current point of view of 
the pathologists would hurt Dr. “Pap” very much. The few times that I presented 
the subject I would conclude by stating that the cytologic smear of the cervix and 
vagina in screening for cancer would eventually become as important as the 
peripheral blood smear in diagnosing hematologic disease. This conclusion, I 
suspect, gave heart to Dr. “Pap” when he made his concluding remarks, since he 
knew I believed it. That conviction, in my humble judgement, remains 
unchanged. Indeed, if facilities for cytologic screening were made available to 




these facilities, currently I am ready to state that death from carcinoma of the 
cervix, in two or three decades, would become unacceptable.” 
 Marchetti’s narrative embodied the essence of the overall micro-dynamics in DC 
prior to 1957 when Papanicolaou retired from CMC-NY. More importantly, however, 
Marchetti’s convictions were prophetic as CxCa has indeed become a preventable 
disease through effective Pap test screening. And, as a result, deaths due to advanced 
CxCa may appropriately be regarded as being proxies of suboptimal Pap test uptakes, or 
of underperforming screening systems (Foltz & Kelsey, 1978; Koss, 1989; Dickey, 2001). 
Salient Impediments To The Development Of The Clinical Pap Test In The 
US, Categorized And Stratified For Two Salient Timeframes: 1928-1941 And 
1941-1957 
 This sub-section organizes the salient historical impediments to the development 
of the clinical Pap test in the US. 
Evolutionary Timeframes Of Pap Test Development 
 Papanicolaou and Traut reintroduced the VFSM to the medical community in 
1941 as being an effective method by which to detect precancerous lesions of the uterine 
cervix through an epic paper, entitled The Diagnostic Value Of Vaginal Smears In 
Carcinoma Of The Uterus (Papanicolaou & Traut, 1941; Austin & Chantziantoniou, 2014). 
Their descriptions of CIS became a formative turning point in the evolution of 
gynecological DC and defined a pivotal historical reference focus. As the clinical Pap test 




associated impediments to its development as stratified before and after 1941. For the 
intents and purposes of this dissertation, the two timeframes are defined as follows: 
 Timeframe 1 (1928-1941): Introduction of the clinical Vaginal Fluid Smear 
Method as a diagnostic test for advanced cervical cancer 
 Timeframe 2 (1941-1957): Reintroduction of the clinical Vaginal Fluid Smear 
Method as a screening test for cervical precancer 
 The salient historical impediments to the overall development of the clinical Pap 
test from 1928 through to 1957, before and after 1941, were summarized specifically 
through nine categories and dedicated Tables: 
1. Socio-economic factors 
2. Socio-political factors 
3. Socio-behavioral factors 
4. Cervical cancer: burden, diagnosis, treatment, and prognosis 
5. Method imperfections, and interruptions 
6. Method framing, public awareness, and advocacy 
7. Clinical application, and validation 
8. Infrastructure, and human resources 
9. Dr. Papanicolaou: vulnerabilities, professional qualifications, and conflicts 
Tables Summarizing The Salient Historical Impediments 
 Tables 1 through 9 summarizing the salient historical impediments to the overall 




TABLE 1: Salient impediments to the development of the clinical Pap test in the United 
States due to socio-economic factors, stratified before and after 1941. 
Impediments: Socio-economic factors 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Great Depression: widespread 
economic and societal declines, 
curtailed medical services 
 Underfunding: ASCC unable to invest 
towards the control of CxCa 
 Papanicolaou’s work in CxCa detection 
not supported at CMC-NY thus 
underfunded 
 Higher rates of CxCa linked with 
poorer women 
 Lack of funding to support research in 
overall cancer control 
 World War II 
 Papanicolaou’s work in CxCa detection 
was underfunded at CMC-NY until 
1944 when the ASCC was rebranded 







TABLE 2: Salient impediments to the development of the clinical Pap test in the United 
States due to socio-political factors, stratified before and after 1941. 
Impediments: Socio-political factors 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Disruptions due to Great Depression, 
societal decline 
 Perceived association between VFSM 
and negative Eugenics movement 
 3rd Race Betterment Conference; not a 
medical conference 
 VFSM deemed unnecessary by 
pathologists, gynecologists 
 Perceived encroachment by VFSM on 
conventional cervical biopsy 
 Lacking support for Papanicolaou’s 
work in CxCa diagnosis by Stockard at 
CMC-NY 
 Societal expectations for cancer control 
unmet by the ASCC 
 Disruptions due to World War II 
 Unmet societal expectations for 
effective cancer control; inaction by the 
ASCC to control CxCa till its 
rebranding in 1944 
 Skepticism and resistance to the VFSM 
by pathologists 
 The Womens Field Army deemed 
inappropriate, disbanded 
 Papanicolaou lacking professional 
credentials and authority in anatomical 
pathology 
 Questioned role of the clinical Pap test 






TABLE 3: Salient impediments to the development of the clinical Pap test in the United 
States due to socio-behavioral factors, stratified before and after 1941. 
Impediments: Socio-behavioral factors 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Etiology and pathobiology of CxCa 
unknown; dreaded disease leading to 
certain death 
 Societal distress, anxiety, hopelessness 
 Stigmatization from CxCa 
 Societal sensitivities, taboos 
 Lacking health literacy; diagnostic 
information withheld from women 
 Lacking women’s sense of 
susceptibility to CxCa 
 Lacking women’s self-empowerment 
 Delayed diagnosis and treatment of 
CxCa 
 Inadequate doctors’ engagement, 
commitment, and buy-in 
 Etiology and pathobiology of CxCa 
unknown; mysterious, dreaded disease 
 Societal distress, anxiety 
 Stigmatization from CxCa 
 Societal sensitivities, taboos 
 Lacking health literacy; diagnostic 
information withheld from women 
 Lacking women’s sense of 
susceptibility to CxCa 
 Lacking women’s self-empowerment 
 Delayed diagnosis and treatment of 
CxCa 
 Inadequate doctors’ engagement, 







TABLE 4: Salient impediments to the development of the clinical Pap test in the United 
States due to cervical cancer burden: diagnosis, treatment, and prognosis, stratified before and 
after 1941. 
Impediments: Cervical cancer burden: diagnosis, treatment, and prognosis 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Death rates due to cancer increasing 
 CxCa burden out-paced population 
growth 
 Diagnosis of CxCa through visual 
inspection of cervix with biopsy 
confirmation 
 Treatment solely through radical 
hysterectomy with surgical mortality 
rates at 20% 
 Poor prognosis due to delayed 
detection of advanced disease at 
presentation, 60% inoperability  
 Pathologists, gynecologists unaware of 
cervical precancer 
 CxCa death rates increasing despite 
availability of VFSM due to inaction 
towards prophylactic screening 
 Unfavorable 5-year survival rates due 
to advanced cancer at delayed 
presentation and time of surgical 
intervention 
 Inconsistent treatment for CxCa 
 Disagreement about cervical CIS, its 







TABLE 5: Salient impediments to the development of the clinical Pap test in the United 
States due to VFSM imperfections, and interruptions, stratified before and after 1941. 
Impediments: VFSM imperfections, and interruptions 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Disruptions due to Great Depression, 
lost decade of cytopathology 
 VFSM smears cumbersome to read due 
to excessive blood, necrosis 
 Poor staining due to air drying, H&E 
 Pathologists lacking skill sets to grade 
single, dyskaryotic cells in smears 
 Opposition to VFSM by pathologists; 
method deemed unnecessary relative 
to conventional biopsy 
 Lacking correlative diagnostic 
nomenclature with anatomical 
pathology 
 Gynecologists and pathologists not 
engaged 
 Disruptions due to WWII following the 
Great Depression 
 Questioned role of the VFSM in 
preventive medicine 
 VFSM perceived as being unnecessary 
relative to conventional cervical biopsy 
 Opposition by pathologists 
 Pathologists resistant to concept of 
cervical CIS, and diagnostic value of 
dyskaryotic cells 
 Resistance to VFSM screening for CxCa 
by medical establishment 







TABLE 6: Salient impediments to the development of the clinical Pap test in the United 
States due to VFSM method framing, public awareness, and advocacy, stratified before and 
after 1941. 
Impediments: VFSM framing, public awareness, and advocacy 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 3rd Race Betterment Conference; not a 
formal medical meeting 
 Perceived association between VFSM 
and negative Eugenics movement 
 Unfavorable initial framing of the 
VFSM in lay press 
 Lacking public awareness of VFSM 
benefits 
 Women lacking sense of susceptibility 
to CxCa 
 ASCC underfunded, leading to 
diminished political influence 
 VFSM not endorsed by ASCC 
 Geographic vastness of the US, 
compromised health literacy 
 Lacking awareness of CxCa etiology, 
pathobiology, and precancer 
 Lacking public awareness of VFSM 
benefits 
 Women lacking sense of susceptibility 
to CxCa 
 Concern of alienating women, 
physicians, and pathologists 
 Reluctance to adopt the ‘simple office 
test’ proposed by Ayre 
 Reluctance by some States to 






TABLE 7: Salient impediments to the development of the clinical Pap test in the United 
States due to VFSM clinical application, and validation, stratified before and after 1941. 
Impediments: VFSM clinical application, and validation 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 VFSM dismissed by pathologists, 
gynecologists 
 Population-based trials lacking due to 
Depression, lost decade of 
cytopathology, and skepticism 
 VFSM imperfections; lacking technical 
optimization, suboptimal staining 
 VFSM unattractive to gynecologists 
due to lacking knowledge of cervical 
precancer 
 VFSM unattractive to pathologists due 
to lacking skill sets in grading single 
abnormal cells in smears using 
unfamiliar stains 
 Widespread resistance to VFSM 
application by pathologists 
 Population-based trials lacking till 1947 
(Erskine) and 1951 (Memphis and 
Shelby County trial) 
 Political push-back against CxCa 
screening as a ‘simple office test’, or 
through cancer detection centers 
 Disagreement amongst clinicians of 
CxCa screening practice; inaction, 
deliberations of Pap test application 
 Lacking infrastructure; laboratories, 
expertise, workforce to sustain 







TABLE 8: Salient impediments to the development of the clinical Pap test in the United 
States due to infrastructure, and human resources, stratified before and after 1941. 
Impediments: Infrastructure, and human resources 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Lacking knowledge and infrastructure 
to support the newly-introduced VFSM 
 Lacking support by Stockard at CMC-
NY for VFSM clinical testing 
 Lacking scientific foundations by 
which to support the VFSM at CMC-
NY 
 Lacking professional multi-disciplinary 
collaborations at CMC-NY till 1939 
 Lacking infrastructure to support 
organized CxCa screening 
 Lacking skilled personnel (i.e., 
pathologists and screening cytologists) 







TABLE 9: Salient impediments to the development of the clinical Pap test in the United 
States due to Dr. Papanicolaou’s vulnerabilities, professional qualifications, and conflicts 
stratified before and after 1941. 
Impediments: Dr. Papanicolaou: vulnerabilities, professional qualifications, and conflicts 
Timeframe 1 (1928-1941) Timeframe 2 (1941-1957) 
 Perceived relationship between 
Papanicolaou and negative Eugenics 
movement 
 Papanicolaou not a licensed clinician; 
lacked qualifications and authority in 
anatomical pathology; concepts 
questioned, dismissed by pathologists 
 The lost decade of cytopathology 
 Papanicolaou’s perceptions of failure, 
inability to solely perfect the VFSM 
 Lacking professional multi-disciplinary 
collaborations at CMC-NY 
 Papanicolaou not a licensed clinician 
 Papanicolaou lacking qualifications 
and authority in anatomical pathology 
 Papanicolaou’s concepts questioned, 
dismissed by pathologists 
 Papanicolaou’s diagnostic terminology 
(i.e., Dyskaryotic cells, Pap Class 
Reporting system) incongruent with 
diagnostic language of anatomical 
pathology leading to push-back 







CHAPTER 3: CERVICAL CANCER BURDEN, 
EPIDEMIOLOGICAL EXPERIENCE, CLINICAL PAP TEST 
UPTAKES, AND HEALTH PROMOTION IN THE STATE OF 
QATAR 
 
Pap Test Uptakes In The Extended Middle East And North Africa Region 
 Practically all the nations that comprise the Extended Middle East and North 
Africa (EMENA) geographic region have not adopted organized, national population-
based Pap test screening programs for the secondary prevention of CxCa in the 
asymptomatic female population; nor strategically in women deemed at risk for 
developing this disease. In the EMENA region, Pap test uptakes are overwhelmingly 
opportunistic (Seoud, 2013; Sancho-Garnier et al., 2013). 
 Opportunistic Pap test sampling may be defined as: The uptake of Pap test 
cervical sampling services as the clinical opportunity warrants (Gustafsson, Ponten, 
Zack, & Adami, 1997). Opportunistic screening systems typically do not involve an 
initial patient call to screening or recall. 
 Essentially all nations and territories in the EMENA region deploy opportunistic 
screening practices in their public and private healthcare sectors (Sancho-Garnier et al., 
2013). However, most of the wealthier nations in this region, notably the Gulf Arab 
States, and Saudi Arabia, operate standard-of-practice tertiary medical institutions, most 
of which serve patients through premier diagnostic laboratory services modeled after 




 As the Pap test is not widely deployed for population-based screening in the 
EMENA region, it is instead utilized as a diagnostic test to rule out or rule in CxCa in 
response to presenting, suspicious symptomatology. Consequently, nearly all cervical 
cancers in this region are initially detected through opportunistic Pap test sampling. 
And, as was the situation in the early 20th century in the US, the majority of cervical 
cancers diagnosed in the EMENA region are characteristically in advanced stages at 
diagnosis (Sancho-Garnier et al., 2013; Alemrayat et al., 2018). In such clinical settings, 
opportunistic Pap test sampling may also be defined as being optional; not strategically 
or formally advocated for disease detection or prevention in the at risk, asymptomatic 
clinical population. 
 In the context of public health and women’s welfare in the EMENA region 
however, the impact of advanced CxCa poses potentially devastating, highly impactful 
societal detriments. This holds particularly true in the predominantly conservative, 
traditional societies that are characteristic of this region largely based on matriarchically-
structured cultural norms, and the considerable societal importance placed upon female 
fertility (Seoud, 2013; Jumaan, Ghanem, Taher, Braikat, AlAwaidy, & Dbaido, 2013). 
 It is important to nonetheless emphasize the remarkable health promotion 
initiatives and campaigns undertaken in the State of Qatar to increase health literacy for 
CxCa, and particularly since 2014. Major initiatives conducted mainly through the 
QMoPH, the PHCC, and the QCS are listed in chronological sequence in subsequent 




Global Cervical Cancer Burden 
Cervical Cancer Burden In Resource-Poor, Developing Global Regions 
 According to World Health Organization (WHO) estimates, over one million 
women globally have CxCa although unaware of their disease. Most of these women in 
developing nations face no prospect of access to Pap testing or to gynecological services 
(Cibas & Ducatman, 2014; World Health Organization, 2014). These women comprise a 
population sub-set harboring preclinical disease and, therefore, the most likely 
beneficiaries of secondary disease prevention through Pap test screening. 
 According to the Institut Catala d’Oncologica (ICO), 527,624 new cases of CxCa 
were diagnosed worldwide in 2012; whereas, 265,672 proved fatal (Institut Catala 
d’Oncologica, 20171). These data equate into a global death rate of 50.3% for new cases 
alone. However, 230,158 of those fatal cases (86.6%) occurred in low- to middle-income 
developing nations due to financial or screening disparities (Institut Catala 
d’Oncologica, 20171). 
 Alarmingly, in the absence of secondary preventative screening, the death rate 
due to CxCa in resource-poor nations is projected to increase by 25% within the next 
decade (Consul, Agrawal, Sharma, Bansal, Gutch, & Jain, 2012). 
 In 2017, according to the ICO World Report (ICO, 20171), CxCa ranked as the 4th 
leading type of cancer in women globally, and the 2nd most common cancer in women in 





Cervical Cancer Burden In The US 
 Of the half million new cases of CxCa anticipated globally and annually 
according to the WHO (World Health Organization, 2014), the ACS estimated that 
13,170 of those cases will be registered in the US for the year 2019; whereas, 4,250 of 
those women would die of their disease (World Health Organization, 2014; Limmer, 
LoBiondo, & Dains, 2014; American Cancer Society, 2018). These ACS estimates suggest 
a 32.2% US-specific death rate due to CxCa in modern clinical practice. 
 Importantly, the 13,170 new cases expected in the US for 2019 equate to nearly 
2.5% of the total global burden of new cases estimated by the WHO and the ACS (World 
Health Organization, 2014; American Cancer Society, 2018). 
Cervical Cancer Burden And Management In The State Of Qatar 
 The State of Qatar is a sovereign nation amongst the Gulf Arab States, and a 
member country of the EMENA region (Seoud, 2013). Qatar is also assigned to the 
greater geographic region of Western Asia by the ICO (Institut Catala d’Oncologica, 
20172). 
 Qatar is an affluent sea-fairing Arab State forming a small Peninsula jutting 
acutely into the Persian Gulf from the eastern flank of the greater Saudi Arabian 
heartland. The State of Qatar boasts a modern, hospitable, educated society, although 
one embedded in the fabric of a traditional, conservative, Bedouin culture as is 
characteristic of most Gulf Arab States (Qatar Ministry of Foreign Affairs, 2019). The 




resulting in remarkable multi-sector modernization (Qatar Ministry of Economy and 
Commerce, Oxford Business Group, 2019). Qatar is currently in the midst of massive 
infrastructure development in the run-up to the FIFA World Cup event in 2022. The 
healthcare sector has similarly expanded medical services in tandem with these national 
developments. 
 According to information published by the World Population Review, pertaining 
to Qatar and to the US, the population of Qatar was estimated to be 2.7 million in July 
2018, relative to 327 million for the US in February 2018 (World Population Review, 
20181; World Population Review, 20182). In Qatar, women comprised 25.09% of the 
entire population, estimated to be 676,137 (World Population Review, 20181). In 2018, the 
minority of these women were Qatari nationals, and the majority expatriate women 
residing in Qatar originating from various countries, predominantly from Asia. 
 Accordingly, the population pyramid of Qatar is significantly skewed towards 
males. The vast majority of the male population comprises an expatriate, blue-collar 
migrant workforce employed in the infrastructural megaprojects. The female population 
is characterized by a primary age group component of 30-34 years, followed by a 
secondary component of 35-39 years (Institut Catala d’Oncologica, 20172). 
 Of the entire female population in Qatar in 2017, 481,127 women (71.1%) were 
over the age of 15 and deemed at risk for developing CxCa according to the ICO (Institut 





Accessing Pap Test Sampling In The State Of Qatar 
 Access to Pap test sampling is currently available through private and public 
healthcare providers in the State of Qatar (QMoPH Guide To Healthcare Services In 
Qatar General Adult Population, 2018). 
 The public healthcare system is robust and multi-tiered. The Qatar Primary Health 
Care Corporation (PHCC) (www.phcc.qa) operates 26 community-based healthcare 
centers strategically located throughout the nation based on population density. The 
community-based centers provide a wide range of primary care services acting as the 
first contact of consultation for non-emergent patients. Depending on the medical 
concern, patients may either undergo treatment locally or be referred to larger centers in 
the capital city, Doha, for additional investigations and treatment. 
 The largest public tertiary hospital in Qatar is the Hamad Medical Corporation 
(HMC) in Doha (www.hamad.qa). The HMC was established in 1979 through Emiri 
decree as a not-for-profit healthcare organization. The HMC currently integrates 12 
specialist hospitals and provides comprehensive standard-of-practice medical services to 
accommodate patients that could not be treated in the community-based setting. The 
HMC houses the largest, comprehensive DC service in Qatar managing the vast majority 
of Pap test cases (approximately 10,000 cases annually) arising from the public system, 
predominantly cases received from PHCC centers. The HMC DC service is modeled 




Pap test cases, as also dictated through the College of American Pathologists (CAP) 
inclusive of HPV reflex genotyping for high-risk HPV. 
 Expatriate residents in Qatar that have a Qatar Identification number (QID) may 
access medical services at PHCC centers or HMC and settle a nominal deductible fee. 
Medical consultations, treatment, and pharmacological prescriptions are heavily 
subsidized by the State. Emergency medical services are provided without fee 
throughout Qatar.  
 Another major establishment in Doha is Sidra Medicine (www.sidra.org). Sidra 
Medicine is a private, fee-for-service, ultramodern academic Women’s and Children’s 
hospital. Sidra Medicine is affiliated with CMC-NY, through the Cornell Medical 
College-Qatar campus located in the Education City complex adjacent to Sidra Medicine. 
The DC service at Sidra was launched in February 2018. The Sidra DC service is likewise 
modeled after American and CAP accreditation guidelines, inclusive of HPV reflex 
genotyping. 
Current Pap Test Uptake Practice In The State Of Qatar 
 At the time of this writing, the State of Qatar has not implemented a formal, 
organized, national population-based Pap test screening program for cervical cancer 
prevention for all asymptomatic resident women inclusive of initial patient call to 
screening or recall. Through guidance from the QMoPH, PHCC, and the QCS, the State 
is currently providing opportunistic Pap testing services due to the low prevalence of 




Cervical Cancer Epidemiology In The State Of Qatar 
Cervical Cancer Rates In The State Of Qatar 
 According to the Human Papillomavirus And Related Disease Report For Qatar in 
2017 (Institut Catala d’Oncologica, 20172), CxCa ranks as the 5th most common cancer in 
women in the State of Qatar, and the 6th most common cancer in women in the 15-44 
years age group. 
 Also according to the ICO (Institut Catala d’Oncologica, 20172), the State of Qatar 
had a crude incidence rate of 3.2 cases per 100,000 for CxCa (relative to 3.8 cases for 
Western Asia); and a crude mortality rate of 0.9 cases per 100,000 (relative to 1.6 cases for 
Western Asia). Recent studies by Sathian, van Teijlingen, & Rajesh (2018) report an age-
standardized incidence and death rate for CxCa in Qatar as being: 5.1 and 2.4 per 
100,000 respectively. In comparison, the age-standardized incidence and death rates for 
CxCa in the US for the period spanning 2011-2015 were: 7.6 and 2.3 per 100,000 
respectively according the American Cancer Society (2018). 
Cervical Cancer Registry, Presentation, And Diagnosis In The State Of Qatar
 Under the auspices of the Qatar National Cancer Program, the National Cancer 
Registry initiative was launched at HMC in 2012 to record prevalence statistics from 
cancer cases (A.A. Hmaidan; personal communication, March 21, 2016). Prevalence 
statistics prior to 2012 were computed from case studies based on treatment course and 




cancer statistics became available in Qatar from 2012 henceforth through the National 
Cancer Program. 
 From 1970-2015, in Qatari women, 61 invasive CxCa cases and 18 CIS cases were 
experienced totaling 79 cases; whereby, 77.2% were invasive cases, and 22.8% were 
precancerous cases. In the same timeframe, in expatriate women, 178 invasive CxCa 
cases and 32 CIS cases were experienced totaling 210 cases; whereby, 84.8% were 
invasive cases, and 15.2% were precancerous cases. 
 The National Cancer Registry, Cancer Incidence 2014 report (Appendix A) (QMoPH 
National Cancer Program, 2014) revealed that 18 cases of CxCa were registered in 2014 
along with 17 cases of CIS of the cervix. The report also declared that of the 18 cases of 
invasive cervical cancer registered, 28% of these cases were in Qatari women while the 
remainder 72% of cases were in non-Qatari, expatriate women. Also, importantly, that 
greater than 60% of all the CxCa cases registered in 2014 were subsequently shown to 
harbor Stage II/III disease at histologic diagnosis; and, that these cases produced a 
bimodal pattern of prevalence distribution based on two peak age groups: 40-44, and 60-
64 years. The clinical and demographic data of CxCa cases arising from the 
contemporary Qatar setting closely align with ICO World Report estimates. The ICO 
(Institut Catala d’Oncologica, 20172) published an anticipated annual CxCa burden of 15 





Cervical Cancer Health Literacy And Healthcare Promotion In The State Of 
Qatar 
Sidra Medicine Symposium: The 1st Century Of Gynecological Cytopathology, The Pap 
Test – Then, Now And The Future 
 The author took employment at Sidra Medicine starting in November 2013. In 
line with the National Cancer Registry, Cancer Incidence 2014 report (QMoPH National 
Cancer Program, 2014), the Sidra DC Section and the Department of Pathology 
organized a dedicated symposium to raise awareness of CxCa, Pap test screening 
practices, and vaccination for HPV. The symposium, entitled The 1st Century Of 
Gynecological Cytopathology, The Pap test – Then, Now And The Future, was conducted on 
December 07, 2014 (Appendix C, D, and E). The symposium was open to all 
stakeholders affiliated with the detection and management of CxCa in the State of Qatar. 
Attendees included clinicians, diagnostic cytologists, and representatives from the 
QMoPH. The symposium and its outcomes were widely acknowledged in the local 
English and Arabic language press and web-based media. 
 Following the Sidra Medicine symposium in 2014, the author was invited to 
participate in an ad-hoc committee at the QMoPH to explore the prospect of organized 
CxCa screening in the State of Qatar. The author’s participation ended in March 2016. 
Guidelines For Cervical Cancer Screening In The State Of Qatar 
 In 2016, the QMoPH, through its National Cancer Program, published draft 
guidelines for the management of CxCa inclusive of screening practice in a report, 




Cancer Program, 20161) (Appendix F). The guidelines produced General Principles 
suggesting: 
“All eligible and asymptomatic women aged 25 to 64 years and sexually active 
should be invited for routine cervical screening at given age ranges and 
screening intervals: 
 Women aged 25 to 49 years should be screened every 3 years; 
 Women aged 50 to 64 years should be screened every 5 years.” 
Moreover: 
“Depending on the cervical screening result, human papillomavirus test (HPV 
test) will be conducted.” 
 The General Principles also recommended that women ought to give consent to 
Pap test sampling after being adequately educated of the risks and benefits of screening. 
 Nevertheless, in due course, the QMoPH decided that CxCa management 
through Pap test population-based screening with patient call and recall shall remain 
under consideration as a work-in-progress. Shortly thereafter, the author was advised 
that given the relatively low incidence rates recorded for this disease in this 
geographically-small clinical setting, Pap test uptakes were to remain opportunistic in 
the State of Qatar (V.V. Recreo; personal communication, March 17, 2016). 
Guideline For Suspected Cancer Referral In The State Of Qatar 
 Also in 2016, the QMoPH, through its National Cancer Program, published its draft 




entitled Guideline For Suspected Cancer Referral In The State Of Qatar (QMoPH National 
Cancer Program, 20162) (Appendix G). The guidelines were based on a flow-chart 
guiding the management of patients depending on presenting symptoms, and suspected 
cancer type; whereas: 
“The suspected cancer referral guidelines have been produced with the 
assistance of a multidisciplinary group of clinicians to provide a comprehensive 
overview of the suspected cancer patient’s journey from referral to timely 
diagnosis and treatment.” 
 The purpose of the guidelines was to assure least possible delays in cancer 
diagnosis and treatment. The proposed Patient Referral Pathway included a flow chart, 
entitled Urgent Suspicion Of Cancer. The referral pathway proposed clinical examinations 
and diagnostic investigations be conducted within 48 hours of patient presentation; and, 
that definitive treatment be initiated within 14 days of diagnosis. Such initiatives are 
highly extraordinary. 
 Specifically for suspected gynecological cancers (i.e., cervical, endometrial and 
ovarian cancers), the clinical criteria for clinicians to apply the 48-hour Urgent Suspicion 
Of Cancer pathway follow: 
 Post-menopausal bleeding 
 Abnormal high grade cervical smear (HSIL, ASC-H, AGC) 
 Suspicious mass 




 Radiological findings strongly suspicious of invasive malignancy 
 Similarly, the clinical criteria for a patient’s referral within 14 days for additional 
investigations follow: 
 LSIL 
 Irregular bleeding in a woman on hormone replacement therapy 
 Purulent vaginal discharge 
 Bloodstained vaginal discharge 
 Inter-menstrual bleeding 
 Post-coital bleeding 
 Persistent abdominal distention/bloating 
 Abdominal/pelvic pain 
 Feeling full quickly and/or having difficulty eating (loss of appetite) 
Qatar Cancer Society Awareness Campaign For Cervical Cancer: “Be Well” 
 In January 2017, the QCS launched an extensive health awareness campaign, 
entitled Be Well (Qatar Cancer Society, 2017) (Appendix H). The campaign ran 
throughout the month of January 2017 to raise awareness of CxCa, of its symptoms, of 
its potential prevention through Pap test screening, and to ultimately encourage women 
to “check out the Pap smear.” The campaign also included lectures and workshops 
conducted by authorized officials. The article posted on January 11, 2017, in the 




“…cervical cancer often does not cause symptoms until it is advanced, so it is 
important to start the early detection tests regularly even when you feel healthy, 
and in Qatar: you can do the Pap test in Primary Health Care Center (Women’s 
Health Clinic).” 
National Health Strategy 2018-2022 
 In 2018, the QMoPH published the National Health Strategy 2018-2022, under the 
subtitle, Our Health Our Future (QMoPH National Health Strategy 2018-2022, 2018) 
(Appendix I). The national strategy stipulated an increased but comprehensive effort for 
the early detection of disease and its possible prevention through improved health 
education and best-practice services for cancer treatment. The ultimate target of the 
strategy, through to 2022, was a 15% reduction in premature mortality due to chronic 
diseases such as cancer (QMoPH National Health Strategy 2018-2022, 2018). 
National Clinical Guidelines For The State Of Qatar (2nd Edition) 
 In April 2017, in the run-up to the National Health Strategy 2018-2022, the QMoPH 
had published its 2nd edition clinical guidelines, entitled National Clinical Guidelines For 
The State Of Qatar – 2nd Edition (Appendix J). The QMoPH capitalized upon the extensive 
internet connectivity and mobile phone networks installed throughout the State to 
provide practice guidelines for all registered clinicians through dedicated websites, 
apps, and e-medicine platforms. The rationale of the guidelines follows (QMoPH 




“The majority of healthcare practitioners working in Qatar have been trained 
overseas. As we draw upon the advantages brought forward by the diverse set of 
specialized skills, languages and perspectives in patient and peer interactions, it 
is also of utmost importance to acknowledge that this may innately contribute to 
a significant variation in the standard of care provided. 
The National Clinical Guidelines project started in April 2015. Initially, through 
consultations with stakeholders, the MoPH NCG team mapped the processes for 
guideline development and localization by different organizations across Qatar’s 
health economy. The gaps between current practice in Qatar and the 
international best practice approach were identified and accordingly a model for 
guideline development was agreed and established.” 
Qatar Ministry Of Public Health Infographic: “What Is Cervical Cancer?” 
 Also in 2017, the QMoPH produced a public health infographic, entitled What Is 
Cervical Cancer (Appendix K(a) and K(b)). The 2-page fold-out brochure illustrated 
salient information about CxCa: Its global incidence; its etiology; what is HPV; the 
symptoms of CxCa and of HPV infection; how women may protect themselves from 
HPV and CxCa; the purpose of HPV vaccination; and, encouragement for women to 
seek medical care (QMoPH What Is Cervical Cancer, 2017). 
HPV Vaccination Protection In The State Of Qatar 
 In February 2018, the QMoPH announced its endorsement and immediate roll-




2018; QMoPH Health Protection & Communicable Disease, 2018). The program 
advocated prompt availability of the HPV vaccine throughout the State to facilitate 
protection and primary prevention of CxCa. The program proposed that HPV 
vaccination be made available to females and males age 12 to 26. 
Opportunities For Healthcare Promotion Research 
 Along with the myriad of initiatives and health literacy campaigns conducted in 
the State of Qatar since 2014, the introduction of HPV vaccination in 2018 manifested an 
unprecedented potential for effective CxCa control. As such, these developments posed 
a unique opportunity for research to assess current public awareness of CxCa, of the Pap 
test, and, of perceptions and attitudes towards HPV vaccination. Similarly, to assess 
likely public support for a formal population-based CxCa screening program for all 
resident women through a needs-assessment survey offered to both women and men. 
 In addition to the knowledge gained from the historical development of the Pap 
test in the US, such survey-based data may reveal gaps to guide the consideration of 
tailored cytopathology and gynecology services at Sidra Medicine in keeping with the 
governmental initiatives and long-term healthcare ambitions for the State. Such research 
data may also aid in the optimization of existing CxCa management philosophies and 
practices in the State of Qatar to mitigate the number of women presenting with 
advanced disease at diagnosis. 
 Through a collaborative research team effort at Sidra Medicine, a needs-




survey-based research designs were reviewed for the development of the needs-
assessment survey: (Kahn, Chiou, Allen, Goodman, Perlman, & Emans, 1999; Badrinath, 
Ghazal-Aswad, Osman, Deemas, & McIlvenny, 2004; Lyva, Byrd, & Tarwater, 2006; 
Denny & Wright, 2009; Fernandez, Diamond, Rakowski, Gonzales, Tortolero-Luna, 
Williams, & Morales-Campos, 2009; Guvenc, Akyuz, & Acikel, 2010; Tanner-Smith & 
Brown, 2010; Ma, Gao, Fang, Tan, Feng, Ge, & Nguyen, 2013; Jaglarz, Tomaszewski, 
Kamzol, Puskulluoglu, & Krzemieniecki, 2014; Lee & Carvallo, 2014; Ebu, Mupepi, 
Siakwa, & Sampselle, 2015; Glanz, Rimer, & Viswanath, 2015; Interis, Anakwenze, Aung, 
& Jolly, 2016). 
 The structure of the survey, along with its questions and responses, and their 






CHAPTER 4: NEEDS-ASSESSMENT SURVEY MATERIALS AND 
METHODS 
 
Preceding Survey-Based Research In The State Of Qatar 
 To uncover relevant, preceding survey-based research from the State of Qatar, a 
PubMed search was conducted using the following four key terms inclusively: Cervical + 
Cancer + Survey + Qatar. The search revealed one indexed survey-based study by Al-
Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) reporting findings arising from a 
needs-assessment project conducted in 2008 reflecting women participants visiting 
PHCC centers in Qatar. Two other studies were also revealed from the PubMed search 
reporting epidemiological data arising from Qatar, but not from needs-assessment 
surveys. A Google search using the same key terms inclusively revealed a second 
survey-based study by Alali, Salem, Elmahdi, Alkubaisi, Alwahedi, Taher, Yousuf, 
Aljaber, & Mostafa (2016) not indexed in PubMed. These two survey-based exercises 
analyzed responses exclusively from women participants. 
 It is the author’s belief that this dissertation comprises the third survey-based 
exercise conducted in the State of Qatar; although, it was the first to assess perceptions 
and magnitude of support for a formal, national Pap test screening program for all 




Needs-Assessment Survey Design 
 The needs-assessment survey research protocol was composed following 
guidelines from the National Institutes of Health (NIH) (National Institutes of Health, 
2018). The research protocol, survey questions, and responses were produced 
collaboratively in both English and Arabic, and submitted to the Sidra Institutional 
Review Board (IRB) Ethics Committee for consideration on November 02, 2017. 
Following two revisions, the research study was formally approved by the Sidra IRB on 
December 11, 2018, under protocol number: MoPH-Sidra-IRB-099. The distribution of 
300 surveys commenced on December 28, 2018, and ended on April 03, 2019. The Sidra 
IRB approval stipulated that survey distribution be conducted within the Sidra Medicine 
caption area. 
 The survey was voluntary, self-reported, and anonymous as no personal 
identification information was requested or recorded. Invited participants were women 
or men, either visitors or patients accessing gynecological services at Sidra Medicine, or 
interested employees. The survey was exclusively in hard-copy format. After 
participants’ completion of the survey, all surveys were enclosed in dedicated envelopes 
and subsequently organized to support data capture. 
 The Sidra IRB committee dictated the final wording of the survey questions and 
responses in both the English and Arabic survey versions to sustain cultural sensitivity 
and the societal norms of the State of Qatar. Specific wording nonetheless aimed to 




Arabic were not always appropriate or comprehensible. The Sidra IRB committee also 
approved a Leaflet to accompany the surveys to welcome the respondents and provide 
an introduction to the aims of the research effort. The Leaflet, produced in both English 
and Arabic, also functioned to document participants’ consent to survey participation, 
with an attestation of their age not being under 18 years. Given the laws and stipulations 
applicable to medical practice and research in the State of Qatar, an exclusion criterion 
was imposed such that the survey would not be made available to participants younger 
than 18 years of age. 
Needs-Assessment Survey Questions, Responses, And Rationale 
 The needs-assessment survey was considered through a collaborative research 
team effort (see Acknowledgments) and consisted of 31 questions. The English version 
of the survey, in its entirety, appears in Appendix B. The survey questions were worded 
with relevance to the current practices for CxCa management in the State of Qatar, and 
took into account preceding survey-based research. The overall intent was to produce 
robust data reflecting the views and opinions of women and men, to support services 
development at Sidra Medicine, and ongoing, follow-up research and academic work. 
Needs-Assessment Survey Questions And Data Categories 
 The needs-assessment questions and responses were designed to capture 
information based on four broad data categories: (1) Socio-demographic; (2) Healthcare 




 The breakdown of questions (i.e., variables) incorporated into the four data 
categories follows: 
 Category 1: Socio-demographic (Questions 1-8, and 31) 
 Category 2: Healthcare Services (Questions 9-11) 
 Category 3: Health Literacy (Questions 12-20) 
 Category 4: Self-efficacy and Perceptions (Questions 21-30) 
Needs-Assessment Survey Questions 









o Middle Eastern 
o Asian 
o European 
o North American 
o South American 
o African 
o Other 
 Rationale: Question 1 aimed to capture socio-demographic data based on: 
Nationality. The intent was to produce a breakdown of the nationalities arising from all 
respondents to facilitate correlation with the proportionality of nationalities amongst all 






 Rationale: Question 2 aimed to capture socio-demographic data based on: 






Age group (Years). 





o Over 60 
 Rationale: Question 3 aimed to capture socio-demographic data based on: Age 
group (years). This question aimed to capture age-related data from all 
respondents based on six age-group categories. The intent was to reveal 
distributions particularly from women to allow correlations with preceding 
epidemiological data arising from Qatar as published by the QMoPH (QMoPH 
National Cancer Program, 2014) in the context of CxCa. This question would also 
facilitate the exclusion of participants younger than age 20. 
Question 4 
Highest education level. 
o Middle School 
o High School 
o University 
o Other 
 Rationale: Question 4 aimed to capture socio-demographic data based on: Highest 
education level. This question aimed to capture the extent of education from all 
respondents to facilitate correlations with population-based statistics arising from the 











 Rationale: Question 5 aimed to capture socio-demographic data from all 
respondents based on: Marital status. This question would also facilitate correlation with 
previously-reported studies, and statistics arising from the State of Qatar. 
Question 6 
Marriage duration. 
o Under 5 
o 5-10 
o 10-20 
o Over 20 
o Not applicable 
 Rationale: Question 6 aimed to capture socio-demographic data from all 






 Rationale: Question 7 aimed to capture demographic data from all respondents 
based on: Employment status. The intent was to reveal extent of likely financial 






You have health insurance coverage? 
o Yes 
o No 
 Rationale: Question 8 aimed to capture socio-demographic data from all 
respondents based on: Health insurance coverage. 
Question 9 
You had a Pap test before? 
o Yes 
o No 
o Not applicable 
 Rationale: Question 9 aimed to capture healthcare services data based on: Pap test 
uptake. This question aimed to assess the likelihood of Pap test uptakes from all women 
respondents; allowing subsequent exclusion of male respondents. 
Question 10 
If you had a Pap test before, when was it performed? 
o 1-3 years ago 
o 4-6 years ago 
o Over 6 years ago 
 Rationale: Question 10 aimed to capture healthcare services data based on: Years 
duration since previous Pap test. This question aimed to assess time-frames of preceding 
Pap test uptakes from all women respondents; allowing subsequent exclusion of male 
respondents. These data may correlate with the screening intervals currently 






Did you, or any member of your family have cervical cancer before? 
o Yes 
o No 
o Don’t know 
 Rationale: Question 11 aimed to capture healthcare services data based on: 
History of cervical cancer in family member. This question aimed to assess awareness of 
CxCa from all respondents. 
Question 12 
Cervical cancer may be preventable. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 12 aimed to capture health literacy data based on: Knowledge 
of cervical cancer preventability. This question aimed to assess awareness pertaining to the 
possible prevention of CxCa from all respondents. 
Question 13 
You are aware of the Pap test smear cytologic method. 
o Yes 
o No 
 Rationale: Question 13 aimed to capture health literacy data based on: Awareness 
of the Pap test smear cytologic method. This question aimed to assess public awareness 






Where did you hear of the Pap test smear cytologic method for the first time? 
o Relatives, friends 
o Gynecologist 
o Mass media (newspaper, internet, television) 
o Family physician 
o Nurse 
o Other 
o Not applicable 
 Rationale: Question 14 aimed to capture health literacy data based on: Source of 
knowledge of the Pap test smear cytologic method. This question aimed to assess the 
predominant sources of information regarding the Pap test cytologic method from all 
respondents. 
Question 15 
You have knowledge of cervical cancer. 
o Yes 
o No 
 Rationale: Question 15 aimed to capture health literacy data based on: Knowledge 







Early detection of cervical cancer is important for effective treatment. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 16 aimed to capture health literacy data based on: Importance 
of early detection of cervical cancer for effective treatment. This question aimed to assess 
awareness pertaining to the importance of early detection of CxCa to facilitate effective 
treatment for all respondents. 
Question 17 
Regular Pap tests may protect you from cervical cancer. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 17 aimed to capture health literacy data based on: Knowledge 
of protection afforded through regular Pap test uptakes. This question aimed to assess 
awareness pertaining to likely disease prevention through protection availed by regular 







Cervical cancer may be curable. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 18 aimed to capture health literacy data based on: Curability 
of cervical cancer. This question aimed to assess awareness pertaining to the likely 
curability of CxCa from all respondents. 
Question 19 
Vaccination for the Human Papilloma Virus protects against cervical cancer 
and other HPV-associated cancers. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 19 aimed to capture health literacy data based on: Knowledge 
of protection for HPV-associated cancers, and cervical cancer, through HPV vaccination. This 
question aimed to assess awareness pertaining to the likely protections offered through 







Menopausal women need a Pap test. 
o Yes 
o No 
o Don’t know 
 Rationale: Question 20 aimed to capture health literacy data based on: Knowledge 
of need of Pap testing for menopausal women. This question aimed to assess knowledge 
pertaining to the need for Pap testing by menopausal women from all respondents. This 
question may reveal significant findings as the peak incidence of CxCa in the State of 
Qatar occurs in the 60-64 years age group as published by the QMoPH (National Cancer 
Program, 2014). 
Question 21 
More information is needed to improve your knowledge of cervical cancer. 




o Strongly disagree 
 Rationale: Question 21 aimed to capture self-efficacy and perceptions data based 
on: Need for additional information to improve participant’s knowledge of cervical cancer. This 
question aimed to assess self-efficacy and agreement/support reflecting the need for 






Regular Pap tests are a good health practice. 




o Strongly disagree 
 Rationale: Question 22 aimed to capture self-efficacy and perceptions data based 
on: Degree of good health practice through regular Pap testing. This question aimed to assess 
self-efficacy and agreement/support of the perceived value embedded in regular Pap 
test uptakes as being a good health practice from all respondents. 
Question 23 
Getting a Pap test performed is too difficult. 




o Strongly disagree 
 Rationale: Question 23 aimed to capture self-efficacy and perceptions data based 
on: Difficulty of getting a Pap test performed. This question aimed to assess degree of self-
efficacy and agreement/support of the likely difficulty in getting a Pap test performed 
from all respondents; allowing subsequent exclusion of male responders. This question 






You would recommend a Pap test to your family, friends, and colleagues. 




o Strongly disagree 
 Rationale: Question 24 aimed to capture self-efficacy and perceptions data based 
on: Recommendation of the Pap test for family, friends, and colleagues. This question aimed to 
assess degree of self-efficacy and agreement/support of the respondent to recommend 
the Pap test to family, friends, and colleagues from all respondents. This question may 
also reveal a reflection of overall knowledge of CxCa and of Pap testing, and of 
perceived barriers to Pap test uptakes. 
Question 25 
Getting a Pap test is a valued investment for good healthcare. 




o Strongly disagree 
 Rationale: Question 25 aimed to capture self-efficacy and perceptions data based 
on: Value of investment in a Pap test for good healthcare. This question aimed to assess 
degree of self-efficacy and agreement/support of the perceived value of investment 






You would support a Pap test screening program for cervical cancer. 




o Strongly disagree 
 Rationale: Question 26 aimed to capture self-efficacy and perceptions data based 
on: Support for a screening program for cervical cancer. This question aimed to assess degree 
of self-efficacy and agreement/support for a Pap test screening program from all 
respondents. 
Question 27 
A formal Pap test screening program for cervical cancer should be established 
for all women in the State of Qatar. 




o Strongly disagree 
 Rationale: Question 27 aimed to capture self-efficacy and perceptions data based 
on: Support for the establishment of a formal screening program for cervical cancer for all 
resident women in the State of Qatar. This question aimed to assess degree of self-efficacy 
and agreement/support for the establishment of a formal, national Pap test screening 






You know where to go to get a Pap test performed. 




o Strongly disagree 
 Rationale: Question 28 aimed to capture self-efficacy and perceptions data based 
on: Knowledge as to where to get a Pap test performed. This question aimed to assess degree 
of self-efficacy and agreement/support for knowledge as to where to get a Pap test 
performed in the State of Qatar from all respondents; allowing subsequent exclusion of 
male responders. 
Question 29 
A Pap test has no value for you. 




o Strongly disagree 
 Rationale: Question 29 aimed to capture self-efficacy and perceptions data based 
on: Value of a Pap test for the respondent. This question aimed to assess degree of self-
efficacy and agreement/support as to if the Pap test has or has not value for the 






If a self-test for cervical cancer was available you would prefer it? 




o Strongly disagree 
 Rationale: Question 30 aimed to capture self-efficacy and perceptions data based 
on: Support (i.e., preference) for a self-test for cervical cancer if available. This question aimed 
to assess degree of self-efficacy and agreement/support as to the preference for a self-test 
for CxCa if available from all respondents; allowing subsequent exclusion of male 
responders. This question may also reveal a reflection of perceived barriers to Pap test 
uptakes. 
Question 31 
If employed, are you employed in the healthcare sector? 
o Yes 
o No 
 Rationale: Question 31 aimed to capture socio-demographic data based on: 
Employment in the healthcare sector. This question aimed to assess likely employment in 
the healthcare sector from all respondents allowing correlation with data from preceding 






CHAPTER 5: NEEDS-ASSESSMENT SURVEY RESULTS 
 
Needs-Assessment Survey Data Set 
 Three-hundred surveys were distributed, completed, and retrieved for this study 
using either the English or Arabic hard-copy versions depending on participants’ 
preference. Completed surveys were organized and registered as per date of data 
capture, and sequentially numbered 001 to 300. 
Needs-Assessment Survey Data Set Analysis 
 Responses from all surveys were transcribed into a dedicated Excel spreadsheet 
designed with columns and drop-down menus to coincide with all survey questions and 
responses. The complete data set from the spreadsheet was imported electronically into 
a dedicated file using the R version 3.5.1 software (The R Foundation©) for the 
generation of contingency tables, figures representing data through bar plots, and for 
bivariate and multi-factorial statistical computations (Diez, Barr, & Cetinkaya-Rundel, 
2015). 
 The entire data set was analyzed through three levels of statistical analysis. As 
the survey produced exclusively categorical data, every question was considered a 
variable for statistical associations. Calculations for standard deviations, confidence 
intervals, and mean were not applicable. 
 Firstly, all data counts (i.e., responses) from all answered questions were 




Percent Response Rate, as: [(n=  /300) Response Rate:  %] for each question (i.e., variable). 
This was done to reflect questions possibly left unanswered by respondents. Thereafter, 
responses were analyzed through univariate categorical data analyses calculating the 
counts and frequencies against the total number of responses captured for every specific 
question. 
 Secondly, every question (i.e., variable) was subjected to bivariate correlations to 
reveal dependencies against all other variables based on category. This was achieved 
using a G-test analysis, a robust version of the Chi-Square test. Bivariate analyses 
produced a matrix revealing the p-values reflecting associations between variables for 
the entire data set. The p-value threshold for statistical significance in this study was set 
at p0.05. 
 Thirdly, multi-factorial analyses were attempted using Multiple Correspondence 
analysis and clustering techniques in an effort to reveal the contributing influence 
towards the dependencies throughout the data set for any one variable. However, these 
multivariate analyses did not produce computations or graphics with sufficient 
definition to contribute additional, meaningful statistical information, and were 
therefore not incorporated in this dissertation. 






Needs-Assessment Survey Data Set Organization 
 Responses arising from each question were tabulated as counts (n) and 
frequencies (%) in dedicated Tables stratified by Gender. The Tables demonstrated the 
complete array of responses for all 31 questions for the entire 300 survey data set. 
Percent values were rounded to 3 significant figures. 
 The entire survey data set was tabulated through nine Tables (Table 10-18). The 
Tables demonstrated survey questions sequentially and descriptively (in italics), with all 
response options as counts (n) and frequencies (%), and this data was thereafter 
segregated through stratification by Gender. 
 The p-values generated from the bivariate statistical analyses were organized in 
five Tables (Table 19-23). These Tables demonstrated matrices of p-values to reveal 
statistically significant associations between variables as organized in the four 
categories: Socio-demographic, Healthcare Services, Health Literacy, and Self-efficacy & 
Perceptions. Significant p-values were highlighted using bold font. 
Needs-Assessment Survey Limitations 
 Listed below are conceivable limitations arising from this survey-based research 
work given its design and clinical context. As a result of these limitations and their likely 
impact, potentially unreliable data or conclusions may have been proposed. Where 
applicable, these limitations were rationalized and addressed in the remarks and 




Discussion (Chapter 6). The intent was to alert the readership of the likely impact posed 
by the following possible limitations. 
 Survey Comprehension: As the needs-assessment survey was voluntary, self-
reported, and anonymous, it remains impractical to presume that all 
respondents comprehended equally the survey questions and/or answer 
options. As such, any possible incomprehension or confusion on the part of 
the respondent may have led to problematic statistical computations; 
 Language Barriers: Nearly 81.5% of the 2.7 million people currently residing in 
the State of Qatar are multi-national expatriates employed through passport-
based work permits and originated from essentially all nationalities and 
regions of the world. It is therefore plausible that a substantial proportion of 
these expatriates may not have had English or Arabic as their mother 
languages, or may not have had proficient command of these languages. 
Language barriers may have impacted on respondents’ comprehension of 
survey questions and answers as alluded to above; 
 Percent Response Rates: Percent Response Rate calculations intended to 
demonstrate the percentage of respondents that answered every question in 
the 300 distributed surveys. It is plausible that questions left unanswered 
may have reflected Survey Comprehension or Language Barriers limitations as 
argued above. However, the Percent Response Rates may also effectively 




Percent Response Rates may reflect conservative cultural norms obstructing 
respondents’ willingness to answer questions that may have been perceived 
as being sensitive; 
 Employment In The Healthcare Sector: As this survey-based research was 
conducted in Sidra Medicine given Sidra IRB stipulations, 54.1% of survey 
respondents indicated being employed in the healthcare sector (Table 18; 
Question 31). It is plausible that healthcare employees may demonstrate 
increased levels of CxCa health literacy compared to the general public by 
virtue of their employment status in a specialized Women’s and Children’s 
hospital; therefore, healthcare employees may not be representative of the 
general public at large in the State of Qatar. Nevertheless, data was 
interpreted cautiously herein under the presumption that responses from 
healthcare workers posed a reasonable representation of the general public; 
 Population Representation: As an extension of the aforementioned limitation, as 
this survey research was conducted within Sidra Medicine, inclusive of 
patients and visitors in a specialized hospital, it is equally plausible that 
survey respondents may not be representative of the general public at large 
in the State of Qatar; 
 Incidence Of Cervical Cancer In The State Of Qatar: The incidence of CxCa in the 
State of Qatar is reported as being 3.2 cases per 100,000 (Chapters 3 & 6). 




incidence rates of CxCa it is plausible that the reported incidence rate is 
under-estimated. Although this potential limitation is neither avoidable nor 
challenged in the context of this dissertation, remarks and interpretations put 
forward in Chapter 6 may need to be considered cautiously; 
 Question 6 (Marriage Duration): Given the overlap of years in the answer 
options for Question 6, data arising from this variable may be erroneous as it 
poses a delimitation on the part of the researchers. The answer options were 
nonetheless intended to represent time periods, and this limitation may not 
be adversely impactful pertaining to the remarks, interpretations or 
conclusions raised relative to the dissertation hypotheses. Nevertheless, this 
potential limitation is emphasized accordingly in the dissertation Discussion 
(Chapter 6). Any additional research work conducted to assess the impact of 
Marriage Duration in the clinical setting of Qatar ought to reconstruct the 
answer options for Question 6 to avoid time period overlap. 
Needs-Assessment Survey Tables For Categorical Data And Statistical Dependencies 
Analyses 






TABLE 10: Categorical data from the survey data set for Questions 1-4 including Response Rates. Data presented as counts (n) with 
corresponding frequencies (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q1  
(n=300/300) 



































































Response Rate: 97.7% 
Gender. N/A N/A n=173 59.0% n=120 41.0% 
Q3  
(n=292*/300) 
Response Rate: 97.7% 
 
*after exclusion of (1) 
male under 20 years 
old 



















































Response Rate: 97.7% 
 







































TABLE 11: Categorical data from the survey data set for Questions 5-9 including Response Rates. Data presented as counts (n) with 
corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q5  
(n=293/300) 






































Response Rate: 88.3% 











































































Response Rate: 96.0% 






























Response Rate: 95.3% 
 

































TABLE 12: Categorical data from the survey data set for Questions 10-13 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q10  
(n=104/300) 
Response Rate: 34.7% 
If you had a Pap test 
before, when was it 
performed? 
1-3 years ago 
4-6 years ago 







































Response Rate: 95.3% 
Did you, or any member of 











































Response Rate: 96.0% 





































Response Rate: 96.0% 
You are aware of the Pap 






































TABLE 13: Categorical data from the survey data set for Questions 14-16 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q14  
(n=280/300) 
Response Rate: 93.3% 
Where did you hear of the 
Pap test smear cytologic 
method for the first time? 
Relatives, friends 
Gynecologist 










































































Response Rate: 96.7% 






























Response Rate: 96.7% 
Early detection of cervical 













































TABLE 14: Categorical data from the survey data set for Questions 17-19 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q17  
(n=286/300) 
Response Rate: 95.3% 
Regular Pap tests may 











































Response Rate: 96.7% 





































Response Rate: 95.7% 
Vaccination for the 
Human Papilloma Virus 
protects against cervical 

























































TABLE 15: Categorical data from the survey data set for Questions 20-22 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q20  
(n=281/300) 
Response Rate: 93.7% 
Menopausal women need 




































Response Rate: 95.3% 
More information is 
needed to improve your 































































Response Rate: 95.3% 
Regular Pap tests are a 





















































TABLE 16: Categorical data from the survey data set for Questions 23-25 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q23  
(n=284/300) 
Response Rate: 94.7% 
Getting a Pap test 


















































Response Rate: 95.0% 
You would recommend a 
Pap test to your family, 
























































Response Rate: 96.0% 
Getting a Pap test is a 



























































TABLE 17: Categorical data from the survey data set for Questions 26-28 including Response Rates. Data presented as counts (n) 
with corresponding percentages (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q26  
(n=287/300) 
Response Rate: 95.7% 
You would support a Pap 

























































Response Rate: 95.3% 
A formal Pap test 
screening program for 
cervical cancer should be 
established for all women 




































































Response Rate: 94.0% 
You know where to go to 




















































TABLE 18: Categorical data from the survey data set for Questions 29-31 including Response Rates. Data presented as counts (n) 
with corresponding frequencies (%) stratified by Gender. 
 Women Men 
Question Description Count Frequency Count Frequency Count Frequency 
Q29  
(n=284/300) 
Response Rate: 94.7% 



















































Response Rate: 94.3% 
If a self-test for cervical 
cancer was available you 
























































Response Rate: 93.0% 
If employed, are you 






































TABLE 19: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q1-
8, 31) in Category 1, and Health Services variables (Q9-11) in Category 2 (significant p-values appear in bold font). 










































Q9 Had a Pap 
test before 
0.00000012 0.000000006 0.000000008 0.03798 0.00000004 0.0000032 0.000018 0.9377 0.0003357 
Q10 If had a Pap 
test before, when 
was it performed 
0.5665 0.6679 0.8776 0.08175 0.3181 0.03648 0.3497 0.1781 0.4238 
Q11 Family 
history of CxCa 






TABLE 20: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q1-
8, 31) in Category 1, and Health Literacy variables (Q12-16) in Category 3 (significant p-values appear in bold font). 









































Q12 CxCa may 
be preventable 
0.6504 0.203 0.5918 0.8562 0.1113 0.3495 0.09697 0.4663 0.0001159 
Q13 You are 
aware of the Pap 
test cytologic 
method 
0.03766 0.009553 0.1407 0.06513 0.9244 0.1719 0.1989 0.004242 0.0000065 
Q14 Where did 
you hear of the 
Pap test method 
before 
0.1212 0.1059 0.04087 0.1308 0.002733 0.02039 0.1255 0.4708 0.0005167 
Q15 You have 
knowledge of 
CxCa 













TABLE 21: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q1-
8, 31) in Category 1, and Health Literacy variables (Q17-20) in Category 3 (significant p-values appear in bold font). 










































Pap tests may 
protect you from 
CxCa 
0.5621 0.2776 0.3541 0.6093 0.4012 0.3052 0.07667 0.08415 0.02428 
Q18 CxCa may 
be curable 
0.004244 0.3612 0.8374 0.9297 0.3412 0.3456 0.01827 0.1408 0.0000623 
Q19 Vaccination 





0.0000026 0.0002238 0.3403 0.6515 0.2085 0.0273 0.1814 0.4581 0.003599 
Q20 
Menopausal 
women need a 
Pap test 






TABLE 22: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q1-
8, 31) in Category 1, and Self-efficacy & Perceptions variables (Q21-25) in Category 4 (significant p-values appear in bold font). 















































0.09256 0.2262 0.04504 0.5698 0.01028 0.02365 0.2134 0.8437 0.2293 
Q22 Regular 
Pap tests are 
good for health 
practice 
0.4393 0.3629 0.1502 0.4466 0.5316 0.8438 0.1016 0.342 0.238 
Q23 Getting a 
Pap test 
performed is too 
difficult 
0.5385 0.3088 0.1085 0.2865 0.1268 0.04028 0.7795 0.7002 0.8119 
Q24 You would 
recommend a 
Pap test to 
family, friends 
0.4181 0.4246 0.07992 0.7831 0.6696 0.514 0.04067 0.1035 0.1419 
Q25 Getting a 
Pap test done is a 
valued 
investment 





TABLE 23: Bivariate analysis matrix revealing dependencies expressed through p-values between Socio-demographic variables (Q1-
8, 31) in Category 1, and Self-efficacy & Perceptions variables (Q26-30) in Category 4 (significant p-values appear in bold font). 










































Q26 You would 




0.09911 0.6406 0.1715 0.05745 0.331 0.5249 0.09047 0.6946 0.6357 
Q27 A formal 
screening 
program should 
be established, all 
women in Qatar 
0.795 0.3409 0.6989 0.8102 0.6961 0.8417 0.2855 0.8942 0.4663 
Q28 You know 
where to go to 
get a Pap test 
performed 
0.003118 0.2504 0.2983 0.1304 0.1847 0.2102 0.6531 0.6023 0.2191 
Q29 A Pap test 
has no value for 
you 
0.06362 0.07646 0.1012 0.2248 0.3868 0.01878 0.4397 0.9227 0.343 
Q30 If a self-test 
for CxCa was 
available you 
would prefer it 





Needs-Assessment Survey Data Set Representation 
 The entire survey data set was represented through 16 Figures. Each Figure 
included 2 bar plots separated by a line for definition where possible. 
 Figure 1 represented responses from survey questions 1 and 2 as illustrated in 
dedicated univariate bar plots. Gender was utilized as the stratification determinant 
thereafter for all questions (i.e., Questions 3-31). 
 Responses from survey questions 3 through 31 were represented in dedicated 
composite bar plots with data stratification between women and men based on counts, 
and contrasted by grey-scale colors (Figures 2-16). 
Needs-Assessment Survey Data Set Figures 






FIGURE 1: Two bar plots representing Socio-demographic survey data captured for 
Questions 1 and 2 reflecting the breakdown of response counts; all respondents, for 







FIGURE 2: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 1 and 3 reflecting 







FIGURE 3: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 4 and 5 reflecting 







FIGURE 4: Composite figure of 2 bar plots representing Socio-demographic survey data captured for Questions 6 and 7 reflecting 







FIGURE 5: Composite figure of 2 bar plots representing Socio-demographic and Healthcare Services survey data captured for 
Questions 8 and 9 reflecting the breakdown of response counts; all respondents, for Health Insurance Coverage and Pap test Uptake 







FIGURE 6: Composite figure of 2 bar plots representing Healthcare Services survey data captured for Questions 10 and 11 reflecting 








FIGURE 7: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 12 and 13 reflecting the 








FIGURE 8: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 14 and 15 reflecting the 








FIGURE 9: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 16 and 17 reflecting the 
breakdown of response counts; all respondents, for perceived Importance of early cervical cancer detection and Protection through regular 







FIGURE 10: Composite figure of 2 bar plots representing Health Literacy survey data captured for Questions 18 and 19 reflecting the 
breakdown of response counts; all respondents, for perceived Cervical cancer curability and HPV vaccination protection respectively 







FIGURE 11: Composite figure of 2 bar plots representing Health Literacy and Self-efficacy & Perceptions survey data captured for 
Questions 20 and 21 reflecting the breakdown of response counts; all respondents, for perceived Need of Pap testing for menopausal 







FIGURE 12: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 22 and 23 
reflecting the breakdown of response counts; all respondents, for perceived Value of Pap testing and Difficulty in getting a Pap test 







FIGURE 13: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 24 and 25 
reflecting the breakdown of response counts; all respondents, for Willingness to recommend the Pap test to others and Perceived healthcare 







FIGURE 14: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 26 and 27 
reflecting the breakdown of response counts; all respondents, for Support for a Pap test screening program and Support for a formal Pap 







FIGURE 15: Composite figure of 2 bar plots representing Self-efficacy & Perceptions survey data captured for Questions 28 and 29 
reflecting the breakdown of response counts; all respondents, for Knowledge of where to go to get a Pap test performed and Perceived 







FIGURE 16: Composite figure of 2 bar plots representing Self-efficacy & Perceptions and Socio-demographic survey data captured 
for Questions 30 and 31 reflecting the breakdown of response counts; all respondents, for Support and preference for possible self-testing 







CHAPTER 6: DISCUSSION AND CONCLUSIONS 
 
 No other diagnostic test for cancer has impacted upon the intimacies of women’s 
healthcare and social welfare to a greater extent than that of the Pap test in the history of 
medicine (Foltz & Kelsey, 1978; Greenwald, Cullen, & McKenna, 1987; Casper & Clarke, 
1998). While the clinical Pap test remains perfect and paradoxically imperfect given 
various limitations, it has a proven legacy for saving lives since its deployment in the US 
in 1957 (Koss, 1989; Gordis, 2014). According to Cibas and Ducatman (2014), nearly 90% 
of women in the US claim to have had a Pap test within a preceding 3 year period. 
Notably, the WHO has cautioned that less than 5% of women in developing, resource-
poor nations had, or may ever have, a Pap test (Sherris, Herdman, & Elias, 2001). This 
striking incongruity is at the heart of this research effort. 
 The experience arising from 62 years of systematic Pap test screening in various 
developed nations since 1957 is incontestable (Habbema, De Kok, & Brown, 2012). As 
CxCa is now widely considered a preventable disease, Garner (2003) alleged that any 
woman presenting with advanced CxCa ought to be viewed as a surrogate indicator of 
failed screening practice. A complementary report by Suba and Raab (2004) pertaining 
to Pap test sampling in developing nations, stated that failures in CxCa screening may 
be attributable to programmatic shortfalls rather than to technical limitations inherent in 




universally warranted to yield improved access to screening hence to improved clinical 
benefits. 
 It is hoped that insights brought forward from the historical experience in the 
US, coupled with emerging technologies both in medicine and through global 
modernization, may alleviate Pap test uptake disparities to facilitate equitable CxCa 
control. Similarly, that data and conclusions drawn from this research may facilitate 
optimization of existing Pap test sampling practices in the State of Qatar. The ultimate 
objective would be a reduction in the number of women presenting with advanced 
CxCa at diagnosis in this small clinical setting. 
Insights Brought Forward From The Historical Development Of The Clinical 
Pap Test In The United States 
 In the first 57 years of the 20th century, both anticipated and unforeseen situations 
influenced the evolutionary course of the VFSM from its experimental prototype 
through to its clinical deployment as the refined Pap test. Despite the various dynamics, 
it was political will prompted by the burden of CxCa, its detection, and its ramifications 
in women’s welfare that drove the evolutionary saga of the Pap test from 1928 through 
to 1957, and henceforth. 
Significance Of Cervical Cancer Definition Through Carcinoma In Situ 
 The most significant milestone was conceptualization and detection of cervical 
precancer proposed by Papanicolaou and Traut in 1941. However, it ought to be 




the diagnostic VFSM in the Battle Creek conference. CxCa assumed definition with the 
emergence of CIS, but this also led to unforeseen challenges. Preclinical, cervical CIS 
posed a hermaphroditic phenomenon in the mid-1940s: On the one hand, it enticed 
gynecologists with a screening tool by which to detect and ablate asymptomatic disease 
and effectively prevent invasive cancer; from the other hand, it antagonized surgeons 
and pathologists perceiving professional threats and challenges to medical tenets and 
practices. History has witnessed the commendable efforts by various individuals and 
organizations to resolve these dilemmas. The recognition of dyskaryotic cells 
purportedly pathognomonic of cervical precancer using unfamiliar cytologic smears and 
stains was a major, understandable challenge to conventional anatomical pathology. Yet, 
in the overall timeline of events, it was cervical precancer that reformed the prospects 
for Papanicolaou, for the Pap test, and for the management and control of CxCa in the 
US, and in other developed nations. 
 Papanicolaou and Traut’s foundational monograph in 1943 produced a tangible 
target for the medical establishment. That target had been elusive until 1943 even 
though cervical CIS was a recognized entity in anatomical pathology. But what wasn’t 
recognized was how to identify CIS, when still preclinical, using a non-invasive method. 
The new target facilitated the revelation of early CxCa in asymptomatic women through 
use of the VFSM. This target transcended into the basis for CxCa prevention through 




epidemiology of CxCa. Through CIS, the preclinical and latent phases of the disease 
became measurable targets diagnostically and therapeutically from 1941 henceforth. 
 It may be reasonable to speculate that neither the success of the Pap test in 
preventive medicine, nor the modern institution of gynecological cytopathology, may 
have materialized had it not been for the cytologic detection and clinical impact of 
cervical precancer. Cervical precancer demarcated a critical threshold for public health 
surveillance and disease control. 
Significance Of Organizational Policy, Promotion, And Advocacy 
 Macro-dynamics revealed the importance of formal organizational advocacy and 
policy prompted by political will, along with allocation of commensurate human and 
financial resources to address societal threats such as CxCa. Ironically, Papanicolaou’s 
introduction of the diagnostic VFSM through his New Cancer Diagnosis presentation in 
1928 coincided with profound, distractive priorities in the US: The Great Depression; an 
increasing burden and death rate due to cancer; and the Eugenics campaign calculating 
the eradication of unwanted human ailments through avant-garde tactics. The overall 
backdrop to Papanicolaou’s 1928 presentation was complex and unaccommodating. 
During the 1920s, the dreaded disease that oftentimes led to indiscriminate silent deaths 
in women was a scientific oddity. Understandably, CxCa elicited adverse attitudes of 
hopelessness, fatalism, and stigmatization in both society and medicine. And the overall 
nature and intimacies of CxCa along with its anatomy and possible detection aroused 




challenges at its onset in 1913 but struggled to resolve them. The evolution of 
policymaking and advocacy in parallel with the momentum generated from the Pap 
test’s development was critical. 
 The contributions by Ayre, Meigs, and Erskine were most timely by the late-
1940s. They offered the reenergized ACS a convenient opportunity to demonstrate 
servant leadership and assuredly claim the defeat of CxCa. This triumph in preventive 
medicine spawned optimism towards the effective control of other cancers based on 
emerging theories of carcinogenesis. These outcomes revealed the importance of 
sponsorship, promotion, and professional collaboration to bring about efficacious 
methods. 
Significance Of Method Framing 
 The seemingly failed presentation by Papanicolaou in 1928 revealed the 
importance of proper framing for a novel concept in medicine, to project its relevance 
and facilitate its acceptance. In the author’s opinion, Papanicolaou’s setback reflected a 
lack of judgement and leadership on the part of Stockard in sanctioning Papanicolaou’s 
presentation in the sidelines of a formal negative Eugenics conference; arguably an 
inappropriate venue to posit a potentially significant advancement in diagnostic 
medicine. 
 The ‘lost decade of cytopathology’ that followed Papanicolaou’s failure led to an 




postponement of screening practices for CxCa in the US. The sheer cost to humanity 
may never be amply grasped. 
Significance Of Political Commitment And Financial Resources 
 Cancer in general and its alarming trends during the 1930s threatened political 
stability in the US in the lead-up to World War II. This reality prompted enactment of 
the National Cancer Act in 1937. The Act created unprecedented energy backed by 
funding to support cancer research through the NCI, to mitigate threats to society posed 
by cancer. But it was not until Dr. Joseph C. Hinsey capitalized upon these collective 
dynamics in 1939 to bring the Act’s intents and purposes to bear for the eventual 
prevention of CxCa. The National Cancer Act and the organizations it spawned revealed 
the importance of policy, advocacy, mission, commitment, and financial reinforcement; 
all driven by societal priorities and mainstream public demands. It was the culmination 
of these dynamics through Hinsey’s administrative directives that revived 
Papanicolaou’s potential, mitigated his vulnerabilities, and decisively ushered the 
renaissance of gynecological cytopathology through the detection of cervical CIS by the 
cytologic method. 
Significance Of Field Testing And Method Modeling 
 The NCI-sponsored Memphis and Shelby County trial field tested the VFSM’s 
potential to discriminate between cervical precancer and invasive disease cytologically. 
Cervical precancer became the essence for the control of CxCa as proposed through a 




prevalence of CxCa may only be appreciated when non-infiltrating and progressive 
epithelial lesions are taken into account as being integral elements of the same disease; 
as was also proposed by TeLinde attending to Henrietta Lacks in 1951 (Skloot, 2010). 
This archetype in epidemiological reasoning further challenged the classical tenets of 
cancer and its purported obligatory invasiveness. Nevertheless, the Memphis study 
produced an actionable model for population-based Pap test screening through cervical 
precancer. Under Dr. Charles Cameron’s directorship, the ACS could not but boldly 
exploit the scientific momentum and endorse the Pap test for prompt deployment in 
population-based screening starting in 1957. 
 It is also speculated by the author that the timing of the ACS’s decision to launch 
Pap test screening in 1957 coincided intentionally with Papanicolaou’s retirement from 
CMC-NY. The ACS presumably assessed that sufficient experience was at hand to 
proceed with screening expansion. And, not doing so would have placed the ACS 
within an unwarrantable predicament. Societal and women’s empowerment in the late-
1950s reinforced the ACS’s decision making. 
Significance Of Professional Collaboration And Perception 
 Micro-dynamics arose predominantly from 1939 onwards following Hinsey’s 
initiatives. They reflected the actions and reactions emerging from within a medical 
system coming to terms with the novelty of cervical precancer, its qualification, its 
detection, and its ablation, and its likely relevance in the control of other cancers with 




Papanicolaou, Mary Lasker, Hinsey, Ayre, Meigs, Erskine, Marchetti, and Cameron; 
organizations such as US Congress, The Commonwealth Fund, and the ACS; also, the 
driving expectations posed by society at large prompting political and organizational 
advocacy and commitment. Disruptive forces reflected push back from pathologists, 
surgeons, and other facets of the medical establishment that perceived impending 
professional insecurities, encroachment, challenges to medical basics, and threats to 
authority. Micro-dynamics also manifested the complex nuances arising from multi-
disciplinary professional collaborations toiling to establish a novel method in diagnostic 
medicine, and to bridge the gaps between varying perceptions, authorities, and skill-
sets. 
Significance Of Adequate Health Literacy And Sense Of Disease Susceptibility 
 Notably, the Memphis and Shelby County trial also revealed concerning gaps in 
health literacy, and therefore restressed the importance of improved public awareness of 
CxCa and of its symptoms if the disease was to be rendered controllable. The Memphis 
trial also demonstrated the importance of clinicians’ participation and commitment, to 
actively promote Pap test utilization. Ultimately, the Memphis trial recommended that 
every woman be made aware that she may develop CxCa in her lifetime, regardless of 
age or societal eminence. An unwavering sense of susceptibility amongst women 
appeared critical for adequate acceptance of the Pap test. 
 Finally, despite extensive health literacy campaigns conducted by the ASCC, the 




of the benefits possible through Pap testing remained insufficient in that clinical setting. 
Cameron’s initiatives through the ACS and through his personal publications aimed to 
increase the public’s sense of self-empowerment in seeking medical attention early, and 
to encourage its active participation to facilitate improved cure rates. His aim was to off-
set a lagging medical establishment by transferring empowerment to the public. This 
empowerment continues to govern the scope of the Pap test in the US, and elsewhere 
through to modern practice. 
Low Incidence Of Cervical Cancer And Screening Policy In The State Of Qatar 
 Based on the National Cancer Framework, currently in effect in the State of Qatar 
for the period 2017 through to 2022, published by the QMoPH (QMoPH National Cancer 
Framework, 2017) (Appendix L), the official position of the Ministry pertaining to 
cervical cancer screening is the following: 
“Cervical cancer screening currently operates within Qatar on an opportunistic 
basis due to the relatively low prevalence of the disease. A situational analysis to 
understand the evidence base for the adoption of a national population-based 
cervical cancer screening service in Qatar is currently under evaluation between 
screening service providers and the MOPH.” 
 The QMoPH’s position is based upon the low prevalence of CxCa in the State of 
Qatar. This position may be argued given the State’s modest society and conservative 
cultural norms pertaining to sexual behavior. However, with opportunistic screening, 




the actual incidence of disease may undermine the currently-enforced strategy. As stated 
in Chapter 2, due to widespread, mature screening practices in the US since 1957, the 
incidence of CxCa was reduced to 7.6 per 100,000 as calculated for the period 2011 
through 2015 by the ACS (American Cancer Society, 2018). In contrast, with 
opportunistic screening practices in the State of Qatar the incidence was 3.2 per 100,000 
in 2017 (Institut Catala d’Oncologica, 20172). 
 Given the importance of accurate assessment of actual CxCa incidence for the 
State of Qatar, the disease’s preclinical and clinical phases ought to be assessed 
collectively. That is, cases of cervical CIS ought to be included in the incidence 
calculations, and therefore in the formal deliberations towards screening practice design, 
as was also proposed by TeLinde and the Memphis trial in 1951 (Dunn & Sprunt, 1955; 
Skloot, 2010). Sherris, Herdman, & Elias (2001) support the concept that CIS cases and 
invasive CxCa cases ought to be viewed as elements of the same disease, and therefore 
taken equally into account epidemiologically, and particularly in clinical settings 
utilizing opportunistic screening practices. 
 Recent efforts by the WHO calling to action the elimination of CxCa globally 
through increased screening and HPV vaccination have inspired development of 
mathematical models predicting the eventual elimination of the disease over a course of 
50 years, from 2020 to 2069 (Simms, Steinberg, Caruana, Smith, Lew, Soerjomataram, 
Castle, Bray, & Canfell, 2019). Although the incidence threshold by which CxCa may be 




thresholds to guide public health initiatives: (1) Under 6 new cases per 100,000, to reflect 
a rare disease; and, (2) Under 4 new cases per 100,000, to reflect an eliminated disease. 
Should these mathematical models prove valid, then CxCa in the State of Qatar is 
arguably both rare and eliminated; however, such arguments rest upon the accuracy of 
actual incidence determination. It is surmised by the author, that in the background of 
opportunistic screening with lacking surveillance of actual intraepithelial and invasive 
disease in the entire female population at large, the incidence rate for CxCa may be 
potentially inaccurate hence misguiding. The potentially under-estimated incidence of 
CxCa in Qatar is an inevitable limitation in this study. 
 Moreover, should organized Pap test screening practices be eventually 
introduced in the State of Qatar, the actual incidence of CxCa may likely increase simply 
due to expanded sampling and the revelation of preclinical, intraepithelial lesions as 
HSIL. A similar phenomenon was reported following increased sampling of papillary 
thyroid cancer nodules due to improved imaging and diagnostic fine needle aspiration 
biopsy methods (Gordis, 2014). 
Data Analyses, Remarks, And Interpretations 
 Tables 10-18 tabulate the categorical data for all variables arising from this 
research. Tables 19-23 tabulate the p-values computed from the bivariate statistical 
analyses between the variables comprising Category 1 (Socio-demographic variables) 




dependency. Socio-demographic variables are utilized as the reference for likely 
dependency consistently with all other survey variables throughout Tables 19-23. 
 The following sub-sections discuss the salient categorical results from this study 
per variable and category. Also, the statistically significant associations with all other 
variables were discussed with p-value insertions. Proposed remarks and interpretations 
were supported by relevant published literature where available. It is emphasized that 
p-values reflected statistically significant differences between correlated variables. 
However, as the questions in this survey listed several answer options, follow-up, and 
targeted research may be required to delve into the data set to explore likelihood of 
significance between specific questions and answers. Such detailed analyses would be 
beyond the scope of this dissertation relative to the hypotheses raised herein. 
Interpretation Of Socio-Demographic Research Data (Questions: 1-8, 31) 
 Category 1 incorporated survey Questions 1-8, and 31, in an effort to generate 
Socio-demographic data. Tables 10, 11 and 18 reflect categorical data captured for all 
variables from all participants; and likewise, thereafter stratified by Gender. These data 
were represented through Figures 1-5, and 16. 
Q1 Nationality. 
Percent Response Rate: 100%, from 300 surveys. Table 10 and Figures 1 and 2 represent the 
breakdown of Nationality from all participants in this study. Figure 1 represents the 




nationalities of all respondents stratified by Gender. Tables 19-23 represent the bivariate 
analyses and matrices of p-values.  
 These data produced statistically significant associations between Nationality 
and: Pap test uptakes (p=0.00000012); Awareness of the Pap test cytologic method (p=0.03766); 
Knowledge of CxCa (p=0.000022); CxCa curability (p=0.004244); Perceived protection through 
HPV vaccination (p=0.0000026); if Menopausal women require a Pap test (p=0.01045); and 
Knowledge of where to get a Pap test performed in Qatar (p=0.003118). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Nationality, in Healthcare Services (Q9-11), Health 
Literacy (Q12-20), and Self-efficacy & Perceptions (Q21-30). 
Remarks: 
 The largest proportion of all respondents by nationality, were Asian. 
Respondents with Asian nationality produced the primary proportion of 26.7% of all 
nationalities; followed by a secondary proportion from Qatari nationals of 17.6%; 
followed by a tertiary proportion with African nationality of 17.0%. Of all Asian 
respondents, 80% were women. 
 The distribution of nationalities in this study suggested a representative 
sampling of the various nationalities of residents currently in the population of the State 
of Qatar. According to the World Population Review report for Qatar for 2018 (World 




expatriates (i.e., Indian (24%), Nepali (16%), Filipino (11%), Bangladeshi/Sri Lankan 
(16%)) collectively comprising 67% of the entire 2.7 million population of Qatar. The 
17.6% of Qatari respondents in this study correlated satisfactorily with the national 
Qatari population in 2018, then 15% of the entire population of Qatar. 
 The most significant association was noted between Nationality and Pap test 
uptakes (p=0.00000012). Given the dominance of Asian women respondents in this study 
relative to all other nationalities (26.7%), it is likely that these women reflected the 
greater variability for Pap test uptakes. Moreover, of the women respondents in this 
study that indicated never been Pap tested, 48.1% had also indicated being of Asian 
nationality. These findings may facilitate targeted health promotion initiatives in Qatar 
based on residents’ nationalities. 
Relevant Research: 
 Survey-based research conducted by Ma et al., (2013) to study the perceptions of 
Vietnamese American women to undergo a Pap test, concluded that 53% of the 
respondents reported ever having a Pap test. The study reported that the most impactful 
health promotion behavioral changes, through the Health Belief Model, occurred after 
an increased sense of susceptibility to developing CxCa. However, the dominant 
barriers to having a Pap test were embarrassment, believing a Pap test was not required 
if feeling well, and, not understanding what is being done during a Pap test. 
 Another survey-based study by Lee & Carvallo (2014) studied the perceived 




the most impactful parameters to influence self-efficacy and a sense of susceptibility to 
CxCa were: marital status and misbeliefs. Women revealed misperceptions of what is 
‘healthy’ in the absence of symptoms, and lacking knowledge of CxCa and of Pap test 
screening regardless of education; educated women lacked knowledge of CxCa 
screening. 
 Similar survey-based studies conducted in South Ghana by Ebu, Mupepi, 
Siakwa, & Sampselle (2015), reported that 68.4% of respondent women had never heard 
of CxCa; 93.6% had no knowledge of risk factors; and 97.7% had no knowledge of the 
Pap test. 
 The significant associations between nationality and Pap test uptakes will be 
discussed below in greater detail in the section for Q9. 
Q2 Gender. 
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 10 and Figure 1 represent the 
Gender distribution from all respondents in this survey. Tables 19-23 represent the 
bivariate analyses conducted and matrices of p-values. 
 From 293 respondents, 173 (59.0%) were women, and 120 (41.0%) were men.  
 These data produced statistically significant associations between Gender and: 
Pap test uptakes (p=0.000000006); Awareness of the Pap test cytologic method (p=0.009553); 
Knowledge of CxCa (p=0.000304); and Perceived protection through HPV vaccination 
(p=0.0002238). However, no significant associations between Gender and Category 4 




 These overall findings suggest that statistically significant differences exist 
between respondents based on Gender, in Healthcare Services (Q9-11) and in Health 
Literacy (Q12-20). 
Remarks: 
 These data suggested a relatively balanced representation of public views 
through the female and male participants in this research. The lack of significant 
statistical associations with Category 4 variables reflecting Self-efficacy & Perceptions 
may also be realized through Figures 11-16 illustrating the relatively equivalent 
response counts between women and men recorded in this study without prominent 
differences. 
Q3 Age group (Years). 
Percent Response Rate: 97.7%, from 292 of 300 surveys. Table 10 and Figure 2 represent the 
Age group distributions from all respondents, also stratified by Gender. Tables 19-23 
represent the bivariate analyses conducted and matrices of p-values. 
 The 97.7% Response Rate was calculated after exclusion of 1 survey from a male 
respondent claiming an age of less than 20. This adjustment complied with the exclusion 
criterion stipulated by the Sidra IRB. 
 These data produced statistically significant associations between respondents’ 
Age group and: Pap test uptakes (p=0.000000008); Where information was received of the Pap 





 These overall findings suggest that statistically significant differences exist 
between respondents based on Age group, in Healthcare Services (Q9-11), in Health 
Literacy (Q12-20), and in Self-efficacy & Perceptions (Q21-30). 
Remarks: 
 The largest proportion of age group for all respondents was the 30-39 year age 
group comprising 40.0% of all respondents. Of these, women accounted for 58.0%. The 
second largest age group proportion was the 20-29 year age group comprising 30.5% of 
all respondents; whereas 57.3% were women. The distribution of age groups (Figure 2) 
suggested a satisfactory representation of the population currently in the State of Qatar; 
as in 2018, according to the ICO (Institut Catala d’Oncologica, 20172), the primary age 
group of all women was 30-34 years, followed by a secondary age group of 35-39 years. 
 The primary age group of all men in Qatar in 2018 was 25-29 years, followed by a 
secondary age group of 35-39 years. The data arising from this research correlated with 
the population pyramid for Qatar being skewed towards males; representing the 
relatively large population proportion comprising young expatriate men employed in 
the State’s megaprojects as discussed in Chapter 3. 
 The highly statistically significant association noted between Age group (Q3) and 
the variable Had a Pap test before? (Q9) warranted particular consideration. From the total 
of 173 women that participated in this study (Table 10), 79 (45.6%) claimed never having 
a Pap test. This group of women showed a primary age group of 20-29 years, followed 




comprised a near 40-year age bracket. As the bimodal peak ages of CxCa cases with 
Stage II/III disease at presentation in Qatar were 40-44 and 60-64 years in 2014 (QMoPH 
National Cancer Program, 2014), the 30-39 year respondent women, that never had a 
Pap test, may represent a cohort at increased risk for developing CxCa. The significance 
of these observations will be discussed in greater detail in a subsequent sub-section in 
this Chapter. 
Relevant Research: 
 Research by Kahn, Chiou, Allen, Goodman, Perlman, & Emans (1999) studied the 
relationship between beliefs about Pap smears and compliance for follow-up 
instructions in adolescents. Their study concluded that strategies to provide adequate 
health literacy, and the implementation of an appointment reminder system, improved 
Pap test uptakes in adolescents. These collaborators also suggested that healthcare 
promotion initiatives ought to be age-group specific. 
Q4 Highest education level. 
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 10 and Figure 3 represent the 
Highest education level distributions from all respondents, also stratified by Gender. Tables 
19-23 represent the bivariate analyses conducted and matrices of p-values. 
 These data produced statistically significant associations between respondents’ 
Highest education level and: Pap test uptakes (p=0.03798); however, no associations with 




weak statistical dependency was noted between Highest education level and: Support for a 
Pap test screening program for CxCa (Q26) (p=0.05745). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Highest education level, in Healthcare Services (Q9-11). 
Remarks: 
 The largest proportion of education level revealed from all respondents and 
between genders was that of University level. From 293 participants, 243 (82.9%) 
indicated a university level education; when stratified by gender, women (83.2%) and 
men (82.5%) indicated a university level education essentially equally. These findings 
correlated with demographic vital statistics arising from the State of Qatar as published 
by the ICO. According to the ICO (Institut Catala d’Oncologica, 20172), the overall adult 
literacy rate from the entire Qatar population age 15 and older in 2017 was 97.8%. 
Moreover, the secondary school enrollment rate from the entire Qatar population was 
94.5%. Overall, the population in Qatar boasts high levels of education and literacy. 
 Nevertheless, these overall findings were surprising given the relatively high 
literacy rates amongst residents in Qatar according to the ICO (Institut Catala 
d’Oncologica, 20172), relative to the alarming proportion of respondent women in this 
study claiming never having a Pap test (47.0%). These findings may facilitate targeted 






 The relationship between Pap test uptakes and women’s education levels in 
Qatar have been researched by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011). 
Their study also reported the statistically significant dependency noted between 
education level and Pap test uptake. They concluded that knowledge of CxCa and of the 
Pap test was inadequate in women less than 30 years of age, and in those women with 
lower education levels. Their research also revealed that knowledge of CxCa was 
significantly greater in women with a University degree education. 
Q5 Marital status. 
Percent Response Rate: 97.7%, from 293 of 300 surveys. Table 11 and Figure 3 represent the 
Marital status distributions from all respondents, also stratified by Gender. Tables 19-23 
represent the bivariate analyses conducted and matrices of p-values. 
 The data produced statistically significant associations between respondents’ 
Marital status and: Pap test uptakes (p=0.00000004); Where information was received of the Pap 
test (p=0.002733); and Perceived need for additional information to improve knowledge of CxCa 
(p=0.01028). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Marital status, in Healthcare Services (Q9-11), Health 







 The largest proportion of marital status revealed from all respondents and 
between genders was that of Married. From 293 participants, 186 (63.5%) indicated being 
married; when stratified by gender: women (61.3%) and men (66.7%) indicated as being 
married. The data also revealed respondents never before married. From all 
respondents, 92 (31.4%) indicated never been married; when stratified by gender: 
women (32.9%) and men (29.2%) indicated never been married. 
 The most significant association was noted between Marital status and Pap test 
uptakes (p=0.00000004). This association is discussed in detail in this Chapter, in the sub-
section describing the subset of married women never before having a Pap test. 
Relevant Research: 
 Consistent with this dissertation, Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail 
(2011) also reported a relationship between marital status and awareness of CxCa and of 
Pap test screening. 
Q6 Marriage duration. 
Percent Response Rate: 88.3%, from 265 of 300 surveys. Table 11 and Figure 4 represent the 
Marriage duration distributions from all respondents, also stratified by Gender. Tables 19-




 These data produced statistically significant associations between respondents’ 
Marriage duration and: Pap test uptakes (p=0.0000032); When was the previous Pap test 
performed (p=0.03648); Where did you hear of the Pap test method before (p=0.02039); Perceived 
protection from HPV vaccination (p=0.0273); Perceived need for additional information to 
improve knowledge of CxCa (p=0.02365); Perception that getting a Pap test done is too difficult 
(p=0.04028); and Perceived no value of the Pap test (p=0.01878). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Marriage duration, in Healthcare Services (Q9-11), Health 
Literacy (Q12-20), and Self-efficacy & Perceptions (Q21-30). However, as marriage 
duration is a potential limitation in this study, conclusions ought to be considered 
cautiously. 
Remarks: 
 Although Q6 posed a limitation in this study, the largest proportion of marriage 
duration revealed from all respondents and between genders was that of Not applicable: 
71 (26.7%). The second largest proportion was for 5-10 years, followed by 10-20 years. 
From 265 participants, 66 (25.0%) indicated being married 5-10 years; when stratified by 
gender: women (18.2%) and men (36.0%) indicated being married 5-10 years. Likewise, 
18.2% of respondent women indicated being married 10-20 years. 
 That 26.7% of the respondents in this study (and 33.3% of women) selected Not 
applicable for Q6 was surprising. The relatively large component of Not applicable may 




findings may also reflect the cultural norms characteristic of a conservative society as the 
one in the State of Qatar. 
Relevant Research: 
 Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) researched women’s 
attitudes in Qatar and likewise reported an association between marriage duration and 
Pap test uptakes. Their research revealed a greater awareness of CxCa particularly 
amongst women married for greater than 15 years, and in women with greater parity. 
However, survey-based research by Alali et al., (2016) reported that increasing parity 
was regarded amongst the risk factors for CxCa development in Qatar. 
Q7 Employment status. 
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 11 and Figure 4 represent the 
Employment status distributions from all respondents, also stratified by Gender. Tables 19-
23 represent the bivariate analyses conducted and matrices of p-values. 
 These data produced statistically significant associations between respondents’ 
Employment status and: Pap test uptakes (p=0.000018); CxCa may be curable (p=0.01827); and 
Recommendation of the Pap test to family and friends (p=0.04067). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Employment status, in Healthcare Services (Q9-11), Health 






 The largest proportion of employment status revealed from all respondents and 
between genders was that of Employed. From 287 participants, 212 (73.9%) indicated 
being employed; when stratified by gender: women (78.1%) and men (67.8%) indicated 
being employed. 
 The highly significant association noted between Employment status and Pap test 
uptakes (p=0.000018) was remarkable as amongst the women that indicated never been 
Pap tested in this study, 83.5% had health insurance coverage through employment. 
These findings are discussed in greater detail in a subsequent sub-section in this 
Chapter. 
Relevant Research: 
 Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) reported greater 
knowledge of CxCa in employed women in Qatar, and particularly in women with a 
University degree education. Their findings are consistent with the associations revealed 
through this research. 
Q8 You have health insurance coverage? 
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 11 and Figure 5 represent the 
Health insurance coverage distribution from all respondents, also stratified by Gender. 




 These data produced no dependencies with variables in Category 2 reflecting 
Healthcare Services; however, significant associations were noted with Awareness of the 
cytologic method (p=0.004242); and Knowledge of CxCa (p=0.03714). No dependency with 
variables in Category 4 reflecting Self-efficacy & Perceptions was revealed. 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Health insurance coverage, in Health Literacy (Q12-20). 
Remarks: 
 From 288 respondents, 229 (79.5%) indicated having health insurance coverage; 
whereas, 20.5% of respondents did not. Of the genders: 83.5% of women and 73.7% of 
men indicated having insurance coverage. 
 The significant associations noted between Health insurance coverage and 
awareness of the cytologic method (p=0.004242) and of CxCa (p=0.03714) was 
remarkable as 83.5% of women participants may have access to Pap testing and 
therefore awareness, although, this study revealed that 45.7% of women participants 
claimed never been Pap tested. These findings suggest that lacking Health insurance 
coverage may be a barrier to Pap test uptakes. These findings may further support 
development of population-based screening practices in Qatar 
Q31 If employed, are you employed in the healthcare sector? 
Percent Response Rate: 93.0%, from 279 of 300 surveys. Table 18 and Figure 16 represent 




Gender. Tables 19-23 represent the bivariate analyses conducted and matrices of p-
values. 
 These data produced significant associations between Employment in the healthcare 
sector and: Previous Pap test uptake (p=0.0003357); CxCa may be preventable (p=0.0001159); 
Awareness of the Pap test cytologic method (p=0.0000065); Where information of the Pap test 
was heard (p=0.0005167); Knowledge of CxCa (p=0.0003576); Knowledge of importance of early 
detection of CxCa for treatment (p=0.0004853); Regular Pap tests may protect from CxCa 
(p=0.02428); CxCa may be curable (p=0.0000623); Perception of protection from HPV 
vaccination (p=0.003599); and Perceptions if Menopausal women need a Pap test (p=0.02444). 
No dependencies with variables in Category 4 reflecting Self-efficacy & Perceptions 
were revealed. 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Employment in the healthcare sector, in Healthcare Services 
(Q9-11), and Health Literacy (Q12-20). 
Remarks: 
 From 279 respondents, 151 (54.1%) indicated being employed in the healthcare 
sector; whereas, 128 (45.9%) of respondents were not. Of the genders: 57.7% of women 
and 49.2% of men indicated being employed in the healthcare sector. These findings 
reveal relatively balanced survey participation by women and men employed in the 




 Although participants’ likely employment in the healthcare sector may be a 
potential limitation in this study, the aforementioned statistical associations may suggest 
that healthcare sector employees continue to lack sufficient awareness of CxCa and of 
the Pap test not unlike the greater population of women in the State of Qatar. These 
findings may reflect conservative cultural norms universal amongst women in this 
nation. 
Relevant Research: 
 Survey-based research by Alali et al., (2016) in Qatar studying the attitudes of 
women employed in PHCC centers as clinical staff reported that 42.2% of these women 
had a Pap test before, and that the most impactful determinant was a sense of 
embarrassment and of being noticed by their colleagues. 
Interpretation Of Healthcare Services Research Data (Questions: 9-11) 
Q9 You had a Pap test before? 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 11 and Figure 5 represent the 
distribution of responses from all respondents for Q9, also stratified by Gender. Table 19 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced statistically significant associations with 8 of the 9 variables 
in Category 1 reflecting Socio-demographic variables (Q1-9, 31). 
 This variable demonstrated remarkable statistically significant associations with 




that statistically significant differences exist between respondents based on Pap test 
uptakes throughout the variables reflecting socio-demographic attributes of all 
respondents. 
Remarks: 
 From 286 respondents, 105 (36.7%) indicated having a Pap test before; whereas, 
149 (52.0%) of respondents had not, and 32 (11.3%) indicated Not Applicable. Of the 
genders: 48.8% of the women had a Pap test, and 47.0% had not. These outcomes are 
considered to be epidemiologically important and warranted detailed analysis. The 
significance of women not having a Pap test before is discussed in a subsequent sub-
section in this Chapter. 
 The sub-set of 19.5% of men that claimed to have had a Pap test before embody a 
study limitation and may be regarded a surrogate of Health Literacy inadequacies. 
Arguably, any lacking awareness of CxCa or of the Pap test may have led to confusion 
in either women or men respondents. It is speculated that these men had confused the 
Pap test as being some other test they may have had, that may also have sounded alike 
phonetically, either through the English or Arabic language. 
 This potential limitation may have been intensified given the variable 
nationalities of the survey respondents and their likely mother languages that may have 






 The findings arising from this study are consistent with survey-based research by 
Alali et al., (2016). In their research, they assessed knowledge of CxCa and of the Pap 
test amongst women employed in PHCC centers in Qatar. Their findings revealed that 
42.2% of respondent women indicated having a Pap test. The most impactful barrier was 
embarrassment (17.3%), followed by inadequate knowledge of CxCa (14.8%), and that 
94.5% of the participating women would prefer a female physician. These findings were 
also corroborated by research from Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail 
(2011) reporting that 39.4% of the respondent women had a Pap test; likewise, studies by 
Metwali, Al Kindi, Shanbleh, Al Akshar, & Sarhan (2015) assessing women in the United 
Arab Emirates, discovered that amongst 212 participating women, 37.2% had a Pap test. 
Q10 If you had a Pap test before, when was it performed? 
Percent Response Rate: 34.7%, from 104 of 300 surveys. Table 12 and Figure 6 represent the 
distribution of responses from all respondents for Q10, also stratified by Gender. Table 19 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced one statistically significant association with 1 Category 1 
variable reflecting Socio-demographics: Marriage duration (p=0.03648). However, as 








 From 104 respondents, 74 (71.1%) indicated having a Pap test in the preceding 1-
3 years; whereas, 21 (20.2%) of respondents had a Pap test in the preceding 4-6 years, 
and 9 (8.70%) over 6 years prior. Of the genders, 82.0% of the respondents were women; 
whereas, 71.9% of which had a Pap test within 1-3 years, 20.7% within 4-6 years, and 
7.32% over 6 years prior. 
 The relatively low Response Rate for this survey question reflected the responses 
predominantly from women. As such, that 71.9% of women that have had a Pap test had 
it in the preceding 1-3 years correlated with the currently-enforced guidelines by the 
QMoPH recommending that women aged 25-49 years should be screened every 3 years 
(QMoPH National Cancer Program, 20161). 
Relevant Research: 
 Survey-based research by Alali et al., (2016), assessing women employed in 
PHCC centers in Qatar, reported that 9.0% had adequate knowledge of their eligibility 
for Pap test sampling and an awareness of the recommended screening intervals as 
endorsed by the QMoPH. 
 Similar survey-based research by Fernandez et al., (2009) studied the relationship 
between self-efficacy and Pap test uptakes in low-income Mexican American women. 
Their study reported that higher self-efficacy correlated with the likelihood of recent Pap 




a 4.22-fold increase in the risk for developing CxCa in women that had a preceding Pap 
test greater than 4-6 years prior. 
Q11 Did you, or any member of your family have cervical cancer before? 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 12 and Figure 6 represent the 
distribution of responses from all respondents for Q11, also stratified by Gender. Table 19 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 
variables reflecting Socio-demographics. 
Remarks: 
 From 286 respondents, 10 (3.49%) indicated having a family history of CxCa; 
whereas, 266 (93.0%) of respondents indicated no family history, and 10 (3.49%) did not 
know. That 93.0% of respondents claimed no family history of CxCa likely reflected the 
low prevalence of this disease as published for the clinical setting of the State of Qatar, 
or, arguably, a lacking awareness of the disease. However, another limitation in this 
study is possible under-estimation of CxCa incidence in Qatar, which may impact public 
perceptions of extent of disease at large. 
Relevant Research: 






Interpretation Of Health Literacy Research Data (Questions: 12-20) 
Q12 Cervical cancer may be preventable. 
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 12 and Figure 7 represent the 
distribution of responses from all respondents for Q12, also stratified by Gender. Table 20 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Employment in the healthcare sector 
(p=0.0001159). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on CxCa being possibly preventable, amongst survey 
participants employed in the healthcare sector, or otherwise. However, as employment 
in the healthcare sector is a potential limitation in this study, this association may be 
potentially unreliable. 
Remarks: 
 From 288 respondents, 242 (84.0%) indicated that CxCa may be preventable; 
whereas, 3 (1.00%) of respondents said no, and 43 (15.0%) did not know. That 84.0% of 
respondents claimed that CxCa may be preventable may reflect adequate awareness of 
CxCa. However, that 15% of respondents did not know suggested insufficient 






 In survey-based research in Qatar by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & 
Ismail (2011), they asked a related question: “Is it possible to detect CxCa with the Pap 
test smear before symptoms appear?” Their study revealed that 62.4% of the 
participating women agreed that the Pap test may detect CxCa early, compared to 37.6% 
that disagreed. 
Q13 You are aware of the Pap test smear cytologic method. 
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 12 and Figure 7 represent the 
distribution of responses from all respondents for Q13, also stratified by Gender. Table 20 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 4 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.03766); Gender (p=0.009553); 
Health insurance coverage (p=0.004242); and Employment in the healthcare sector 
(p=0.0000065). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on awareness of the cytologic method, in Health Services 
(Q9-11). 
Remarks: 
 From 288 respondents, 191 (66.3%) indicated awareness of the cytologic method; 




indicated not having an awareness of the Pap test cytologic method is relevant to the 
hypotheses in this dissertation. These findings suggest insufficient knowledge of the 
cytologic Pap test method overall; accordingly, 27.6% of women respondents indicated 
no knowledge of the Pap test cytologic method. Furthermore, this variable revealed a 
statistically significant association between women’s nationality, health insurance 
coverage, and whether employed in the healthcare sector or not. 
Relevant Research: 
 These data are consistent with research outcomes from work by Al-Meer, Aseel, 
Al-Khalaf, Al-Kuwari, & Ismail (2011). Their research revealed that 76% of surveyed 
women in Qatar indicated having adequate knowledge of the Pap test smear method; 
although, levels of health literacy decreased significantly in women recently married, in 
those under age 30, and in those with lower education levels. Their findings are 
corroborated by research conducted in the United Arab Emirates by Metwali, Al Kindi, 
Shanbleh, Al Akshar, & Sarhan (2015). Their work concluded that of 212 women 
surveyed, 74.5% knew of the Pap test.  
Q14 Where did you hear of the Pap test smear cytologic method for the first time? 
Percent Response Rate: 93.3%, from 280 of 300 surveys. Table 13 and Figure 8 represent the 
distribution of responses from all respondents for Q14, also stratified by Gender. Table 20 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 4 statistically significant associations with Category 1 




(p=0.002733); Marriage duration (p=0.02039); and Employment in the healthcare sector 
(p=0.0005167). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on acquisition of knowledge of the Pap test smear method. 
Remarks: 
 From 280 respondents, the largest proportion of responses indicated Gynecologist, 
72 (25.7%); followed by Other, 52 (18.6%), and Not applicable, 48 (17.1%). That 26.9% of 
women heard of the Pap test from a Gynecologist suggests these women may have had 
a Pap test and therefore received medical consultation. However, the second largest 
frequency of women’s responses (17.9%) indicated Not applicable. These findings may 
also suggest a sub-set of women lacking health literacy for CxCa. 
Relevant Research: 
 Research conducted in Qatar by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail 
(2011) revealed a significant finding: That the majority of women respondents obtained 
knowledge of CxCa from their social network (i.e., relatives and friends) rather than 
from physicians. These outcomes may explain the 17.1% of respondents in this study 
that indicated Not applicable for Q14. Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail 
(2011) attributed this surprising finding to the absence of a well-organized screening 




 In another study by Badrinath, Ghazal-Aswad, Osman, Deemas, & McIlvenny 
(2004), assessing the knowledge of CxCa amongst female primary care physicians in the 
United Arab Emirates, revealed that of the participating 98 physicians, 40.0% reported 
ever performing a clinical Pap test procedure on their patients. These findings may not 
only reflect insufficient health literacy amongst clinicians, they may also reflect lacking 
procedural competencies, and perhaps a lack of Pap test promotion. 
Q15 You have knowledge of cervical cancer. 
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 13 and Figure 8 represent the 
distribution of responses from all respondents for Q15, also stratified by Gender. Table 20 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 4 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.000022); Gender (p=0.000304); 
Health insurance coverage (p=0.03714); and Employment in the healthcare sector 
(p=0.0003576). 
 The overall findings suggest that statistically significant differences between 
respondents exist relevant to knowledge of CxCa.  
Remarks: 
 From 290 respondents, the largest proportion of responses indicated knowledge 
of CxCa, 203 (70.0%); followed by No knowledge, 87 (30.0%). That 30.0% of respondents 
indicated not having knowledge of CxCa is relevant to the hypotheses in this 




between nationality, health insurance coverage, and employment in the healthcare 
sector between the women and men participants. Given the limitations outlined for this 
study, in-depth follow-up research may explore specific parameters in these associations 
to facilitate health promotion initiatives in the State of Qatar. 
Relevant Research: 
 Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) 
surveying women in Qatar revealed that over 85% of women participants had heard of 
CxCa, and that knowledge of CxCa increased significantly in women in the 30-49 years 
age group, in those employed, and in those with a University degree education. Studies 
by Metwali, Al Kindi, Shanbleh, Al Akshar, & Sarhan (2015) surveying 212 women in 
the United Arab Emirates revealed that 29% of participating women had knowledge of 
CxCa. 
Q16 Early detection of cervical cancer is important for effective treatment. 
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 13 and Figure 9 represent the 
distribution of responses from all respondents for Q16, also stratified by Gender. Table 20 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Employment in the healthcare sector 
(p=0.0004853). 
 These overall findings suggest that statistically significant differences exist 




treatment and likely employment in the healthcare sector. However, as employment in 
the healthcare sector is a potential limitation in this study, this association may be 
unreliable.  
Remarks: 
 From 290 respondents, the largest proportion of responses indicated that early 
detection of CxCa is important for effective treatment, 271 (93.4%); followed by No, 1 
(0.40%), and Don’t know, 18 (6.20%). That 6.20% of respondents indicated that early 
detection of CxCa was not important is relevant to the hypotheses in this dissertation. Of 
the women respondents, 7.51% indicated not knowing if early detection of CxCa is 
important for effective treatment. 
Relevant Research: 
 Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) 
in Qatar, revealed that 62.4% of participating women agreed that early detection of 
CxCa is important for effective treatment; whereas, 37.6% of women disagreed. 
Q17 Regular Pap tests may protect you from cervical cancer. 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 14 and Figure 9 represent the 
distribution of responses from all respondents for Q17, also stratified by Gender. Table 21 
represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 




 These overall findings suggest that statistically significant differences exist 
between respondents based on protection through regular Pap tests. However, as 
employment in the healthcare sector is a limitation in this study, this association may be 
unreliable. 
Remarks: 
 From 286 respondents, the largest proportion of responses indicated that regular 
Pap tests may protect from CxCa, 243 (84.9%); followed by No, 8 (2.79%), and Don’t 
know, 35 (12.3%). That 12.3% of respondents indicated that regular Pap testing does not 
protect from CxCa is relevant to the hypotheses in this dissertation. 
Relevant Research: 
 Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) 
in Qatar, revealed that 64.8% of participating women agreed that the Pap test may 
protect them from CxCa; whereas, 35.2% of women disagreed. 
Q18 Cervical cancer may be curable. 
Percent Response Rate: 96.7%, from 290 of 300 surveys. Table 14 and Figure 10 represent 
the distribution of responses from all respondents for Q18, as also stratified by Gender. 
Table 21 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 3 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.004244); Employment status 





 From 290 respondents, the largest proportion of responses indicated that CxCa, 
may be curable, 190 (65.5%); followed by No, 8 (2.70%), and Don’t know, 92 (31.8%). That 
31.8% of respondents indicated no knowledge that CxCa may be curable is relevant to 
the hypotheses in this dissertation, and considered a significant finding. These findings 
may facilitate targeted health promotion initiatives in Qatar. 
Relevant Research: 
 Survey-based research by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) 
in Qatar, revealed that 82.4% of participating women agreed that CxCa may be curable; 
whereas, 17.6% of women disagreed. 
Q19 Vaccination for the Human Papilloma Virus protects against cervical cancer and 
other HPV-associated cancers. 
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 14 and Figure 10 represent 
the distribution of responses from all respondents for Q19, also stratified by Gender. 
Table 21 represents the bivariate analyses conducted and matrices of p-values. 
 These data revealed: 4 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.0000026); Gender (p=0.0002238); 
Marriage duration (p=0.0273); and Employment in the healthcare sector (p=0.003599). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on likely protection through HPV vaccination. However, 





 From 287 respondents, the largest proportion of responses indicated that HPV 
vaccination may protect against CxCa, 180 (62.7%); followed by No, 6 (2.10%), and Don’t 
know, 101 (35.2%). That 35.2% of respondents indicated no knowledge that HPV 
vaccination may protect against CxCa is relevant to the hypotheses in this dissertation, 
and perhaps a major finding as HPV vaccination was recently rolled out in the State of 
Qatar in February 2018. Of the women respondents, 26.5% indicated no knowledge of 
protection against CxCa from HPV vaccination. 
 Nevertheless, despite the study limitations and the recent introduction of HPV 
vaccination in Qatar, it may take numerous years before the impact of this initiative may 
be epidemiologically validated. As such, this initiative should not be taken to imply that 
Pap testing be diminished. Therefore, health promotion for both Pap testing and for 
HPV vaccination ought to be executed in parallel, and their effectiveness would depend 
on public awareness and acceptance, and on framing approaches to convey awareness 
considering the various nationalities of expatriates residing in Qatar. 
Relevant Research: 
 No pertinent survey-based research pertaining to HPV vaccination could be 
identified arising from Qatar. Nevertheless, a literature search was conducted to 
uncover studies to correlate with the data generated from this dissertation. That 35.2% of 
all respondents in this dissertation indicated having no knowledge of HPV vaccination 




 Studies by Senapati, Nayak, Kar, & Dwibedi (2017) reported that the risk 
associated with the potential development of CxCa is HPV genotype specific, and may 
be linked with HPV genotype co-infections, or multiple infections. Therefore, an 
awareness of the prevalent HPV genotypes in the Qatar clinical setting would be of 
epidemiological value as vaccination programs are being implemented. Jumaan, 
Ghanem, Taher, Braikat, Al Awaidy, & Dbaido (2013) studied the likely prospects and 
challenges that may arise from HPV vaccination in the EMENA region. Of the barriers 
that they uncovered, they reported the most impactful may be the relatively poor 
understanding of CxCa and HPV vaccination amongst parents, physicians, and 
government officials. Their study concluded that for HPV vaccination to be successful in 
the EMENA countries, and as physicians are very influential, it is crucial that clinicians 
are well aware of the target practices in order to promote vaccination. 
 Jumaan, Ghanem, Taher, Braikat, Al Awaidy, & Dbaido (2013) also emphasized 
that physicians’ awareness of HPV vaccination in the EMENA region is scarce. In a 
study by Saqer, Ghazal, Barqawi, Babi, AlKhafaji, & Elmekresh (2017) to assess 
knowledge of HPV vaccination in Sharjah, a United Arab Emirate, revealed that despite 
the general public’s lack of knowledge pertaining to HPV vaccination, parents showed a 
willingness to vaccinate their daughters if government recommended the practice, and 
also provided the vaccine. The prevalence of HPV and CxCa in Qatar was studied by 
Afifi, Altaher, & Abushareeda in 2005. Their studies revealed that HPV infections 




increasing number of pregnancies, and that these parameters are associated with 
cervical carcinogenesis amongst women in Qatar. Moreover, their studies revealed that 
older women in Qatar failed to realize that the risk of developing CxCa does not reduce 
with age; therefore, it is important that they seek cervical sampling accordingly. 
 Bansal, Elmi, Skariah, Haddad, Abu-Raddad, Al Hamadi, Mohamed-Nady, 
Affifi, Ghedira, Hassen, Al-Thani, Al-Ansari, & Sultan (2014) studied the distribution of 
HPV genotypes amongst Arab women in the State of Qatar. Their studies analyzed the 
prevailing HPV genotypes depending on cytologic findings. Bansal et al., (2014) 
reported that HPV 16 was the prevalent genotype amongst women with normal 
cytologic findings, and that HPV 16, 18 and 56 were the most prevalent amongst women 
with abnormal cytologic findings. Moreover, Bansal et al., (2014) discovered a high 
prevalence of HPV 81 amongst the low-risk HPV lesions. They claimed these findings 
are unique to the Arab population in Qatar, and unlike the epidemiology of HPV 
infection in western nations. 
 Work by Leader, Weiner, Kelly, Hornik, & Capella (2009) revealed that women 
may be more receptive to HPV vaccination if it is framed as a tool by which to prevent 
CxCa, rather than for the prevention for sexually transmitted infections. Moreover, as 
HPV vaccination is targeted towards adolescents and young adults, the school and 
academic settings may play a significant role in promoting the uptake of HPV 




Battista, Cipriani, & Conversano, 2017). Such an approach would greatly improve the 
overall knowledge base of CxCa and that of the Pap test in the State of Qatar. 
Q20 Menopausal women need a Pap test. 
Percent Response Rate: 93.7%, from 281 of 300 surveys. Table 15 and Figure 11 represent 
the distribution of responses from all respondents for Q20, also stratified by Gender. 
Table 21 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 2 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.01045); and Employment in the 
healthcare sector (p=0.02444). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on menopausal women needing a Pap test, depending on 
nationality and employment in the healthcare sector although such employment is a 
potential limitation in the study. As such, the aforementioned associations may be 
unreliable. 
Remarks: 
 From 281 respondents, the largest proportion of responses indicated that 
menopausal women need a Pap test, 194 (69.0%); followed by No, 8 (2.80%), and Don’t 
know, 79 (28.2%). That 28.2% of respondents indicated no knowledge that menopausal 
women need a Pap test is relevant to the hypotheses in this dissertation. Of the women 




 It is speculated that such lacking health literacy amongst women may result from 
equally lacking perceptions of susceptibility to CxCa development. 
Relevant Research: 
 No pertinent survey-based research pertaining to menopausal women and their 
need for Pap testing could be identified arising from Qatar. It is believed that this 
dissertation reflects the first such initiative. However, Afifi, Altaher, & Abushareeda 
(2005) revealed that older women in Qatar were inadequately aware that their risk of 
developing CxCa does not diminish with age; therefore, it is important they seek 
cervical sampling accordingly. The data arising from this dissertation are consistent with 
such findings. 
Interpretation Of Self-Efficacy And Perceptions Research Data (Questions: 21-
30) 
Q21 More information is needed to improve your knowledge of cervical cancer. 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 15 and Figure 11 represent 
the distribution of responses from all respondents for Q21, also stratified by Gender. 
Table 22 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 3 statistically significant associations with Category 1 
variables reflecting Socio-demographics: Age group (p=0.04504); Marital status 
(p=0.01028); and Marriage duration (p=0.02365). 
 These overall findings suggest that statistically significant differences exist 




group, marital status, and marriage duration; although marriage duration is a potential 
limitation in this study, hence the association may be unreliable. 
Remarks: 
 From 286 respondents, the largest proportion of responses indicated Strongly 
agree, 147 (51.4%); followed by Agree, 117 (40.9%). That 92.3% of respondents indicated 
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women 
respondents, 52.7% indicated strong agreement for additional information about CxCa. 
Relevant Research: 
 No pertinent research identified. 
Q22 Regular Pap tests are a good health practice. 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 15 and Figure 12 represent 
the distribution of responses from all respondents for Q22, also stratified by Gender. 
Table 22 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 
variables reflecting Socio-demographics. 
 However, these findings may represent women’s perceptions of beneficial health 
protection through regular Pap testing; perhaps Pap test rhythmicity is perceived 
positively. Nevertheless, of the women respondents in this study, 4.14% were 






 From 286 respondents, the largest proportion of responses indicated Strongly 
agree, 196 (68.5%); followed by Agree, 72 (25.1%). That 93.7% of respondents indicated 
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women 
respondents, 69.8% indicated strong agreement. 
Relevant Research: 
 Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) posed a related question 
in their survey: “Is early detection of CxCa good for treatment outcome?” Their study 
reported that 64.8% of the surveyed women agreed with this question, whereas, 35.2% 
disagreed. 
Q23 Getting a Pap test performed is too difficult. 
Percent Response Rate: 94.7%, from 284 of 300 surveys. Table 16 and Figure 12 represent 
the distribution of responses from all respondents for Q23, also stratified by Gender. 
Table 22 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Marriage duration (p=0.04028). However, 
marriage duration is a limitation in this study and the association may be unreliable. 
Remarks: 
 From 284 respondents, the largest proportion of responses indicated Strongly 




indicated Strongly disagree, is relevant to the hypotheses in this dissertation. However, of 
the women respondents, 38.1% indicated disagreement, but 6.55% strongly agreed that 
getting a Pap test performed is too difficult. These findings may suggest that 6.55% of 
women faced overwhelming barriers to Pap test uptakes. 
Relevant Research: 
 Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) posed a related question 
in their survey: “If you were told that a Pap test is a simple, painless and good for early 
detection of CxCa, would you like to have one?” Their study reported that 85.8% of the 
surveyed women agreed with this question, whereas, 14.2% disagreed 
Q24 You would recommend a Pap test to your family, friends, and colleagues. 
Percent Response Rate: 95.0%, from 285 of 300 surveys. Table 16 and Figure 13 represent 
the distribution of responses from all respondents for Q24, also stratified by Gender. 
Table 22 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Employment status (p=0.04067). 
 These overall findings suggest that employed women, being likely more health 
literate of CxCa, may be more willing to recommend the Pap test to other women. 
Remarks: 
 From 285 respondents, the largest proportion of responses indicated Strongly 




strongly agreed to recommend the Pap test to family, friends, and colleagues; however, 
5.32% of respondent women were undecided, although none disagreed. 
Relevant Research: 
 No pertinent research identified. 
Q25 Getting a Pap test is a valued investment for good healthcare. 
Percent Response Rate: 96.0%, from 288 of 300 surveys. Table 16 and Figure 13 represent 
the distribution of responses from all respondents for Q25, also stratified by Gender. 
Table 22 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 
variables reflecting Socio-demographics. 
 Overall findings may suggest positive perceptions amongst women for the likely 
investment value in Pap testing. 
Remarks: 
 From 288 respondents, the largest proportion of responses indicated Strongly 
agree, 177 (61.5%); followed by Agree, 95 (33.0%). That 94.4% of respondents indicated 
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. Of the women 








 No pertinent survey-based research pertaining to value of investment in a Pap 
test could be identified arising from Qatar. It is believed that this dissertation reflects the 
first such initiative. 
Q26 You would support a Pap test screening program for cervical cancer. 
Percent Response Rate: 95.7%, from 287 of 300 surveys. Table 17 and Figure 14 represent 
the distribution of responses from all respondents for Q26, also stratified by Gender. 
Table 23 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 
variables reflecting Socio-demographics. 
 These overall findings suggest equivalent perceptions of screening practice for 
CxCa amongst women and men in the State of Qatar. 
Remarks: 
 From 287 respondents, the largest proportion of responses indicated Strongly 
agree, 196 (68.3%); followed by Agree, 81 (28.2%). That 96.5% of respondents indicated 
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. The frequencies 
of support for a screening program between women and men respondents were 
essentially equal: 69.0% and 67.2% respectively. These findings reflecting public support 






 No pertinent survey-based research pertaining to public support for a Pap test 
screening program for CxCa could be identified arising from Qatar. It is believed that 
this dissertation reflects the first such initiative and data. 
Q27 A formal Pap test screening program for cervical cancer should be established for 
all women in the State of Qatar. 
Percent Response Rate: 95.3%, from 286 of 300 surveys. Table 17 and Figure 14 represent 
the distribution of responses from all respondents for Q27, also stratified by Gender. 
Table 23 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 
variables reflecting Socio-demographics. 
 These overall findings suggest equivalent perceptions of screening practice for 
CxCa amongst women and men in the State of Qatar. 
Remarks: 
 From 286 respondents, the largest proportion of responses indicated Strongly 
agree, 193 (67.4%); followed by Agree, 78 (27.2%). That 94.8% of respondents indicated 
Strongly agree + Agree, is relevant to the hypotheses in this dissertation. The frequencies 
of support for a screening program between women and men respondents were 
essentially equal: 69.0% and 65.3% respectively. These findings demonstrated strong 




a formal screening program for all resident women. These findings reflecting public 
support may facilitate targeted health promotion initiatives in Qatar. 
Relevant Research: 
 No pertinent survey-based research pertaining to public support for the 
establishment of a formal Pap test screening program for CxCa for all women in the 
State of Qatar could be identified arising from Qatar. It is believed that this dissertation 
reflects the first such initiative and data. 
Q28 You know where to go to get a Pap test performed. 
Percent Response Rate: 94.0%, from 282 of 300 surveys. Table 17 and Figure 15 represent 
the distribution of responses from all respondents for Q28, also stratified by Gender. 
Table 23 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Nationality (p=0.003118). 
 These overall findings suggest that statistically significant differences exist 
between respondents based on Nationality, relevant to knowledge of where to get a Pap 
test performed. 
Remarks: 
 From 282 respondents, the largest proportion of responses indicated Strongly 
agree, 88 (31.2%); followed by Agree, 84 (29.8%). That 61.0% of respondents indicated 




women respondents, 16.4% were undecided, 12.7% disagreed, and 6.67% strongly 
disagreed to knowing where to get a Pap test performed. These findings likely reflected 
inadequacies in healthcare services availability and health literacy in general. 
Relevant Research: 
 Survey-based research by Alali et al., (2016) revealed that 94.5% of respondent 
women in Qatar preferred female physicians to male clinicians; and survey research by 
Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, & Ismail (2011) revealed that 55.4% of clinical 
staff employed in PHCC centers in Qatar would agree to see gynecologists in well 
women’s clinics. Nonetheless, data from this dissertation revealed that 16.4% of 
respondent women were undecided as to where to get a Pap test performed. This is 
regarded a significant finding. 
Q29 A Pap test has no value for you. 
Percent Response Rate: 94.7%, from 284 of 300 surveys. Table 18 and Figure 15 represent 
the distribution of responses from all respondents for Q29, also stratified by Gender. 
Table 23 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced 1 statistically significant association with Category 1 
variables reflecting Socio-demographics: Marriage duration (p=0.01878). However, 







 From 284 respondents, the largest proportion of responses indicated Strongly 
disagree, 138 (48.5%); followed by Disagree, 103 (36.3%). That 84.9% of respondents 
indicated Strongly disagree + Disagree, is relevant to the hypotheses in this dissertation. Of 
the women respondents, 54.5% indicated strong disagreement; however, 6.58% were 
undecided. These overall findings likely reflect inadequacies in Self-efficacy & 
Perceptions, and Health literacy, and may facilitate targeted health promotion initiatives 
in Qatar. 
Relevant Research: 
 No pertinent survey-based research pertaining to public perceptions of personal 
value gained from a Pap test could be identified arising from Qatar. It is believed that 
this dissertation reflects the first such initiative and data. Nonetheless, survey-based 
research by Alali et al., (2016) revealed that 57.8% of respondent women in Qatar did not 
perceive that they were at risk for developing CxCa therefore a Pap test was not a 
priority for them. 
Q30 If a self-test for cervical cancer was available you would prefer it? 
Percent Response Rate: 94.3%, from 283 of 300 surveys. Table 18 and Figure 16 represent 
the distribution of responses from all respondents for Q30, also stratified by Gender. 
Table 23 represents the bivariate analyses conducted and matrices of p-values. 
 These data produced no statistically significant associations with Category 1 




 These overall findings may be reflective of cultural norms in a conservative 
society as that in the State of Qatar. 
Remarks: 
 From 283 respondents, the largest proportion of responses indicated Strongly 
agree, 123 (43.4%); followed by Agree, 88 (31.0%). That 74.6% of respondents indicated 
Strongly agree + Agree for a preference for self-testing for CxCa is an important finding. 
Of the women respondents, 43.5% strongly agreed, and 29.2% agreed. These findings led 
to a combined 72.6% agreement from women respondents that they would prefer a self-
sampling approach if available. 
Relevant Research: 
 No pertinent survey-based research pertaining to self-testing for CxCa could be 
identified arising from Qatar. As HPV vaccination was recently rolled out in the State of 
Qatar in February 2018, a literature search was conducted to uncover studies to correlate 
with the data generated from this dissertation relevant to self-testing 
 In the US, Des Marais, Zhao, Hobbs, Sivaramam, Barclay, Brewer, & Smith (2018) 
studied the likely acceptance of home self-collection of samples for HPV and sexually 
transmitted infections. Their studies revealed that most participants (93.6%) indicated 
not having difficulties in understanding the method and purpose of self-collection, and 
that 96.3% of the participating women showed a willingness to apply this method. 




determine likelihood of women in Taiwan to apply self-sampling methods for HPV to 
screen for CxCa. Their studies concluded that outreach efforts to promote self-sampling 
for HPV ought to target women that have had a Pap test, who perceive themselves as 
being susceptible to both HPV infection and CxCa, and women who declare a 
willingness to apply the method. 
 Gupta, Palmer, Bik, Cardenas, Nunez, Kraal, Bird, Bowers, Smith, Walton, 
Goddard, Almonacid, Zneimer, Richman, & Apte (2018) concluded that self-sampling 
for HPV is a method potentially well suited to mitigate barriers such as embarrassment, 
and particularly for women not participating in screening programs. It is surmised that 
in the clinical setting of Qatar, self-testing methods may overcome various barriers to 
Pap test sampling either perceived or experienced by women. Bais, van Kemenade, 
Berkhof, Verheijen, Snijders, Voorhorst, Babovic, van Ballegooijen, Helmerhorst, & 
Meijer (2006) concluded that cervicovaginal self-sampling using brushes may be an 
effective alternative method to protect women that may not respond to calls for Pap test 
sampling. 
Particular Consideration: Sub-Set Of Married Women In The State Of Qatar 
Never Before Having A Pap Test 
 The highly statistically significant association (p=0.000000008) revealed from this 
research between the variables: Age group (Q3) and Had a Pap test before? (Q9) warranted 




of women respondents that had never had a Pap test. An effort was launched to filter 
through the data to uncover the likely barriers, and potential epidemiological impact. 
 This sub-set of women respondents that claimed never before having a Pap test 
was particularly relevant to the basis of this research work. As such, the aforementioned 
association was regarded as being epidemiologically significant and likely to yield 
impactful insights relative to the hypotheses posed through this dissertation. 
 To explore this association in greater detail, categorical data captured specifically 
from these women respondents were sorted and analyzed to initially determine their 
ages. From the total of 173 women that participated in this study (Table 10), 79 (45.7%) 
claimed never to have had a Pap test. This group of women produced a primary age 
group of 20-29 years (53.2%), followed by a secondary age group of 30-39 years (30.4%). 
For practicality, combined, these women formed a sub-set of respondents accounting for 
45.7% of all the women that participated in this survey-based research. 
 The age range of this sub-set of women may be epidemiologically significant 
particularly in the clinical setting of the State of Qatar. As the bimodal peak ages of 
CxCa cases presenting with Stage II/III disease in Qatar in 2014 were 40-44 and 60-64 
years respectively (QMoPH National Cancer Program, 2014), this sub-set of respondent 
women that never had a Pap test may represent a cohort of women with preclinical 
CxCa; whereby, their progressing cervical pathobiology may be asymptomatic, and 
therefore not clinically suspected. In theory, based on the discussions in Chapter 3, such 




their cervical disease as estimated by the WHO (World Health Organization, 2014). 
Thus, it may be these very women that would benefit the most from optimized Pap test 
screening practices in the State of Qatar. Likewise, an increased sense of disease 
susceptibility through targeted health promotion may also encourage these women 
particularly to actively seek medical care, as was concluded by the Memphis and Shelby 
County trial in 1951. 
 Analysis of additional categorical data specifically sorted from this sub-set of 
respondent women revealed the following parameters; that: 82.2% had a University 
level education; 83.5% had health insurance coverage; and, that their nationalities were 
Asian, African, and Qatari by decreasing frequencies (i.e., 48.1%, 18.9% and 12.7% 
respectively). 
 More importantly, however, of these 79 women, 35 (44.3%) were married, and 42 
(53.2%) were never married. When analyzed in greater detail, this differential produced 
valuable epidemiological insights. 
 The 53.2% of these 79 women that were neither married nor Pap test screened 
correlated with the clinical recommendations enforced in the State of Qatar. Currently, it 
is recommended that Pap test services be made available to women aged 25 to 64, and 
when sexually active, according to the Guidelines For Cervical Cancer Screening In The State 
of Qatar (QMoPH National Cancer Program, 20161) (Appendix F). Therefore, Pap testing 
in these unmarried women would be discouraged by the medical establishment, unless 




 However, the 44.3% of these 79 respondent women that were married and 
sexually active and not Pap tested, posed a unique opportunity for methodical review. 
These married women may be at greater risk for developing CxCa than the women 
never married. This presumption may be valid as these women could have been Pap test 
screened given the current guidelines, but were not. It was prudent to conduct a 
methodical data analysis to explore the responses arising from this specific sub-set of 35 
respondent women. 
 The analysis revealed the following categorical data reflecting Healthcare 
services, Health literacy, and Self-efficacy & Perceptions, as indicated by the respondent 
35 women: 
 20.0% had no health insurance coverage (Q8); 
 31.4% had no awareness of the Pap test cytologic method (Q13); 
 22.9% had no knowledge of CxCa (Q15); 
 11.4% had no knowledge that early detection of CxCa is important for 
effective treatment (Q16); 
 14.2% had no knowledge that regular Pap tests may protect for CxCa (Q17); 
 28.6% did not know that CxCa may be curable (Q18); 
 31.4% did not know that HPV vaccination may protect against CxCa (Q19); 
 48.5% strongly agreed to needing additional information of CxCa (Q21); 




 85.7% strongly agreed + agreed that a formal screening program be 
established in the State of Qatar for all women (Q27); 
 34.2% agreed to knowing where to go to get a Pap test performed (Q28); 
 42.9% strongly disagreed that a Pap test has no value for them (Q29); 
 77.1% strongly agreed + agreed that they would prefer a self-test for CxCa if 
this option was available. 
 If the frequencies revealed from this sub-set of women respondents may be taken 
as being representative, then their extrapolation onto the entire population of women in 
the State of Qatar in 2018, may potentially reflect 45.7% of 676,137 women, equating to 
308,994 women in Qatar never before having a Pap test (World Population Review, 
20181). And similarly, 44.3% of these 308,994 women may potentially equate to 136,884 
women in Qatar that may be married, eligible to receive a Pap test, but not being Pap 
test screened unless symptomatic. Such plausible realities may also explain, at least 
partially, the purportedly relatively low prevalence of CxCa in the State of Qatar largely 
due to opportunistic screening practice.  
 From the remarkable data that emerged reflecting this specific sub-set of 
respondent women, preliminary findings arising from this research were described in an 
Abstract/ePoster, and submitted for publication and presentation in the International 




Conclusions Arising From Dissertation Aims 
 In this section, salient data and figures are converged in an effort to support the 
hypotheses raised in this dissertation; and based on this discussion, to propose 
Opportunities for Improvement with relevance to the clinical setting in the State of 
Qatar. 
Dissertation Aim 1 
 Dissertation Aim 1 proposed an evaluation of the degree of health literacy in 
women and men in the State of Qatar of CxCa; of Pap test screening and of its benefits 
and uptakes; and, of HPV vaccination. Based on Dissertation Aim 1, it was hypothesized 
that: 
The majority of women and men in the State of Qatar have adequate health 
literacy of CxCa; however, they lack commensurate awareness of the disease 
prevention benefits possible through Pap test screening and HPV vaccination. 
 The overall data captured from this needs-assessment research upheld the 
hypothesis put forward. From the entire data set reflecting the views of women and 
men, the following was revealed relevant to Hypothesis 1: 
Health Literacy Of Cervical Cancer: 
 Q12 (CxCa may be preventable): Yes (84%), Don’t know (15%) (Table 12, Figure 
7) 




 Q16 (Early detection of CxCa is important for treatment): Yes (93.4%), Don’t 
know (6.2%) (Table 13, Figure 9) 
 Q18 (CxCa may be curable): Yes (65.5%), Don’t know (31.8%) (Table 14, Figure 
10) 
 Q21 (More information is needed about CxCa): Strongly agree (51.4%) (Table 15, 
Figure 11) 
Health Literacy Of Pap Test Screening: 
 Q13 (You are aware of the Pap test cytologic method): Yes (66.3%), No (33.7%) 
(Table 12, Figure 7) 
 Q17 (Regular Pap test may protect you against CxCa): Yes (84.9), Don’t know 
(12.2%) (Table 14, Figure 9) 
 Q20 (Menopausal women need a Pap test): Yes (69%), Don’t know (28.2%) (Table 
15, Figure 11) 
 Q22 (Regular Pap tests are a good health practice): Strongly agree (68.5%) (Table 
15, Figure 12) 
 Q25 (Getting a Pap test is a valued investment): Strongly agree (61.5%) (Table 16, 
Figure 13) 







Health Literacy Of HPV Vaccination: 
 Q19 (HPV vaccination may protect against CxCa): Yes (62.7%), Don’t know 
(35.2%) (Table 14, Figure 10) 
 Of the aforementioned 12 survey questions, 8 revealed statistically significant 
associations with respondents’ likely employment in the healthcare sector. These 
findings emphasized the impact of differences in health literacy between individuals 
that work in healthcare, arguably more medically literate, compared to those that did 
not. Overall, the data suggests that women and men in the State of Qatar are generally 
aware of CxCa (70% of all respondents indicated Yes); however, a commensurate 
awareness of the disease prevention benefits possible through Pap test screening and 
HPV vaccination was relatively lower; whereas, 66.3% of respondents indicated an 
awareness of the Pap test cytologic method; and 62.7% of respondents indicated an 
awareness of HPV vaccination benefits. Nevertheless, while these frequencies reflecting 
awareness may appear relatively similar, the indications by respondents reflecting no 
awareness are more significant; whereas, 31.8% of respondents did not know that CxCa 
may be curable, as compared with 33.7% of respondents that did not know of the Pap 
test; and 35.2% of respondents that did not know HPV vaccination may protect against 
CxCa. 
 Therefore, if indeed 33.7% of the general public in Qatar has no awareness of the 




developing CxCa also not knowing the benefits of Pap test sampling. This reality may be 
deemed alarming.   
 These differences in awareness may be explained by the relatively high degree of 
academic literacy amongst the public in Qatar and the astonishing initiatives by the 
QMoPH and the QCS to raise awareness of CxCa overall, and, by the lack of organized 
screening in Qatar. As Pap test screening is neither endorsed as a population-based 
disease prevention tool, nor recommended equivalently for all women deemed at risk 
for developing this disease, a differential of awareness potentially exists between the 
public’s knowledge of the disease, and its knowledge of the methods through which to 
detect it and protect one’s self from it. 
 Relative to Dissertation Aim 1, and the arising hypothesis, another remarkable 
finding was the identification of the sub-set of married women that never had a Pap test. 
Given their specific ages ranging between 20 and 39 years of age, these women likely 
comprise a cohort at highest risk for developing CxCa. This research revealed that of 
these specific women: 22.9% indicated no knowledge of CxCa; compared with 31.4% 
that indicated no awareness of the Pap test; and, also 31.4% that indicated no awareness 
of the disease prevention benefits possible through HPV vaccination. Moreover, 48.5% 
of these specific women indicated a need to acquire additional knowledge of CxCa. 
 Therefore, while this dissertation demonstrated adequate health literacy amongst 




health literacy for disease prevention benefits possible through Pap test cytopathology 
and HPV vaccination. 
Dissertation Aim 2 
 Dissertation Aim 2 proposed an evaluation of the degree of support in women 
and men in the State of Qatar for the establishment of a formal Pap test screening 
program for all women. Based on Dissertation Aim 2, it was hypothesized that: 
The establishment of a formal Pap test screening program for CxCa for all 
women in the State of Qatar is strongly supported by women and men. 
 The overall data captured from the needs-assessment research upheld the 
hypothesis put forward. From the entire data set reflecting the views of women and 
men, the following was revealed relevant to Hypothesis 2: 
Support For Population-Based Cervical Cancer Screening In The State Of Qatar: 
 Q26 (You would support a Pap test screening program): Strongly agree (68.3%), 
Strongly disagree (0.00%) (Table 17, Figure 14) 
 Q27 (A formal Pap test screening program for cervical cancer should be established 
for all women in the State of Qatar): Strongly agree (67.4%), Strongly disagree 
(0.00%) (Table 17, Figure 14) 
 Although neither of the aforementioned questions revealed notable statistically 
significant dependencies with other variables, the data suggests that women and men in 




program for all women. Of all respondents, 67.4% strongly agreed with this proposition. 
In contrast, from the sub-set of married women that had never before had a Pap test, 
85.7% strongly agreed + agreed to the establishment of a formal screening program. 
 Therefore, this dissertation demonstrated strong support by women and men 
respondents for the establishment of a formal Pap test screening program for CxCa for 
all women in the State of Qatar. 
Dissertation Aim 3 
 Dissertation Aim 3 proposed an evaluation of possible similarities of extent of 
CxCa at presentation and diagnosis between the contemporary Qatar experience and the 
historical experience in the US prior to the introduction of clinical population-based Pap 
test screening in 1957. Based on Dissertation Aim 3, it was hypothesized that: 
The extent of CxCa at presentation and diagnosis in the historical US experience, 
prior to the introduction of clinical population-based Pap test screening in 1957, 
bears similarities with the current experience of CxCa presentation in the State of 
Qatar mainly due to opportunistic Pap test uptakes. 
 The data that was reviewed and correlated relevant to Dissertation Aim 3, 
revealed various parallels between the historical experience in the US and the 
contemporary experience in the State of Qatar pertaining to CxCa management, and 





Opportunistic Cervical Sampling: 
 Arguably, the detection of CxCa during the 1920s and 1930s in the US, and in the 
modern Qatar setting, aligned with opportunistic cervical sampling. In the US, 
symptomatic women received a reflex biopsy; in Qatar they received a reflex Pap test. In 
either situation, disease identification was prompted by clinical symptoms raising the 
suspicion of CxCa. However, what is unique from this parallel between the US and the 
Qatar experiences is that the potential benefits from systematic Pap test screening were 
unknown in the 1920s and 1930s. 
Advanced-Stage Cervical Cancer At Presentation: 
 The alarming priorities due to CxCa experienced in contemporary developing 
regions are not unlike the presentation and burden of disease experienced in the US 
prior to formalization of Pap test screening in the late-1950s. A striking parallel between 
the historical experience in the US and the contemporary Qatar experience was the 60% 
of inoperable CxCa cases at presentation and diagnosis during the mid-1940s in the US 
(Meigs, Graham, Fremont-Smith, Kapnick, & Rawson, 1943). Those outcomes were 
remarkably similar with the 60% of cases presenting with Stage II/III CxCa in Qatar 
primarily because of opportunistic screening in 2014 (QMoPH National Cancer 
Program, 2014). 
 Also, Meigs, Graham, Fremont-Smith, Janzen, & Nelson (1945) reported that 




death rate would likely have been essentially 60%. These findings form another possible 
parallel with the contemporary Qatar experience of advanced disease at presentation. 
Death Rates Due To Cervical Cancer: 
 Despite the aforementioned likely death rates from CxCa in the mid-1940s in the 
US, the death rate in modern practice as a result of Pap test screening practices has fallen 
to a 32.2% US-specific death rate according to the ACS (American Cancer Society, 2018). 
Currently in Qatar, from the 15 CxCa cases estimated annually by the ICO, the estimated 
death rate from CxCa is at 26.7% (Institut Catala d’Oncologica, 20172). The literature 
reviews conducted for this dissertation did not reveal a plausible scenario to explain this 
parallel; however, as 72% of the CxCa cases in Qatar are seen typically in expatriate 
women, it is likely that these women repatriate to their homelands post-diagnosis for 
treatment, and may be therefore lost to follow-up. 
Cervical Cancer Case Registries: 
 In 1914, the ASCC collaborated with the Department Of Commerce, United States of 
America, Bureau Of The Census, to produce a detailed registry of deaths throughout the 
US based on estimated population growth; cancer type; patient age group; gender; and, 
State of residence. This initiative produced a mammoth publication listing numbers of 
deaths; it was essentially a death registry. However, it was not until 1952, and 
henceforth, that the American Cancer Society published Cancer Facts And Figures 
annually to include data for CxCa (Thun, Calle, Rodriguez, & Wingo, 2000). This was 




Facts And Figures not only tracked death rates, it also tracked actual incidence rates 
based on robust data collection and analysis. 
 Currently in Qatar, the National Cancer Registry initiative was launched at HMC 
in 2012 to record prevalence statistics from cancer cases (A.A. Hmaidan; personal 
communication, March 21, 2016). Prevalence statistics prior to 2012 were computed from 
case studies based on treatment course and outcomes, hence regarded potentially 
inaccurate. As such, epidemiologically-accurate cancer statistics became available in 
Qatar from 2012 henceforth through the National Cancer Program. Hence a major part of 
historical case and death statistics due to CxCa is unavailable. These realities form 
another parallel between the US and Qatari experiences. 
 Therefore, epidemiological data reviews and correlations conducted for this 
dissertation demonstrated various parallels between the historical US experience and 
the contemporary experience arising from CxCa management in the State of Qatar. It is 
concluded that these parallels stemmed from the commonality of opportunistic cervical 
sampling. 
Opportunities For Improvement 
 In this section, the author proposes opportunities for improvement in an effort to 
optimize existing Pap test cervical sampling practices in the State of Qatar. The below-
mentioned proposals arise based on the research outcomes herein described. It is once 
again prudent to emphasize the remarkable investments allocated towards 




in Qatar. However, data arising from this dissertation revealed major gaps in Health 
Literacy and in the public’s sense of Self-efficacy & Perceptions towards the uptake of 
Pap test services and HPV vaccination. 
Tumor Registry: 
 Proposed is the development and implementation of a robust Tumor Registry in 
the State of Qatar for CxCa. 
 The likely benefits may be potentially significant. Habbema, De Kok, & Brown 
(2012) described the impact of such a system in the burgeoning screening systems for 
CxCa in the Netherlands. A Tumor Registry designed to track all cases may also suffice 
as a registry of all women residing in Qatar age 15 and older, and therefore those 
women deemed at risk for developing CxCa. As all residents in Qatar have a QID 
residency number, the Tumor Registry may track all women using the QID system. Such 
a Registry may also form the platform for organized screening by registering initial call 
to screening, by tracking adherence to rescreening recommendations based on 
cytopathologic findings, and by monitoring the follow-up timelines and surgical 
pathology outcomes arising from pathologic cases. 
 Such a Tumor Registry would better track intraepithelial and invasive disease, 
and therefore result in accurate epidemiological statistics inclusive of CIS and invasive 
CxCa, leading to reliable statistics by which to assess incidence, prevalence, and 
treatment effectiveness. A Tumor Registry would also track women regardless of 




women that may be lost to follow-up would pose a significant limitation in the 
calculation of actual incidence of CxCa in this small clinical setting. Ultimately, a 
potential decision to implement systematic Pap test screening in Qatar would rest upon 
accurate prevalence data. Therefore, a Tumor Registry may prove to be a most 
significant prerequisite infrastructure for system optimization. 
 Another potential benefit from a Tumor Registry would be the standardization of 
diagnostic and therapeutic practices conducted in Qatar between the private and public 
healthcare providers. Alignment of these disciplines may produce substantial 
information upon which to consider cervical sampling methods that would be tailored 
to this clinical environment (Al-Naggar, 2012, Khan & Woolhead, 2015). 
 A Tumor Registry may also facilitate targeted health literacy through specific 
apps disseminated throughout the extensive mobile phone networks in Qatar, based on 
age-group, nationality, and mother language. 
Implementation Of Population-Based Screening For All Women: 
 Data revealed through this dissertation research amply support the design and 
implementation of population-based Pap test screening in Qatar. 
 The survey-based research conducted by Al-Meer, Aseel, Al-Khalaf, Al-Kuwari, 
& Ismail (2011) formed the closest study to the intents and purposes of this dissertation. 
Their report concluded that the gaps in health literacy that they uncovered were 
attributable to the lack of organized Pap test screening in Qatar. As such, based on the 




support for such a system as evidenced by the survey respondents, population-based 
screening ought to be formally considered and implemented. 
 Another significant justification for Pap test population-based screening in Qatar 
is the recent implementation of HPV vaccination in this nation. Given the health literacy 
gaps pertaining to the awareness of HPV vaccination amongst the general public as 
represented by the respondents in this research, the impact of vaccination may not be 
fully realized for some time. 
 Another epidemiological determinant may be the unique prevalence of HPV 
genotypes in this clinical setting as reported by Bansal, Elmi, Skariah, Haddad, Abu-
Raddad, Al Hamadi, Mohamed-Nady, Affifi, Ghedira, Hassen, Al-Thani, Al-Ansari, & 
Sultan (2014). As HPV 16 was shown to be prevalent in women in Qatar even with 
normal cytologic findings, continuous Pap test screening may be appropriate to track 
likely progressive cervical disease. 
 Whereas the Pap test may not prevent the biological initiation of cervical 
neoplasia, it may effectively prevent its progression to infiltrating disease by facilitating 
early detection, leading to timely surgical intervention and effective ablation. 
Furthermore, HPV vaccination may not protect women already infected, and which are 
therefore at risk for developing cervical cancer. Therefore, despite the potential for 
primary disease prevention through HPV vaccination in Qatar, systematic Pap test 




deemed at risk for developing this disease as it may require decades of surveillance 
before the effect of vaccination is realized in this nation. 
Managing Reallocation Of Financial Resources: 
 It is speculated that with a potential reduction in CxCa cases in the State of Qatar 
that may arise due to systematic screening, reallocation of saved financial resources may 
support expanded and financially sustainable Pap test screening (Goldie, Gaffikin, 
Goldhaber-Fiebert, Gordillo-Tobar, Levin, Mahe & Wright, 2005; Kim, Sharma, O’Shea, 
Sweet, Diaz, Sancho-Garnier, & Seoud, 2013). Based on studies by Pendrith, Thind, 
Zaric, & Sarma (2016), mitigation of the 18 cases of advanced CxCa that were reported in 
2014 in Qatar, and the associated costs for treatment and follow-up, may have translated 
into an, albeit conservative, saving of 1.75 million Riyals. Such savings, possible through 
Pap test screening, and assuming the cost for a Pap test to be 200 Qatari Riyals (i.e., 
$54.79 USD), may have supported reallocation of funds to support 8,750 Pap tests. 
 Although 83.5% of the 170 respondent women that participated in this research 
indicated having healthcare insurance, the remainder 16.5% of women claimed that they 
did not. Therefore, a relatively significant proportion of women in the State of Qatar 
may be facing financial obstacles in seeking and actually getting a Pap test performed. 
 Based on the overall discussions in Chapter 6, the converged survey-based data 
and conclusions arising from this dissertation, optimization and transformation of 




the State of Qatar may be feasible, and particularly given the advanced cytopathology 





CHAPTER 7: EPILOGUE 
 
 It is an unfortunate contradiction that in the clinical setting of opportunistic 
screening, any woman ought to present with classical symptoms of invasive disease 
before the Pap test may have an opportunity to forewarn that she has cervical cancer. It 
is equally perplexing that in the modern epoch of unprecedented medical experience of 
cervical cancer and near-complete epigenetic and molecular characterization of this 
dreaded disease that any woman globally may not be able to undergo at least one 
episode of cervical sampling to test for likely preclinical disease. 
 Cervical sampling may take various forms: It may be a classic Pap test, a 
molecular HPV test, a self-test for HPV, or, simply, visualization of the uterine cervix to 
inspect for anatomical aberrations through the Schiller’s iodine or acetic acid method. 
Options for secondary prevention of cervical cancer both basic and sophisticated are 
abound. HPV vaccination for primary prevention of the disease is also available but 
requires time to mature, to yield clinical results. However, every effort is ethically 
required by the medical establishment to avoid the need for tertiary prevention: The 
radical methods oftentimes necessary to treat advanced cervical cancer, largely resulting 





 The author has witnessed the impact of systematic cervical cancer screening in 
the backdrop of opportunistic screening vividly and definitively through specific career 
phases in the EMENA region. 
 After a 14-year career phase at the Health Sciences Center in Winnipeg, Canada, 
applying North American practices to manage cervical cancer, the author relocated to 
the King Faisal Specialist Hospital & Research Center (KFSH&RC) in Riyadh, Saudi 
Arabia, in December 1994. The KFSH&RC catered to the Royal family and employed 
6,500 staff. The KFSH&RC had an outreach for nearly 25,000 individuals eligible to avail 
its medical services. The cytopathology service at KFSH&RC analyzed 8,000 Pap test 
cases annually. By applying systematic screening practices stipulated through CAP 
accreditation, none of the women with detected intraepithelial cervical disease 
developed invasive cancer. Yet, nearly 10 cases of advanced cervical cancer were 
experienced annually. These women presented to Emergency seeking much delayed 
care, and originated from outside the cervical sampling outreach of the KFSH&RC. 
 Subsequently, at King Abdulaziz Medical City hospital, in Riyadh, Saudi Arabia, 
where the service outreach expanded to over 54,000 individuals, predominantly military 
personnel and their extended families, intraepithelial disease was likewise managed, 
and development of invasive cervical cancer was negated successfully. Nevertheless, 
annually, nearly 12 cases of advanced cervical cancer were experienced; and, none of 




 These tertiary hospital experiences clearly distinguished the demarcations 
between opportunistic and systematic screening practices for cervical cancer. In essence, 
the screening outreach orbits of these two impressive medical institutions formed 
pockets of organized screening superimposed, not unlike islands, upon a greater 
landscape characterized as a sea of opportunistic screening throughout the vast Saudi 
Arabian heartland. Arguably, incremental expansion of the organized screening orbits 
would gradually phase out the opportunistic screening landscape; such a scenario 
would mirror the clinical screening experience in the US that has formed since 1957. 
 Most of those diseased women that presented to cytopathology declined 
treatment despite, oftentimes, favorable prognoses depending on disease-stage at 
diagnosis. The societal impact of cervical cancer in this conservative, matriarchically-
structured culture is not only devastating it is also incalculable, due to its compounding 
ripple effect throughout all strata of society. 
 At the onset of this research work, it was merely hoped that the uncovered 
insights, data, and conclusions drawn, may possibly serve to optimize screening practice 
in the State of Qatar. With composition of this Epilogue, it is essentially assured that 
indeed, they may. 
 In the midst of this experience, insofar as cervical cancer is concerned, there is 
ample opportunity for political commitment, for revision of clinical philosophies, and 




initiatives. And, in the opinion of the author, these convictions have a global relevance, 
not just for the State of Qatar. 
 In closing, the author expresses utmost gratitude and extends sincere thanks to 
the University of Nebraska Medical Center for seeing merit in this scientific work in 
Preventive and Societal Medicine. 
 
Nikolaos Chantziantoniou 
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Appendix A: National Cancer Program, Qatar National Cancer Registry 2014 















ANONYMOUS SURVEY FOR MEN AND WOMEN 
 
Questions (English)  
1   Nationality 
 
o Qatari 
o Middle Eastern 
o Asian 
o European 
o North American 












AWARENESS, KNOWLEDGE, AND PERCEPTIONS OF 
SCREENING FOR CERVICAL CANCER, AND HUMAN 






3   Age group (Years) 
 





o Over 60 
 
 
4   Highest education level 
 
o Middle School 





5   Marital status 
 






6   Marriage duration (Years) 
 
o Under 5 
o 5-10 
o 10-20 
o Over 20 
o Not applicable 
 
 





















o Not applicable 
 
 
10   If you had a Pap test before, when was it 
performed 
 
o 1-3 years ago 
o 4-6 years ago 
o Over 6 years ago 
 
 
11   Did you, or any member of your family 




o Don’t know 
 
 




o Don’t know 
 
 











14   Where did you hear of the Pap test smear 
cytologic method for the first time 
 
o Relatives, friends 
o Gynecologist 
o Mass media (newspaper, internet, 
television) 
o Family physician 
o Nurse 
o Other 
o Not applicable 
 
 






16   Early detection of cervical cancer is 




o Don’t know 
 
 





o Don’t know 
 
 











19   Vaccination for the Human Papilloma 
Virus protects against cervical cancer and 




o Don’t know 
 
 




o Don’t know 
 
 
21   More information is needed to improve 
your knowledge of cervical cancer 
 




o Strongly disagree 
 
 
22   Regular Pap tests are a good health 
practice 
 




o Strongly disagree 
 
 
23   Getting a Pap test performed is too 
difficult 
 











24   You would recommend a Pap test to your 
family, friends, and colleagues 
 




o Strongly disagree 
 
 
25   Getting a Pap test is a valued investment 
for good healthcare 
 




o Strongly disagree 
 
 
26   You would support a Pap test screening 
program for cervical cancer 
 




o Strongly disagree 
 
 
27   A formal Pap test screening program for 
cervical cancer should be established for all 
women in the State of Qatar 
 











28   You know where to go to get a Pap test 
performed 
 




o Strongly disagree 
 
 
29   A Pap test has no value for you 
 




o Strongly disagree 
 
 
30   If a self-test for cervical cancer was 
available you would prefer it 
 




o Strongly disagree 
 
 

















Appendix C: Symposium Compendium (The 1st Century Of Gynecological 
Cytopathology, The Pap test – Then, Now And The Future), conducted 









Appendix D: Symposium Goals and Objectives (The 1st Century Of 
Gynecological Cytopathology, The Pap test – Then, Now And The Future), 









Appendix E: Symposium Program Schedule (The 1st Century Of Gynecological 
Cytopathology, The Pap test – Then, Now And The Future), conducted 










Appendix F: National Cancer Program, Guidelines For Cervical Cancer 
Screening In The State Of Qatar report (2016) published by the Qatar Ministry 









Appendix G: National Cancer Program, Guideline For Suspected Cancer 











Appendix H: Cervical cancer health literacy campaign: “Be Well”, produced by 










Appendix I: The National Health Strategy 2018-2022; Our Health Our Future 










Appendix J: The National Clinical Guidelines For The State Of Qatar (2nd 











Appendix K(a): Infographic, What Is Cervical Cancer; a 2-page fold-out 
brochure produced by the Ministry of Public Health, State of Qatar (Front and 







Appendix K(b): Infographic, What Is Cervical Cancer; a 2-page fold-out 
brochure produced by the Ministry of Public Health, State of Qatar (Pages 2 







Appendix L: The National Cancer Framework – Achieving Excellence In Cancer 









Appendix M: Abstract/ePoster, International Academy of Cytology Congress, 
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